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ESBL prevalence is increasing globally and travellers visiting South Asia have high rates of 
acquisition of CTX-M-producing-E. coli (CTX-M-EC). A prospective observational cohort study 
of volunteers traveling from the UK to South Asia was undertaken to determine the 
mechanism of CTX-M-producing E. coli (CTX-M-EC) acquisition. CTX-M-EC was acquired by 
16/18 (89%) of volunteers, and polyclonal acquisition of CTX-M-EC was seen in 8/15 
volunteers, suggesting multiple acquisition events during travel. CTX-M-EC clones were 
detectable in faecal samples at six months after travel for 6/6 volunteers. Indistinguishable 
pre-travel non-CTX-M-EC were found in post-travel faecal samples after CTX-M-EC had been 
lost in 5/15 cases. Therefore, pre-travel non-CTX-M E. coli remain as a minority population in 
the gut until the CTX-M-EC are lost. Ten plasmids were sequenced using WGS with short and 
long reads. Plasmid transfer after filter-mating occurred in CTX-M-EC from 45% of volunteers, 
suggesting that conjugation also has a role in the human gut. However, in-vivo horizontal 
transfer of a blaCTX-M plasmid was not detected. Plasmids are closely related to those 
previously sequenced, isolated from humans, animals and the natural environment. 
Determining the mechanism of spread of CTX-M-EC will underpin infection prevention and 
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Chapter 1: Introduction 
 
1.1 Escherichia coli 
1.1.1 Origins and discovery 
Escherichia coli (E. coli) was first described as part of the intestinal flora of a neonate, and 
named ‘Bacterium coli commune’ by the German physician, Theodore Escherich (Escherich, 
1885, English translation 1988), then subsequently renamed in honour of Escherich 
(Castellani and Chalmers, 1919).  
 
E. coli is a rod-shaped gram negative bacterium which is part of the family 
Enterobacteriaceae within the order Enterobacteriales and sits in the 
class Gammaproteobacteria (Adeolu et al., 2016). E. coli are motile, non-spore forming, 
facultative anaerobes, and are usually lactose fermenting bacteria. They form part of the  
faecal microbiome in mammals (Edwards and Ewing, 1972), and make up <1% of the normal 
faecal microbiome of humans (Arumugam et al., 2011). 
 
1.1.2 E. coli classification and typing 
Early investigations into the taxonomic position of E. coli were carried out using DNA 
hybridisation and polynucleotide sequence divergence (Brenner et al., 1972). The earliest 
use of O antigen serotyping to differentiate E. coli strains was carried out in the early 1940s 
(Kauffmann, 1943; Orskov et al., 1977). Subsequent serotyping schemes were developed 
utilising the H and K antigens (Orskov et al., 1977).  
 2 
 
The differentiation of E. coli strains using gel electrophoresis of enzymes produced by each 
strain (Milkman, 1973), led to the first system for phylogenetic analysis, named multilocus 
enzyme electrophoresis (MLEE) (Selander and Levin, 1980). In order to carry out 
phylogenetic analysis, a large E. coli reference collection (ECOR) was compiled, which 
included both pathogenic and commensal strains from humans and animals, aiming to 
capture the diversity of the E. coli species (Ochman and Selander, 1984). The MLEE approach 
was then applied to the ECOR collection, resulting in the designation of four major E. coli 
phylogenetic groups: A, B1, B2, and D (Selander et al., 1987). Restriction fragment length 
polymorphism (RFLP) and randomly amplified polymorphic DNA (RAPD) (Desjardins et al., 
1995) superseded MLEE for E. coli strain discrimination, but confirmed the 4-group 
phylogenetic designation (Chaudhuri and Henderson, 2012).  
 
The widespread uptake of PCR in clinical and research laboratories led Clermont and 
colleagues to develop a PCR-based assay for designation of E. coli into one of the four 
phylogenetic groups (A, B1, B2 and D), based on the amplification of three conserved genes 
(Clermont, Bonacorsi and Bingen, 2000). The most widely used nucleotide-based scheme for 
E. coli typing is multilocus sequence typing (MLST) which was devised for a number of 
bacterial species, including E. coli (Maiden et al., 1998).  
 
MLST uses PCR to determine the variants of seven or eight housekeeping genes, resulting in 
the grouping any particular strain into a numbered ‘sequence type (ST),’ allowing greater 
strain discrimination than phylogenetic grouping in isolation (Maiden et al., 1998; Clermont 
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et al., 2013). Typing schemes, such as MLST which are based on so-called ‘housekeeping’ 
genes in E. coli, are limited by the high rate of core genome homologous recombination, 
which often includes the genes used in the typing scheme, and furthermore using seven or 
eight genes will never be representative of whole genomic diversity (Chaudhuri and 
Henderson, 2012). The target genes used in MLST schemes are derived from the original 
MLEE profiles (Maiden et al., 1998). 
 
Since the publication of the whole genome sequence of E. coli K-12 (Blattner et al., 1997), 
whole genome sequencing of bacterial genomes using high-throughput short-read 
sequencers  has become highly accessible and affordable. The large number of freely 
available bioinformatic tools for the analysis of draft genomes, means that typing strains 
using WGS datasets for research purposes or as part of clinical outbreak investigations, has 
become commonplace.  
 
Typing strains to high resolution is now possible using WGS draft genomes of different E. coli 
strains and comparing the number of single nucleotide polymorphisms (SNPs) that differ 
between each test strain and the reference genome. SNP-typing has now become the gold 
standard method in investigation of E. coli population structure. Intergenic SNPs are 
classified as either synonymous, which have no effect on the amino acid sequence, and non-





1.2 Clinical significance of E. coli 
Pathogenic strains of E. coli affecting humans can be broadly divided into: (1) strains which 
cause gastroenteritis in humans, and (2) strains which cause urinary tract infections, intra-
abdominal infections, or biliary infections, any of which may lead to E. coli bacteraemia.  
 
1.2.1 E. coli causing gastrointestinal disease  
The terms used to classify intestinal pathogenic E. coli are largely derived from whether or 
not the strain produces exotoxin, the resulting disease process, or the pathophysiological 
changes in the gut.   
 
Enteropathogenic E. coli (EPEC) and Enteroaggregative (EAEC) are associated with 
remodelling of enterocytes leading to distinct macroscopic and microscopic changes in the 
gut epithelium. Adherent invasive E. coli (AIEC) is notable for its strong association with 
Crohn’s disease. Enterohaemorrhagic E. coli (EHEC) and entero-invasive E. coli (EIEC) cause 
gastrointestinal haemorrhage resulting from production of Shiga toxin. Extreme disease can 
lead to haemolytic uraemic syndrome (HUS) and death. A very similar disease process may 
occur in gastroenteritis due to Shigella spp. Enterotoxigenic E. coli (ETEC) produce heat-
stable and heat-labile enterotoxins, and are a significant cause of diarrhoea in the 
developing world (Chaudhuri and Henderson, 2012).  
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1.2.2 Extra-intestinal pathogenic E. coli (ExPEC) 
Extra-intestinal pathogenic E. coli (ExPEC) make up the biggest burden of E. coli disease in 
the developed world, including the UK, and are the subject of the remainder of this thesis.  
The vast majority ExPEC strains include uropathogenic E. coli (UPEC) which are the 
commonest cause of urinary tract infection (UTI). ExPEC are also commonly implicated in 
intra-abdominal infections such as diverticulitis, appendicitis, as well as biliary tract 
infections. ExPEC infections may be localised to these anatomical locations. However, severe 
disease often leads to bacteraemia and severe sepsis, which carries a high mortality.  
 
Particular E. coli phylogenetic groups (PG) are associated with extra-intestinal infection. In 
immunocompetent hosts, phylogenetic groups leading to ExPEC infection are usually B2 and 
D (Dale and Woodford, 2015). The most predominant clonal group of ExPEC is MLST type 
ST131 which has become globally disseminated, (Price, Johnson and Aziz, 2013), although 
other STs have been associated with uropathogenicity (Dale and Woodford, 2015). The role 
of successful ExPEC clones in the spread of blaCTX-M genes will be discussed in chapter 2, 
section 2.5.2. 
 
1.3 Antimicrobial chemotherapy  
Since the discovery and mass production of the first antibiotics in the 20th Century, (Ehrlich, 
1913; Fleming, 1929; Domagk, 1935; Chain et al., 1940), a plethora of both natural and 
synthetic agents have been utilised in human medicine. Unfortunately, for each drug 
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utilised, a corresponding resistance mechanism exists, which usually limits the usefulness of 







  Figure 1.1. Timeline of antibiotic corresponding AMR mechanism discovery. 




Following the discovery and widespread use of antibiotics in the early 20th Century, a 
plethora of antibiotics were developed, including semi synthetic agents such as amoxicillin 
(Rolinson and Stevens, 1961), and mould-derived compounds such as cephalosporins 
(Burton and Abraham, 1951; Bo, 2000). 
 
Beta lactam antibiotics, which include cephalosporins, are a large family of agents with a 
beta-lactam ring. Beta lactams bind to D-alanyl-D-alanine carboxypeptidase, in the bacterial 
cell wall, leading to inhibition of cell division, lysis, and cell death (Ogawara, 1981). 
 
The most widely used semi-synthetic penicillin, amoxicillin, is useful in the treatment of 
infections due to gram positive bacteria such as community acquired pneumonia, as well as 
infections due to susceptible gram-negative bacteria such as urinary tract infection. 
(Sutherland, Croydon and Rolinson, 1972). Amoxicillin is often used in combination with the 
beta-lactamase inhibitor clavulanic acid, (co-amoxiclav) in the modern era. 
 
In the present day, the mainstays of managing E. coli bacteraemia depend on local 
epidemiology of antibiotic-resistance but may involve amoxicillin, co-amoxiclav, 




1.4 Antimicrobial resistance in E. coli 
1.4.1 Antimicrobial susceptibility testing 
Antimicrobial susceptibility is determined through measurement of the minimum inhibitory 
concentration (MIC). This is the minimum antibiotic concentration required to achieve 
inhibition of bacterial growth. This is traditionally determined using broth microdilution. 
However, in the modern hospital microbiology laboratory, susceptibilities are determined 
using e-test strips or automated methods such as the VITEK2. 
 
Antibiotic breakpoints are set after the analysis of a bacterial population and the 
susceptibility profile for each particular antibiotic. Breakpoints are decided after expert 
review by international committees such as the European Committee on Antimicrobial 
Susceptibility Testing, which publish annual interpretive criteria and guidance on 
susceptibility testing (EUCAST, 2018). 
 
1.4.2 Early reports of antibiotic resistance in Enterobacteriaceae 
The heavy use of a new antibiotic has often led to the development of corresponding 
antimicrobial resistance, and this has historically, been the case in the treatment of gram-
negative bacterial infections. The plethora of new antibiotics being developed led to the 
discovery of antimicrobial resistance mechanisms. New antibiotics with gram negative 
activity used in human medicine such as streptomycin (Schatz, Bugie and Waksman, 1944), 
tetracycline (Duggar, 1948), and chloramphenicol (Eherlich et al., 1947), showed early 
evidence of acquired antibiotic resistance. 
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Early reports of antibiotic resistance in E. coli were described in the context of patients 
treated with streptomycin for tuberculosis. Faecal E. coli were found to be streptomycin-
resistant (Hamburger et al., 1951), due to the presence of antibiotic target site mutations in 
ribosomal RNA (Springer et al., 2001). 
 
Chloramphenicol was discovered by Ehrlich in the late 1940s (Eherlich et al., 1947) and was 
the first broad spectrum antibiotic, which is still in widespread use today. Resistance to 
chloramphenicol is usually mediated via acetylation and inactivation by chloramphenicol 
acetyltransferases (CATs) which are usually found on mobile genetic elements (Maclaren and 
Shann, 2010).  
 
Tetracycline resistance is usually due to efflux pumps encoded on mobile genetic elements, 
including plasmids or due to target mutations leading to ribosomal modification (Eisen, 
2010). The prevalence of tetracycline resistance was low in the years before tetracycline was 
used in clinical practice, being around 2% in Enterobacteriaceae isolated between 1917 and 
1954 (Datta and Hughes, 1983). However, tetracycline is no longer used in routine clinical 
practice for treating infections due to Enterobacteriaceae, due to the high rates of resistance 
in this family of bacteria.  
 
In the early days of antimicrobial chemotherapy, ampicillin and amoxicillin were often used 
in the treatment of E. coli infections, and their use acted as a driver for the emergence of 
resistant strains. Resistance to ampicillin and amoxicillin in E. coli, encoded by the TEM beta-
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lactamase, was found to be transferrable, encoded on the newly discovered plasmid, R1 
(Datta and Richmond, 1966) 
 
1.4.3 Extended-spectrum beta lactamases 
After the introduction of cephalosporins into clinical practice, resistance to these agents 
became widespread. During the 1980s, cephalosporins including ceftazidime, cefotaxime 
and ceftriaxone were used heavily as broad-spectrum empirical antibiotics. This overuse led 
to the dissemination of resistance mediated by extended spectrum beta lactamases (ESBLs) 
(Livermore and Hawkey, 2005).  
 
Extended spectrum beta lactamases (ESBL) are enzymes which hydrolyse the beta lactam 
ring of penicillins and third-generation cephalosporins (3GC). ESBLs are defined as any 
acquired beta-lactam-hydrolysing enzyme which confers increased resistance to oxyimino-
cephalosporins in comparison to other members of its genetic family (Livermore, 2008). 
They are mainly produced by Enterobacteriaceae, including Escherichia coli and Klebsiella 
pneumoniae. ESBL-producing strains may be part of the normal bowel flora, but can also be 
pathogenic, causing ExPEC infections including bacteraemia, which carry an increased 
mortality (Davies, 2013).   
 
Classification of beta lactamases is based on two schemes: (1) The molecular classification 
based on amino acid sequence; and (2) functional classification based on substrates and 
clinical phenotype (Bush and Jacoby, 2010). The first ESBLs originated by mutations from the 
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TEM and SHV family of beta-lactamases (Kliebe et al., 1985), but by far the most common 
ESBL is the CTX-M family, which will be described in detail in the following sections. 
 
1.4.4 Surveillance of AMR in E. coli 
There has long been a paucity of surveillance of AMR globally, particularly in 
Enterobacteriaceae. The most useful hospital-based surveillance data comes from several 
publications for The Study for Monitoring Antimicrobial Resistance Trends (SMART), which 
collates isolates from intra-abdominal infections from different world regions (Hsueh et al., 
2010; Chaudhuri et al., 2011; Hawser et al., 2011; Lob et al., 2015). A SMART study from the 
Asia-Pacific region in 2008 showed that ESBL-producing E. coli rates were particularly high 
for India (61%), China (59%), Thailand (53%), Singapore (12.3%), and Malaysia (2.9%).  
 
In 2015 the World Health Organisation announced the inception of the Global Antimicrobial 
Resistance Surveillance System (GLASS) which published an initial report. However, notably 
there is not yet any GLASS-data for the UK, or any South Asian countries, relevant to this 
thesis (WHO, 2017). However, the European Antimicrobial Resistance Surveillance Network 
(EARS-Net) has been operational since 1998, providing country-by-country epidemiological 
data on resistance rates for various bacteria including E. coli (ECDC, 2018). Figure 1.2 is a 
heat map from ECDC showing the latest European epidemiology of 3rd-generation 
cephalosporin resistant isolates across Europe (ECDC, 2018). There is a particular problem in 
Southern and Eastern Europe, where 3GC resistance prevalence for E. coli is up to 50% in 







Figure 1.2. Percentage of third-generation cephalosporin-resistant invasive E. coli isolates, 2017 (ECDC, 2018) 
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1.4.5 UK incidence of E. coli bacteraemia 
The incidence of E. coli bacteraemia in the UK is rising, and the reasons for this are likely to 
be the combination of an aging population with increasingly complex medical needs. One 
third of all cases of bacteraemia in the UK are due to E. coli and the source of infection in 
50% is the urinary tract (Abernethy et al., 2017). Risk factors strongly associated with E. coli 
bacteraemia are recent antibiotic exposure and urinary catheterisation, and the majority of 
cases are community-acquired rather than hospital-acquired infections (Abernethy et al., 
2017). The rate of E. coli bacteraemia in England increased by 22% between 2012 and 2017, 
and is forecast to rise by a further 22% by 2021 if no action is taken (Bhattacharya et al., 
2018). Mortality associated with E. coli bacteraemia is high, even with appropriate 
treatment. The all-cause 30-day case fatality rate of E. coli bacteraemia was 14.7% in 
2016/17 (Bhattacharya et al., 2018). The UK government has set a target to reduce the 
incidence of gram negative bacteraemia by 50% by 2021 (NHS Improvement, 2017). 
 
1.4.6 Antimicrobial-resistant E. coli in the UK 
Antimicrobial resistance (AMR) in England is subject to a national surveillance programme, 
The English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) 
(Public Health England, 2018). For E. coli, ESPAUR reports rates of resistance to ciprofloxacin, 
gentamicin, third-generation cephalosporins, carbapenems, piperacillin/tazobactam, and co-
amoxiclav (Public Health England, 2018). Although the proportion of resistant E. coli isolates 
causing bacteraemia has remained stable, there is an overall increase in antibiotic resistant 
strains due to the increased rate of total E. coli bacteraemia (Figure 1.3) (Hawkey et al., 
2018; Public Health England, 2018). 
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Most concerning is the rise in incidence of infections due to Extended spectrum beta 
lactamses (ESBLs), which encode resistance to third generation cephalosporins and to most 
beta-lactam antibiotics. There is no mandatory surveillance of clinical ESBL-producing 
bacteria in the UK, however, the prevalence of community carriage for England as a whole 
has been estimated to be 7.3% (McNulty et al., 2018). Since gut colonisation is a reservoir of 
E. coli strains and colonisation with ESBL-producers usually precedes clinical infection (Asir et 










Figure 1.3 Estimated burden of bloodstream infections due to AMR bacteria in England. Adapted from the 
ESPAUR report, 2018 (Public Health England, 2018). 
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Burden of antibiotic resistance 
While the proportion of isolates of the above pathogens showing non-susceptibility to 
key antibiotics generally remained stable over time, the year-on-year increases in the 
incidence of bacteraemia shown in Figures 2.1 and 2.2 meant that the burden of 
resistance, as reflected by the numbers of resistant infections, nonetheless increased 
over time. Using the methodology described in Annex – Chapter 2, the estimated total 
numbers of bloodstream infections caused by pathogens resistant to 1 or more key 
antibiotics increased from 12,250 in 2013 to 16,504 in 2017, a rise of 35% (Figure 2.3). 
As shown in Figure 2.3, and in more detail in Table 2.2 for infections that occurred in 
2017, the burden of antibiotic-resistant bloodstream infections is particularly marked for 
those caused by Enterobacteriaceae, particularly E. coli, as they are the infections with 
the highest incidence, comprising 84.4% of the total. The burden of resistant infections 
igure 2.3 Estimated trends in burd n f bloodstream infections due to antibiotic-
resistant pathogens in England, 20 3 to 2017 
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1.5 Plasmids and horizontal gene transfer 
Horizontal gene transfer (HGT) is the process by which genetic material passes between 
closely or distantly related organisms, and can take place in prokaryotes and eukaryotes 
(Gogarten, Gogarten and Olendzenski, 2009). For the purpose of this thesis, HGT will be 
referred to in terms of transfer between bacteria. HGT typically occurs in one of three ways: 
(1) by transformation of DNA, that is, uptake of DNA from the extracellular environment; (2) 
by transduction, whereby DNA is transferred by bacteriophage; (3) by movement of mobile 
genetic elements such as plasmids, transposons, integrons or insertion sequences (Thomas 
and Nielsen, 2005). 
 
Plasmids are extra-chromosomal, self-replicating DNA molecules which are usually double 
stranded and circular (Gogarten, Gogarten and Olendzenski, 2009). It has been argued that 
plasmids constitute a distinct life-form, because they are autonomous and have their own 
discrete evolutionary lineages (Carattoli, 2013). Plasmids vary in size from 1 kbp – 500kbp, 
with variation in copy number per bacterium, whereby smaller plasmids often exist in high 
copy number. Conversely, the copy number of larger plasmids may only be 1-2 per cell. 
 
Plasmids are found naturally in bacteria, and often encode genes which are beneficial to the 
host such as antibiotic (Datta and Richmond, 1966) or metal resistance genes (Smith, 1967), 
virulence factors allowing the host cell to be pathogenic (Elwell and Shipley, 1980), or genes 
allowing the bacterium to adapt to stressful external conditions (Winther and Gerdes, 2011). 
In addition, plasmids often encode the machinery necessary for horizontal gene transfer by 
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conjugation, as well as maintenance systems to ensure inheritance in future bacterial 
progeny, which is especially important for plasmids in Enterobacteriaceae (Carattoli, 2009; 
Gogarten, Gogarten and Olendzenski, 2009).  
 
Plasmid compatibility grouping was a classification originally devised by grouping plasmids 
into categories based on their ability to co-exist in the same bacterium (Datta and Hedges, 
1971), and subsequently developed into a PCR based typing system (Carattoli et al., 2005). 
Since the widespread availability of WGS, and in particular long read sequencing, whole 
plasmid sequencing has become possible (Ashton et al., 2015; Lemon et al., 2017). 
 
Conjugation is a process by which a portion of DNA, usually a circular plasmid, passes from 
one bacterium to another by direct cell-to-cell contact (Cabezón et al., 2014). The first 
description of antibiotic resistance gene transfer by conjugation was made in relation to 
clinical isolates of Shigella spp. in Japan (Watanabe and Fukasawa, 1961). Conjugative 
plasmids encode the genes required for transfer (the tra operon) which proteins necessary 
for formation of the bacterial pilus. The pilus, sometimes referred to as the ‘sex-pilus’ is a 
protrusion of the bacterial cell membrane and cell wall, allowing contact with a neighboring 
bacterium, thus allowing horizontal gene transfer of the plasmid (Cabezón et al., 2014). 
 
Several reports have demonstrated the in vivo transfer of antimicrobial resistance genes by 
plasmid conjugation in the gut of animals (Stecher et al., 2012; Card et al., 2017) and 
humans (Smith, 1969; Neuwirth et al., 2001; Goren et al., 2010; Mata et al., 2010; Naseer et 
al., 2012; Knudsen et al., 2018). The first demonstration of plasmid transfer between strains 
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in the human gut was demonstrated in an elegant experiment by Herbet William Smith who 
consumed bacterial cultures and then analysed serial faecal cultures, showing that in-vivo 
conjugation had occurred from a consumed E. coli strain, onto a pre-existing host E. coli 
(Smith, 1969). More recently, Knudsen and colleagues used WGS to show that horizontal 
transfer of a plasmid bearing blaCTX-M-1 occurs between different E. coli clones in the gut of a 
patient with cystic fibrosis (Knudsen et al., 2018). 
 
1.6 The domination of CTX-M 
1.6.1 Origin of CTX-M enzymes 
The commonest and most globally predominant of ESBLs are the CTX-M family of enzymes. 
Humeniuk and colleagues demonstrated that Kluyvera ascorbata,  associated with the 
rhizosphere, carries the chromosomal blaKLUA gene which confer resistance to 3GCs.The 
blaKLUA gene and the flanking regions are highly related to blaCTX-M enzymes and the flanking 
sequences carried on plasmids (Humeniuk et al., 2002). Each main cluster of CTX-M 
genotypes has a corresponding progenitor gene sharing homology with different Kluyvera 
spp. (Zhao and Hu, 2012).  
 
Chromosomal blaKLUA from K.ascorbata share 100% homology with plasmid mediated blaCTX-
M-2 (Di Conza et al. 2002). Similarly, CTX-M-14 originates from a chromosomal gene in K. 
georgiana (Olson et al., 2005) which also share close homology with CTX-M-8 (Poirel, Ka and 
Nordmann, 2002), and CTX-M-25 (Rodriguez et al., 2010). The CTX-M group 1 variant blaCTX-
M-3 originated from K. ascorbata (Rodríguez et al., 2004), whereas CTX-M-37 is derived from 
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K. cryocrescens (Decousser, Poirel and Nordmann, 2001). It is likely that the insertion 
sequence ISEcp1, frequently found upstream of blaCTX-M-14 (Kim et al., 2011) and blaCTX-M-15 
(Dhanji, Patel, et al., 2011) in human isolates of E.coli played a key role in the mobilisation of 
the progenitor ESBL genes from Kluyvera spp. (Humeniuk et al., 2002). 
 
CTX-M was first identified in  in Germany (Bauernfeind, Grimm and Schweighart, 1990), 
France (Bernard et al., 1992; Karim et al., 2001), and South America (Bauernfeind et al., 
1992) . They have become globally disseminated, with CTX-M-15 and CTX-M-14 being the 
predominant subtypes. CTX-M-15 is the most common ESBL in the UK and globally. The first 
description of this enzyme from multiple centres in India in the early 2000s, suggests that it 
originated from there (Ensor et al., 2006). CTX-M-14 is also globally distributed, especially in 
China and the surrounding regions, probably originating in China, being first described there 
in 1998 (Chanawong et al., 2002). 
 
The increasing prevalence of the CTX-M ESBLs since 2000 (Woerther et al., 2013), presents 
huge challenges to healthcare  with restricted options to treat infections caused by CTX-M-
producing bacteria.  This has  led to increased use of carbapenems, (Laxminarayan et al., 
2013),  leading to the emergence and spread of carbapenemase-producing 
Enterobacteriaceae (Hawkey, 2015). Developing countries with low levels of  sanitation, 
provide opportunities for the transfer of antimicrobial resistance (AMR) genes, including bla-
CTX-M, between humans, animals and the natural environment (Wellington et al., 2013; 
Pehrsson et al., 2016).  
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1.6.2 Global spread of CTX-M 
Since first being described, the global prevalence of CTX-M-producing Enterobacteriaceae 
has grown significantly (Woerther et al., 2013; Bevan, Jones and Hawkey, 2017). The spread 
and global dissemination is due to a combination of interlinked factors. These can be divided 
into two inter-linked categories: (1) Features of blaCTX-M which include the genetic context, 
the role of plasmids and E. coli clonal lineages; and (2) anthropogenic factors which include 
human travel, environmental pollution with human and animal waste, and antibiotic misuse 
in humans and animals. The transfer pathways for AMR genes, especially ESBLs, between, 
humans, animals, food and the environment are outlined in Figure 1.4. The global 
epidemiology and drivers for the geographical and temporal shifts in blaCTX-M genotypes is 






Figure 1.4 The spread of AMR bacteria can be attributed to a network of interactions between humans, 
animals, and the natural environment. Adapted from The Garrod Lecture, 2017 (Hawkey, 2018). 
  
This raises the question as to what impact this route has on
antimicrobial resistance in humans. As yet we do not have clear
data on these ecosystems and further research is needed.80
However, in a recent study, people exposed to bathing waters had
a higher rate of colonization with CTX-M-producing E. coli than con-
trols (6.3% versus 1.5%; risk ratio 4.09, P"0.05).83
Conclusions and future prospects
Antimicrobial resistance in Gram-negative bacilli is very similar to
climate change in that both are the result of human activity, both
have a global impact and it is likely that interventions will need to
be made on a massive scale without results becoming immediate-
ly apparent or even being certain of success.
The development of new antimicrobial agents has been the
mainstay of ensuring effective treatment of infections caused by
Enterobacteriaceae. The succession of agents described in this lec-
ture, from aminopenicillins to aminoglycosides, extended-spectrum
cephalosporins, carbapenems, polymyxins and now diaza-bicyclo-
octane b-lactamase inhibitors, is driven by the successive spread of
resistance to each class. The rate of emergence of resistance to an
agent is highly unpredictable and picking which gene(s) are going to
be successful is almost impossible. The rise of different carbapene-
mase genes following the widespread use of carbapenems to treat
infections caused by ESBL-producing Enterobacteriaceae is well
documented, with the KPC, NDM and OXA enzymes being most com-
mon currently.77 When carbapenems were first used it was the IMP
metallo-b-lactamases that were most common, particularly in
Japan. The first carbapenemase genotype to be described in China
was IMP-4 in a single isolate of Citrobacter in 199884 and would have
been expected to spread. Initially IMP-4 was absent from surveys of
Enterobacteriaceae for many years, before appearing in Australia in
2004 where it spread rapidly in different species and was associated
with different mobile elements to become the most important car-
bapenemase in Australia.85 Recently, WGS of the original plasmid
from China showed it to have a completely different evolutionary ori-
gin to those seen in Australia; an unexpected finding.86
The interventions that are likely to have an effect are not par-
ticularly novel but require implementation across the globe. The
disparity in the size of reservoirs of antimicrobial-resistant
Enterobacteriaceae is driven by high levels of human usage of anti-
biotics, so the implementation of good practice for treatment and
infection control recently published for the UK is to be com-
mended.67, 87 Translating those for use in other parts of the world
is difficult but not impossible. Action by highly influential countries
which is then scaled up has been suggested to be a feasible model
to achieve global action over antimicrobial resistance.88 The UK’s
actions through the G7 and other world fora, together with con-
tinuing leadership in this area, is very important. China has,
through national surveillance, shown that E. coli bacteraemia
caused by CTX-M-producing ESBLs has reached very high levels
(55% of those acquired in the community).89 There is a determin-
ation in government in China to address antimicrobial resistance.
A recent analysis has identified barriers such as perverse incentives
to prescribing (i.e. linking prescribing to income) as well as poor
prescribing practices.90 The review also suggested policy changes
which, if implemented, could greatly improve the situation.90
Possibly the biggest problem, and if solved the biggest opportunity
for success, is in dealing with the agricultural use of antibiotics.
Agricultural systems for food production, particularly in India and
China, have become industrialized and globalized, which at the
moment demands the extensive use of antibiotics. The rise of the
use of supermarkets globally as personal incomes rise91 has and
will continue to drive the increased rise in the industrial production
of food which will have to be addressed.
As molecular microbiologists we now have the tools to investi-
gate the multiple genetic events occurring in the gut that are
involved in the spread of antibiotic resistance. A recent study of the
transfer of blaCTX-M-1 in strains of E. coli in a patient receiving mul-
tiple antibiotics revealed a dramatic diversity of strain/plasmid
combinations.92 Clearly the relationship that bacteria have with
their resident R plasmids and they with their host bacterium is
unique and it was shown by a recent study that the fitness cost for
plasmid carriage varies according to the host bacterium.93
Antibiotics have been widely used in large amounts for the last
70 years, but we have witnessed a plethora of genes emerge to en-
code resistance to each new antibiotic active against the
Enterobacteriaceae. Moreover, the core plasmids carrying these
genes appear to be capable of evolving and staying at the forefront
of the selection battle. Indeed, the plasmid carried by a K. pneumo-
niae strain from China encoding blaCTX-M-14 originated from R100, a
plasmid identified in the 1960s.94
We have the tools at our disposal to understand the biology of
antimicrobial-resistant Enterobacteriaceae and have sufficient
knowledge of the interventions likely to reduce that resistance.
The only real question remaining is whether we have the political
will to act to sustain effective treatment for patients suffering from
infections due to this important group of bacteria.
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Figure 3. The resistome cycle-diagram outlining the transfer pathways
for antibiotic resistance genes/bacteria between humans, animals, food
and the environment.95














1.7 Global dissemination of ESBL-producing organisms via 
human travel  
 
A literature review of studies which assessed the ESBL-acquisition rate in returning travellers 
was carried out (Table 1.1). The first prospective traveller study of this kind was carried out 
by Kennedy and Collignon in 2008-2009 (Kennedy and Collignon, 2010). They recruited 102 
healthy volunteers in Australia, and found a 21.6% acquisition rate of ESBL- and AmpC 
producing E. coli, and a 57% acquisition rate for those who travelled to the Indian 
subcontinent (Kennedy and Collignon, 2010). 
 
Since the work of Kennedy and Collignon, there have been 21 travel studies, with the highest 
acquisition rates reported in studies which included travel to ‘South Asia,’ ‘the Indian 
subcontinent,’ or ‘India.’ The largest of these studies recruited 2001 healthy volunteers who 
travelled from The Netherlands to a variety of destinations, including 90 participants who 
visited India (Arcilla et al., 2017). Arcilla found an overall ESBL-Enterobacteriaceae 
acquisition rate of 34.3%, but this was 89% in those who travelled to India (70/79), and 75% 






Figure 1.5. Rates of acquisition of ESBL-producing Enterobacteriaceae by Dutch travellers. 
The highest rate of acquisition is in individuals who travel to South Asia (75%) 
 
 
Table 1.1. Traveller studies performed assessing the acquisition of ESBL-producing Enterobacteriaceae.  
  




































116 CAN South Asia: 
India (83%),  
Before and after (7 
days and 6 months) 
6 64 73 (66/90) CTX-M-15 21% going to South 















Before and after 
travel, 1,3,6,12 
months after 
6.1 34.3 89 (70/79) CTX-M-15 (G1) 
CTX-M-14 (G9) 


















After travel, 6 
months, 12 months 
N/A 72.1 72^ (69/96) Group 1 and 
Group 9 CTX-M 
28% (17/61) positive 
at 6 months 
India NA NA 




15 SWI India Before and after 
travel, 3 and 6 
months 
20 100 100 (15/15) CTX-M-15 (G1) 
CTX-M-14 (G9) 
40% (6/15) at 6 
months 








188 SWE South Asia, 
North Africa, 
Middle East 
Before and after 
travel 













445 NED Global Before and 2 weeks 
after travel 
6.1 23.4+ 55^ (27/49) CTX-M-15, CTX-
M-14 and CTX-M-
27 commonest 






2012 57 JAP Global Pre and post travel 14 44.9 55^ (6/11) CTX-M-15, CTX-
M-14 and CTX-M-
27 
NA NA NA NA 
(Bengtsson-









574 FRA Tropical 
regions only 
Before and after; up 
to 12 months post 
11.6 50.9% 85.4+ (53/62) Group 1 CTX-M 
Also one each of 
NDM-1, OXA-48, 
OXA-181 
2.2% after 12 
months; 3.7% for 










430 FIN Asia Middle 
East, Sub-
Saharan Africa 
Before and after 
travel 
1.2 21 45.9^ 28/61 CTX-M-15 (G1) 
CTX-M-14 (G9) 
 















Table 1.1 Continued.  
 
AUS, Australia; CAN, Canada; FIN, Finland; FRA, France; GER, Germany; JAP, Japan; NED, the Netherlands; SPA, Spain; SWE, Sweden; SWI, Switzerland. NA: not analysed. EPE: ESBL-producing Enterobacteriaceae. 
*Includes ESBL and AmpC enzymes. +includes CPE and AmpC. ^Indian subcontinent. MCROne CTX-M-EC strain also carried mcr-1, presumed acquisition after travel to Thailand





































205 GER Global Before and after 
travel 
6.8 30.4 73.3 (11/15) CTX-M-15 
predominated 
8.6% (3/35) positve 
at 6 months 










After travel only NA 31.4 NA CTX-M-15 CTX-
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(von 
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et al., 2014) 
2010-
2012 
122 NED Southeast Asia, 
South Asia 
Before and after 
travel 
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(Weisenberg 
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101 SWE Global Before and after 
travel 
1 24 88 (7/8) CTX-M-15 24% at 6 months 
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NA India or Egypt, 
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1.7.1 Risk factors for acquisition of ESBL-producing Enterobacteriaceae 
The most widely reported risk factor which is strongly associated with ESBL acquisition in 
returning travellers is, visiting India, (Tham et al., 2010; Kuenzli et al., 2014; von Wintersdorff 
et al., 2014; Yaita et al., 2014; Lübbert et al., 2015; Barreto Miranda et al., 2016; Peirano et 
al., 2017) ‘Indian subcontinent,’ (Tängdén et al., 2010; Ostholm-Balkhed et al., 2013; Vading 
et al., 2016) or ‘South Asia’ (Paltansing et al., 2013; Angelin et al., 2015; Kantele et al., 2015). 
This particular association with ESBL-acquisition and travel to India and the surrounding 
region can be explained by high population density, increased human travel, and 
contamination of drinking water supplies with faecal waste (Bevan, Jones and Hawkey, 2017) 
(see section 1.5.6 in this thesis). 
 
The mode of acquisition of Enterobacteriaceae is likely to be through drinking contaminated 
food and water, therefore a number of studies have considered the dietary habits of 
travellers in risk factor analyses. Specific risk factors which were significantly associated with 
acquisition were consuming meals with locals (Peirano et al., 2017), consuming street food 
(Arcilla et al., 2017), or eating ice cream/pastries (Kuenzli et al., 2014). 
 
Antibiotic use during travel has also been found to be a risk factor for acquisition of ESBL-
producing bacteria (Kennedy and Collignon, 2010; Kantele et al., 2015; Ruppé et al., 2015; E. 
A. Reuland et al., 2016; Vading et al., 2016; Arcilla et al., 2017; Peirano et al., 2017). 
Fluoroquinolone consumption was also found to be an independent risk factor for 
acquisition (Arcilla et al., 2017). It is not surprising that antibiotic use is a risk factor for 
acquisition, as this would result in (1) direct selection of ESBL-producing bacteria; and (2) 
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disruption of the normal faecal microbiome, allowing colonization of new strains. The 
association of fluoroquinolone use and acquisition of ESBL-producers, points towards a 
mechanism of co-selection, where resistance genes to fluoroquinolones are present on MDR 
cassettes which also include ESBL genes.  
 
Diarrhea during travel, which is also related to the disruption of the normal faecal flora, has 
also been found to be a risk factor for ESBL-acquisition (Ostholm-Balkhed et al., 2013; Ruppé 
et al., 2015; Vading et al., 2016; Arcilla et al., 2017). Travellers with pre-existing 
gastrointestinal disorders were also more likely to acquire ESBL-producers (Kennedy and 
Collignon, 2010; Lübbert et al., 2015; E. A. Reuland et al., 2016). Therefore, host gut 
inflammation in travellers with an underlying condition, such as inflammatory bowel disease, 
probably results in higher rates of colonization with travel-acquired bacteria.  
 
Travellers diarrhea is usually caused by bacterial, parasites or viruses, and is usually self-
limiting. However, the resulting acute gut inflammation is likely to explain why diarrhea is a 
risk factor for acquisition. A hypothesis follows that a ‘more inflamed’ gut, is more 
susceptible to colonization. In a mouse colitis model, gut inflammation was associated with 
Enterobacterial blooms and increased tendency for HGT (Stecher et al., 2012), although 
murine gut flora is not representative of the human faecal microbiome. A human 
metagenomic study of the post-travel faeces of 35 Swedish travellers found that travel 
results in a spike in abundance of the phylum Proteobacteria (which includes the 
Enterobacteriales), (Bengtsson-Palme et al., 2015). Increased abundance of clinically 
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relevant Enterobacteriales in the gut may then provide greater opportunities for resistance 
gene or strain acquisition.  
 
1.7.2 Duration of carriage of ESBL-producers 
The post-travel duration of carriage was determined in a number of studies (Table 1.1) 
(Kennedy and Collignon, 2010; Tängdén et al., 2010; Paltansing et al., 2013; Kantele et al., 
2015; Lübbert et al., 2015; Ruppé et al., 2015; Barreto Miranda et al., 2016; Pires et al., 
2016; Arcilla et al., 2017; Peirano et al., 2017). The longest period of follow-up was 12 
months. Colonization rates at the 12 month post-travel time point varied considerably 
between studies, with rates of 0% (Kantele et al., 2015); 2.2% (Ruppé et al., 2015); and 
11.3% (Arcilla et al., 2017).  
 
Colonisation rates are variable between studies, which reflects differing host microbiome 
factors, as well as the differing ability of strains to colonise the faecal microbiome, which is 
defined as the microbial content of a faecal sample. Travel to Asia was associated with 
significantly longer carriage duration (p= <0.001) at 12 months post-travel compared with 
travel to other regions (Ruppé et al., 2015). Therefore, it seems likely that regions associated 
with high ESBL acquisition rates such as India, are also associated with a longer duration of 
ESBL-strain carriage, compared to other regions. It is logical that strains that are easily 
acquired by travellers in these ‘high risk’ regions are also good at long term colonisation of 
the faecal microbiome.  
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1.7.3 Onward transmission after travel 
Two studies have investigated whether ESBL-producing organisms can be passed to ESBL-
negative household members post-travel (Paltansing et al., 2013; Arcilla et al., 2017).  
 
However, only one study showed that onward transmission to close contacts does occur 
(Arcilla et al., 2017). The lack of research in this area may be due to the more complex study 
design, high sample size requirement, and more detailed ethical considerations in 
broadening the numbers of people screened for ESBL-producing organisms. Arcilla et al 
found that 168 ESBL-negative co-habitants of ESBL-positive travellers were ‘at-risk’ of ESBL-
acquisition. The acquisition rate was found to be 7.7% (13/168), and the risk of onward 
transmission to a household member was calculated to be 12% (Arcilla et al., 2017). 
 
There are a number of limitations to the aforementioned onward transmission data (Arcilla 
et al., 2017). Firstly, no typing of ESBL-producers was carried out, e.g. MLST or WGS os 
isolates. Only ESBL-PCRs including CTX-M grouping PCRs were carried out, which confirmed 
that acquired strains by householders had the same bla genotype, as the corresponding 
ESBL-positive traveller (Arcilla et al., 2017). Proving onward transmission would require SNP 
typing of Enterobacterial strains to demonstrate person-to-person transfer. Secondly, there 
is likely to be a degree of bias in that returning travellers and their household contacts would 
be ‘unblinded’ and fully aware of the possibility of ESBL-strain acquisition. Therefore, entry 
into the study is likely to have had an effect on the hand-washing habits of participants, 
leading to a potential underestimate of ‘real-life’ transmission rates in the home after travel.  
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The importance of onward transmission of ESBL-producing strains depends on the baseline 
ESBL-prevalence in the country under question. In the Netherlands, the baseline community 
prevalence of ESBL/AmpC-producing Enterobacteriaceae is 5.2% (Teunis et al., 2018), and in 
the UK, CTX-M-EC community carriage is 7.3% (McNulty et al., 2018). However, when one 
considers urban cosmopolitan areas in the UK, such as central Birmingham, the rate of CTX-
M-EC colonisation is 16%. The reason behind such a high rate in a UK city, compared to the 
UK as a whole, is likely due to the high rates of travel between Birmingham and South Asia 
(McNulty et al., 2018). 
 
1.7.4 Acquisition of carbapenemase-producing Enterobacteriaceae and mcr-1-
producers 
Carbapenems and colistin, are last resort antibiotics used for the treatment of MDR-gram 
negative infections, and have been put on the ‘reserve’ antibiotic list by the WHO (WHO, 
2015). Therefore, research into the global spread and epidemiology of carbapenemase-
producing Enterobacteriaceae (CPE) and mcr-1 producing bacteria, is of critical importance. 
CPE and mcr-1 do not fall into the category of ESBLs and are not the focus of this thesis. 
However, the increase in worldwide prevalence of ESBL-producing Enterobacteriaceae drives 
the prescription of carbapenems and colistin, which in turn propagates CPE and mcr-1 
(Bevan, Jones and Hawkey, 2017). 
 
Acquisition of CPE by travellers is much less frequent than acquisition of ESBL producers 
(Arcilla et al., 2017). As part of the COMBAT study (Arcilla et al., 2017), Hattem and 
colleagues described a CPE travel-related acquisition rate of 0.3% (6/2001), which included 
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blaIMI-2, blaNDM-1, blaOXA-244 and blaOXA-48 (Hattem et al., 2016). These CPE acquisitions were in 
travellers who did not have any healthcare exposure during their excursions (Hattem et al., 
2016). The same research group found that 0.9% of CTX-M-EC isolates (6/633 isolates 
screened) also possessed the plasmid-mediated mcr-1 gene (Arcilla et al., 2015). 
 
The importance of onward transmission for CPE has been demonstrated by Nordmann et al, 
who showed that outbreaks of NDM-1-producing isolates in Western Europe and North 
America can be traced back to the Indian subcontinent (Nordmann et al., 2011; Nordmann, 
Naas and Poirel, 2011). Episodes of infections with NDM-1-producers in the UK are mostly 
related to patient-repatriations from overseas hospitals with high rates of CPE (Public Health 
England, 2013). Due to the low rates of acquisition by travellers, formal screening of patients 
with a recent travel history, without hospitalization abroad, is not routinely carried out.  
 
1.7.5 Molecular analysis of travel-acquired strains 
A limited number of traveller studies carried out bacterial strain typing and plasmid analysis. 
PCR-based multilocus sequence typing (MLST) of selected isolates was reported in a limited 
number of studies (Weisenberg et al., 2012; Paltansing et al., 2013; Valverde et al., 2015; 
Pires et al., 2016), while one study used phylogenetic grouping PCR only (Vading et al., 
2016). PCR plasmid replicon typing was also performed in a few traveller studies (Tham et 
al., 2010; Kuenzli et al., 2014; Pires et al., 2016). 
 
No previous traveller studies could be identified where whole genome sequencing of isolates 
pre- or post-travel had been carried out. WGS in necessary to answer several important 
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questions relating to the dynamics of acquisition of CTX-M-EC: (1) Is the CTX-M plasmid 
transferred onto a pre-travel commensal E. coli strain? (2) How many E. coli clones do 
travellers acquire? (3) Do CTX-M-EC completely displace pre-travel commensal E. coli? (4) 
What are the characteristics of the plasmids carrying CTX-M in post travel E. coli? 
 
 This thesis will address these questions, providing a unique insight into the mechanism and 






Epidemiology of CTX-M beta-lactamases: temporal and geographical shifts in genotype 
(CHAPTER 2) 
1. Plasmids play a key role in the dissemination of blaCTX genotypes. Epidemic plasmids are 
responsible for the horizontal gene transfer of blaCTX-M genes.  
2. Internationally successful E. coli clonal lineages have also led to the global dissemination 
of particular blaCTX-M genotypes 
3. A number of anthropogenic factors drive the spread of CTX-M-producing 
Enterobacteriaceae. These factors can be subdivided:  
a. The role of food animals carrying CTX-M determinants and the overuse of 
antibiotics in food animals 
b. Poor sanitation in the developing world leads to the contamination of the 
environment and drinking water supply with human faecal waste 
c. The natural environment which contains human and animal strains of 
Enterobacteriaceae, acts as a reservoir of blaCTX-M genes, and provides the 
opportunity for the emergence of novel genotypes. 
 
Traveller Study Volunteer recruitment, demographics, and acquisition of CTX-M-EC 
(CHAPTER 3) 
1. The rate of acquisition of CTX-M-EC will be similar to previous studies with volunteers 
travelling from developed countries to South Asia.  
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2. Risk factors known to be associated with CTX-M-EC acquisition will be identified from the 
post-travel questionnaires completed by volunteers.  
 
The molecular dynamics of acquisition of ctx-m-producing E. coli and relationship to 
sensitive E. coli (CHAPTER 4) 
1. Acquisition of CTX-M-E. coli is due to multiple acquisition events which leads to 
colonisation with multiple E. coli clones after travel 
2. CTX-M-EC are maintained in the faecal microbiome after return to the UK 
3. CTX-M-EC do not displace non-CTX-M E. coli which were present before travel 
4. Non-CTX-M strains persist as a minority population in the faecal microbiome, despite 
CTX-M-EC acquisition 
5. CTX-M-EC are usually multi-drug resistant 
 
Plasmid identification and analysis (CHAPTER 5) 
1. The blaCTX-M genes from the CTX-M-EC colonising the faecal microbiome in returning 
travellers are primarily plasmid mediated, rather than chromosomal in origin; 
2. Travel acquired blaCTX-M-containing plasmids are more closely related to plasmids 
previously identified from South Asia, than to plasmids of UK-origin; 
3. The genetic context of blaCTX-M will be reflective of non-UK-type genetic contexts; 
4. The ISECp1-CTX-M spacer sequence will vary according to region of origin of the CTX-M-
EC isolate; 
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5. The CTX-M-bearing plasmids in post travel E. coli strains will be transferrable by 
conjugation.  
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Chapter 2: Epidemiology of CTX-M beta-lactamases: 
temporal and geographical shifts in genotype 
 
2.1 Introduction 
Extended spectrum beta lactamases (ESBLs) hydrolyse the beta lactam ring of penicillins and 
third-generation cephalosporins (3GC) and are mainly found in Enterobacteriaceae, 
especially in E. coli.  E. coli are part of the normal bowel flora in humans, but can also be 
pathogenic, causing urinary tract infections and bloodstream infections (Davies, 2013). 
 
The largest group of ESBLs are CTX-M, first identified in Germany, (Bauernfeind, Grimm and 
Schweighart, 1990) France, (Bernard et al., 1992) and South America (Bauernfeind et al., 
1992). They have become globally disseminated, with CTX-M-15 and CTX-M-14 being the 
predominant genotypes. CTX-M ESBLs have increased in prevalence since 2000, (Woerther 
et al., 2013) and this presents huge challenges to healthcare,  with restricted options to treat 
infections caused by CTX-M-producing bacteria.  This has  led to increased use of 
carbapenems, (Laxminarayan et al., 2013) leading to the emergence and spread of 
carbapenemase-producing Enterobacteriaceae (Hawkey, 2015). Developing countries with 
low levels of  sanitation provide opportunities for the transfer of antimicrobial resistance 
(AMR) genes in Enterobacteriaceae, including blaCTX-M, between humans, animals and the 
natural environment (Wellington et al., 2013; Pehrsson et al., 2016). 
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Understanding the global epidemiology of ESBL-producing bacteria is essential if outbreaks 
of strains with novel ESBL genotypes are to be detected early and controlled. Although 
reviews of CTX-M-producing Enterobacteriaceae have been published in the past (Cantón 
and Coque, 2006; Hawkey and Jones, 2009; Zhao and Hu, 2012), no studies were identified 
describing the temporal trends in blaCTX-M epidemiology. Therefore, a fresh analysis of the 
literature in this area was undertaken, with identification of the key drivers leading to the 
change in global CTX-M epidemiology. 
 
2.2 Hypotheses 
1. Plasmids play a key role in the dissemination of blaCTX-M genes. Epidemic plasmids are 
responsible for the horizontal gene transfer of blaCTX-M genes. 
2. Internationally successful E. coli clonal lineages have also led to the global dissemination 
of blaCTX-M  
3. A number of anthropogenic factors drive the spread of CTX-M-producing 
Enterobacteriaceae. These factors can be subdivided: 
a. The role of food animals carrying CTX-M determinants and the overuse of 
antibiotics in food animals 
b. Poor sanitation in the developing world leads to the contamination of the 
environment and drinking water supply with human faecal waste 
c. The natural environment which contains human and animal strains of 
Enterobacteriaceae, acts as a reservoir of blaCTX-M genes, and provides the 
opportunity for the emergence of novel genotypes. 
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2.3 Methods 
2.3.1 Search strategy and selection criteria 
The NCBI PubMed database was searched without restrictions using the following terms: 
“CTX-M” and “extended spectrum beta lactamase (ESBL)” plus “Europe,” “North America,” 
“South America,” “Africa,” “Australasia,” “Asia,” or “South East Asia,” as well as individual 
country names. These searches generated 2735 papers. Article inclusion criteria: (1) human 
Enterobacteriaceae isolates from community or hospital origin: these were from studies 
reporting infecting strains or from faecal carriage studies; (2) isolates must have been 
identified using suitable screening media; (3) collection dates and location of sampling; (4) 
blaCTX-M genotyping or multiplex PCR grouping data must be provided. Articles were 
screened by reading abstracts. Using the inclusion criteria, we identified 220 English articles 
for review, which were also checked for additional references not captured in original 
searches.  
 
2.3.2 Assessing changing trends in CTX-M-producers over time 
Based on published epidemiological data, and to allow a meaningful display of temporal 
changes in blaCTX-M epidemiology, three time periods were chosen: pre-2005; 2005-2008; 
and 2009-present. This allows a straightforward visual comparison of blaCTX-M genotypes 
between time periods. As well as assessing the changing trends in human isolates, a sub-
analysis considered trends in animal isolates from China using the same time periods.  
Linear regression plots for the frequency of ESBL faecal carriage over time were plotted for 
each WHO region (Figure 2.1) and for developing countries (Figure 2.2).  
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2.3.3 Investigating relationship between ESBL prevalence and access to basic 
sanitation 
Data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) 2008-2009 
(Hawser et al., 2010, 2012; Chen et al., 2011), and WHO data on ‘access to improved 
sanitation facilities during the same time period’ (WHO, 2016), was used to assess the 
relationship between ESBL prevalence and sanitation access. Improved sanitation facilities 
are defined as access to a functioning latrine (WHO, 2016). 
 
2.4 Results 
2.4.1 Trends in global blaCTX-M epidemiology 
ESBL prevalence increased in all WHO geographical regions, but these upward trends are 
only statistically significant for Europe (R2= 0.429, p=0.04) (Figure 2.1). A linear regression 
analysis was of global community ESBL rates over time was undertaken which showed a 
statistically significant rise in community ESBL rates (R2= 0.22, p<0.005), supporting previous  
analyses (Woerther et al., 2013; Karanika et al., 2016). In particular, there is a strong upward 
trend in ESBL rates when this analysis is undertaken for developing countries only (R2=0.814, 
p=0.0004, Figure 2.2).  
 
The global picture of CTX-M variants is a complex one, but it is clear that the proportion of 
blaCTX-M-15 has increased over time in most countries and is dominant in most regions (Figure 
2.3). Exceptions are China, South East Asia, South Korea, Japan and Spain, where group 9 
 41 
variants (especially CTX-M-14) are dominant, and South America, where blaCTX-M-2 is still an 





Figure 2.1 Prevalence rate (%) of community faecal ESBL carriage by World Health Organisation (WHO) 
region. Where there was >1 study per year within a region, the ESBL frequency and denominator values were 
added for that year, producing one data point (%) per year for each region. Europe was the only region 





Figure 2.2 Prevalence (%) community faecal ESBL carriage for developing countries only. (Developing 
countries here are defined as all countries excluding North America and WHO region: Europe). Each data point 
is the mean of global community faecal carriage rates for that year for developing countries. Large circles: 










of interlinked factors as explanations for these global changes: (i)
plasmids and horizontal gene transfer (HGT); (ii) successful E. coli
clones; (iii) food animals; (iv) the natural environment; and (v)
human migration and access to basic sanitation.
Methods
Search strategy and selection criteria
We searched the NCBI PubMed database without restrictions using the fol-
lowing search terms: ‘CTX-M’ and ‘extended spectrum beta lactamase
(ESBL)’ plus ‘Europe’, ‘North America’, ‘South America’, ‘Africa’, ‘Australasia’,
‘Asia’ or ‘South East Asia’, as well as individual country names. These
searches generated 2735 papers. Article inclusion criteria were as follows:
(i) human Enterobacteriaceae isolates from community or hospital origin,
from studies reporting infecting strains or from faecal carriage studies; (ii)
isolates must have been identified using suitable screening media; (iii) col-
lection dates and location of sampling; and (iv) blaCTX-M genotyping or
multiplex PCR grouping data had to be provided. Articles were screened by
reading abstracts. Using the inclusion criteria we identified 220 English art-
icles for review, which were also checked for additional references not cap-














































Figure 1 (a, b, c) CTX-M trends over three time periods for Europe (data include both hospital and community isolates). An asterisk indicates that, for
these areas, only CTX-M grouping was done and these were not subdivided into genotypes. Note: many countries have no published data for certain
time periods. Colour shades represent CTX-M groups: red, group 1; blue, group 9. (d, e, f) CTX-M trends over three time periods for the rest of the world
(data include both hospital and community isolates). An asterisk indicates that, for these areas, only CTX-M grouping was done and these were not
subdivided into genotypes. Note: many countries have no published data for certain time periods. South-East (SE) Asia includes Cambodia, Indonesia,
Malaysia, The Philippines, Taiwan and Vietnam. Gulf States include Kuwait, Saudi Arabia and United Arab Emirates. Data for Australia and New
Zealand are combined. GB!, Guinea-Bissau. Colour shades represent CTX-M groups: red, group 1; green, group 2; orange, group 8/25; blue, group 9.
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Figure 2.3 a,b,c  CTX-M trends over 3 time periods for Europe; (data include 
both hospital and community isolates). 
*indicates that f r these areas, only CTX-M grouping was done, and these 
were not subdivided into genotypes. Note: man  countrie  have no published 
data for certain time periods. C lour shades represent CTX-M groups: red, 













of interlinked factors as explanations for these global changes: (i)
plasmids and horizontal gene transfer (HGT); (ii) successful E. coli
clones; (iii) food animals; (iv) the natural environment; and (v)
human migration and access to basic sanitation.
Methods
Search strategy and selection criteria
We searched the NCBI PubMed database without restrictions using the fol-
lowing search terms: ‘CTX-M’ and ‘extended spectrum beta lactamase
(ESBL)’ plus ‘Europe’, ‘North America’, ‘South America’, ‘Africa’, ‘Australasia’,
‘Asia’ or ‘South East Asia’, as well as individual country names. These
searches generated 2735 papers. Article inclusion criteria were as follows:
(i) human Enterobacteriaceae isolates from community or hospital origin,
from studies reporting infecting strains or from faecal carriage studies; (ii)
isolates must have been identified using suitable screening media; (iii) col-
lection dates and location of sampling; and (iv) blaCTX-M genotyping or
multiplex PCR grouping data had to be provided. Articles were screened by
reading abstracts. Using the inclusion criteria we identified 220 English art-
icles for review, which were also checked for additional references not cap-














































Figure 1 (a, b, c) CTX-M trends over three time periods for Europe (data include both hospital and community isolates). An asterisk indicates that, for
these areas, only CTX-M grouping was done and these were not subdivided into genotypes. Note: many countries have no published data for certain
time periods. Colour shades represent CTX-M groups: red, group 1; blue, group 9. (d, e, f) CTX-M trends over three time periods for the rest of the world
(data include both hospital and community isolates). An asterisk indicates that, for these areas, only CTX-M grouping was done and these were not
subdivided into genotypes. Note: many countries have no published data for certain time periods. South-East (SE) Asia includes Cambodia, Indonesia,
Malaysia, The Philippines, Taiwan and Vietnam. Gulf States include Kuwait, Saudi Arabia and United Arab Emirates. Data for Australia and New
Zealand are combined. GB!, Guinea-Bissau. Colour shades represent CTX-M groups: red, group 1; green, group 2; orange, group 8/25; blue, group 9.
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Figure 2.3 d,e,f. CTX-M trends over 3 time periods for rest of the world. (data include 
both hospital and c mmunity isolates). *i dicates that for these areas, only CTX-M 
grouping was done, and these were not subdivided into ge otypes. South-Eas  (SE) Asia 
includes Cambodia, Indonesia, Malaysia, The Philippin s, Ta wan and Vi tnam. Gulf States 
include Kuwait, Saudi Arabia and United Arab Emirates. Data for Australia and New 
Zealand are combined. GB, Guinea-Bissau. Colour shades represent CTX-M groups: red, 
group 1; green, group 2; orange, group 8/25; blue, group 9.  
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2.4.2 Diversity of blaCTX-M genotypes in food-animal isolates in China 
Due to the plethora of data on blaCTX-M genotypes from food animal-derived E. coli in China 
(Ma et al., 2012; Rao et al., 2014; Xia et al., 2014; S. Li et al., 2015), this country has been 
used as an example of the trends in blaCTX-M genotypes in  food animals (Figure 2.4). The 
trend over time is an early complete dominance of group 9 blaCTX-M genotypes, especially 
blaCTX-M-14 (Figure 2.4). Since 2009, the rise of group 1 blaCTX-M has occurred, especially blaCTX-
M-55 which has begun to replace group 9 enzymes (Figure 2.4). 
 
2.4.3 Sanitation  
The relationship between access to improved sanitation facilities and ESBL community 
carriage by country was determined (Figure 2.5).  A linear regression analysis showed a 
modest but significant association between ESBL carriage and access to basic sanitation with 






Figure 2.4 Epidemiology of blaCTX-M in isolates from food animals in China. Genotypes are superimposed on 















































Figure 2.5 Access to basic sanitation and ESBL prevalence. Sanitation access is access to improved sanitation 










countries. However, the poor standards of sanitation and the con-
tamination of drinking water supplies in the developing world
allow increased cycling of CTX-M-producing E. coli between
humans and the environment.7 This explains our finding of a sig-
nificant upward trend in ESBL community carriage rates in de-
veloping countries (Figure S2), notably in India, where ESBL
carriage rates are amongst the highest in the world.111 Moreover,
the environmental–human exchange of AMR genes is highly rele-
vant to the spread of other faecally carried genes, such as mcr-1
and blaNDM-1.
112
The presence of resistance genes in an environment is closely
related to anthropogenic activities. For example, the prevalence of
class I integrons carrying resistance genes in sewage sludge,
pig slurry and textile mill effluent is significantly higher than
levels found in undisturbed soil. The common practice of using ani-
mal manure as fertilizer creates opportunities for species of
Enterobacteriaceae to capture resistance genes on mobile genetic
elements from soil bacteria.9 More recently, a metagenomic ap-
proach was used to assess the AMR gene content across human,
environmental and animal microbiomes in two developing regions
in South America, and showed that mobile genetic elements
played a significant role in the transfer of ESBLs between different
resistomes.8
Environmental contamination with fluoroquinolones is espe-
cially worrisome, as these drugs are known to persist in rivers and
soil, and have the ability to select bacteria bearing class I integrons
which carry resistance cassettes, including qnr genes and blaCTX-M
genes.9 In India, high levels of ciprofloxacin in the waste water
effluents of pharmaceutical factories and in nearby sources of
drinking water is a serious issue which is likely to be a contributory
factor in the emergence and spread of blaCTX-M in human popula-
tions and in the environment.113
ESBL rates, migration and access to
basic sanitation
There is increasing community prevalence of ESBL-producing
Enterobacteriaceae worldwide (Figure S1), especially CTX-M-15,
which is reflected by much higher faecal carriage rates in Asia
compared with Europe and North America.5 Individuals with ethnic
origins in the Middle East or South Asia (MESA) who reside in
Europe have significantly higher carriage rates of CTX-M-15-
producing E. coli compared with indigenous Europeans, which is
likely to be due to the high frequency of travel by MESA people to
these areas.114 Prospective cohort studies have shown that travel-
lers from Western countries visiting countries with a high preva-
lence of ESBLs become asymptomatic carriers: 75% of those
travelling to Southern Asia acquired ESBL-producing bacteria.115
Access to improved sanitation facilities, as defined by WHO/
UNICEF, is a key indicator of social and economic development,
and is important in reducing the spread of diarrhoeal diseases.116
We hypothesize that such access is also critical to controlling the
spread of ESBLs. This has been identified by the O’Neill report as a
key intervention in controlling resistance.117
Figure 2 shows access to improved sanitation facilities and ESBL

































































Figure 2. Sanitation access and ESBL prevalence. Sanitation access is access to improved sanitation facilities, 2008–09, as defined by WHO/UNICEF
(data.worldbank.org/indicator/SH.STA.ACSN). ESBL prevalence is for 2008–09 and is derived from SMART study data.111,147,148 This figure appears in
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2.5 Discussion 
The investigation of ESBL global epidemiology outlined in this chapter has focussed on the 
temporal and regional changes in blaCTX-M (figure 2.3). Several interlinked factors can be used 
to account for these global changes: (1) plasmids and horizontal gene transfer; (2) successful 
E. coli clones; (3) Food animals; (4) The natural environment; (5) Human migration, and (6) 
access to basic sanitation. 
 
2.5.1 The role of epidemic plasmids and other mobile genetic elements 
The role of a plasmid in the mobilisation of a beta-lactam gene was first described in relation 
to transfer of multiple drug resistance phenotypes between E. coli and Shigella spp. by a 
Japanese research group (Watanabe and Fukasawa, 1961). The first beta-lactamase in E. coli 
was identified from the blood culture of a Greek patient named Temoneira, hence the 
enzyme was named TEM, which was transferrable via plasmid conjugation (Datta and 
Richmond, 1966). 
 
The horizontal transfer of blaCTX-M genes on conjugative plasmids is fundamental to their 
evolution and global spread (Carattoli, 2013). Plasmids in Enterobacteriaceae tend to be well 
adapted to their host, often encoding plasmid addiction systems such as post segregational 
killing systems, which promote plasmid maintenance in progeny, even in the absence of 
antibiotic selective pressure (Carattoli, 2009). This helps to explain increased community 
ESBL carriage globally (figure 2.1). Furthermore, indistinguishable plasmids found across 
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different strains in Enterobacteriaceae are referred to as “epidemic plasmids” (Carattoli, 
2009) (see Chapter 5). 
 
In addition to the role of plasmids, other mobile genetic elements, such as insertion 
sequences, transposons, and integrons, play a large part in the dissemination of bacterial 
resistance genes, including blaCTX-M genes (Toleman and Walsh, 2011). The role of plasmids 
and these other mobile genetic elements in blaCTX-M dissemination, will be outlined in detail 
later in this thesis (Chapter 5). 
 
2.5.2 The role of E. coli clonal lineage ST131  
The clonal spread of virulent strains such as uropathogenic E.coli B2,025:H4-ST131, which 
commonly carries  blaCTX-M-15, play an important role in the global dissemination of these 
genes (Nicolas-Chanoine et al. 2014, Woodford et al. 2011). The most widespread ST131 
sub-clone is H30-Rx, which has a propensity for carriage of blaCTX-M-15 (Price, Johnson and 
Aziz, 2013).    
 
Worldwide surveys in 2008 led to the discovery of the international ESBL E.coli clone ST131 
which belongs to phylogenetic group B2, serotype O25b:H4 (Coque et al., 2008; Nicolas-
Chanoine et al., 2008). ST131 has been found mostly in human E.coli isolates, but also in 
animals (Platell et al., 2011) and the environment (Zurfluh et al., 2013; Amos et al., 2014). 
Successful in Western Europe and North America (Banerjee and Johnson, 2014), ST31 has 
only been found occasionally in India (Hussain et al., 2012; Roy et al., 2015), and China 
(Zhong et al. 2015; Wang et al. 2016; Xia et al. 2014). The most common blaCTX-M genotype in 
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most regions of the world is blaCTX-M-15 (Figure 2.3), and it is reasonable to suggest that most 
of the CTX-M-15-producing E. coli isolates in the world are ST131, however there is a notable 
lack of MLST data to support this claim, especially in developing countries.  
 
Due to its relatively low prevalence in non-human isolates, ST131 probably originated from 
human sources (Banerjee and Johnson, 2014). The most common ST31 lineage, H30,  has 
acquired fluoroquinolone resistance, followed by blaCTX-M-15 acquisition on a plasmid; both 
are associated with the sub-lineage H30Rx (Price, Johnson and Aziz, 2013). Recent sequence 
analysis of global ST131 isolates suggests that H30Rx originated in North America  around  
1991 (Stoesser, et al 2016). The capture of fluoroquinolone resistance and blaCTX-M-15 by 
ST131 was a highly evolutionarily advantageous event given the high rates of use of 
fluoroquinolones and cephalosporins in the USA at this time (Stoesser, et al 2016). It seems 
likely that human carriage of blaCTX-M-15 and blaCTX-M-14 to North America from India and China 
respectively occurred, then leading to the capture of these genotypes by ST131 (onto pre-
existing plasmids in ST131 strains, via IS26-mediated transposition as discussed above), and 
clonal dissemination thereafter. Presumably the spread of ST131 E. coli out of North America 
was a later event. However, it must be noted that this hypothesis is based on the 
assumption that because blaCTX-M-14 and blaCTX-M-15 were first described in China and India 
respectively, that these countries were also the origin of these variants.  
 
Importation of the successful H30Rx sub-clone via human migration has probably led to the 
dominance of ST131 E.coli with blaCTX-M-15 in many regions of the world such as Canada 
(Pitout et al., 2009; Peirano et al., 2012), Japan (Osawa et al., 2015), Israel (Karfunkel et al., 
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2013), and there is evidence of worldwide dissemination of H30Rx including in India and 
China (Peirano et al., 2014). Human migration is likely to be the cause of the worldwide 
dissemination of ST131 and has probably led to the displacement of existing genotypes with 
blaCTX-M-15 in other regions, especially South America, and much of Western Europe (figure 
2.3). ST131 is also known to carry bla-CTX-M variants from all four main CTX-M groups, and 
notably is associated with blaCTX-M-14 (particularly in Canada, China, Japan and Spain) 
(Nicolas-Chanoine, Bertrand and Madec, 2014). 
 
The E.coli ST131 clonal group is associated with a host of specific virulence genes which, 
combined with antimicrobial resistance genes has made this a uniquely successful extra-
intestinal pathogenic E.coli (ExPEC) strain (Johnson et al., 2010).  
 
2.5.3 Role of food animals in the spread of blaCTX-M 
The use of antimicrobials in food animals provides selective pressure for the propagation of 
AMR bacteria in animals which are often relevant human pathogens (Robinson et al., 2016). 
Variants of blaCTX-M often colonise the gut in farmed birds, mammals (Stokes et al., 2012; 
Zheng et al., 2012), as well as raw meat for human consumption (Doi et al., 2010; 
Overdevest et al., 2011).  
 
There is evidence for the transmission of ESBL-producing E.coli between animals and 
humans, (de Been et al., 2014; Lazarus et al., 2015), and data from the UK suggests animal 
E.coli strains probably acquired the bla-CTX-M plasmid from human strains (Hunter et al., 
2010). A systematic review showed that there is a role for both bacterial clonal transmission 
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and horizontal gene transfer of ESBL and ampC genes between human and food animal 
reservoirs. Transmission of ESBL-producers between poultry sources and human sources 
appears to be more common than transmission from other food animals (Lazarus et al., 
2015). 
 
Epidemic plasmid spread among animal and human E.coli strains has been found in The 
Netherlands (de Been et al., 2014), China (Ho et al., 2012) and in the UK (Stokes et al., 2012).  
In The Netherlands, horizontal gene transfer between human and animal strains appears to 
have a greater role than the clonal spread of E. coli strains between these niches. Assembled 
plasmids in genetically diverse human and animal strains had almost identical plasmid 
backbones  (de Been et al., 2014). Moreover, further evidence suggesting the role of plasmid 
spread between human and animal strains comes from Bolivia, where two plasmids from 
Klebsiella pneumoniae encoding blaCTX-M-65 (a rare genotype in South America), isolated from 
clinical samples, were found to be almost identical to the E.coli plasmid pHN7A8 (Sennati et 
al., 2016), which had previously been isolated from a dog in China in 2008 (He et al., 2013).  
 
The potential spread of blaCTX-M between animals and humans via the food chain 
(Overdevest et al., 2011; de Been et al., 2014), through animal handling (Nakane, Kawamura 
and Goto, 2016), and from animals to the environment (Ma et al., 2012; S. Li et al., 2015) is 
made worse  by the high prevalence of unregulated wet food markets in the developing 
world, for example in China (P. L. Ho et al., 2011). This microbial habitat, combined with 
heavy use of antibiotics in food animal production in China (Zhang et al., 2015), provide the 
perfect conditions for horizontal gene transfer from animal to human strains. This dynamic 
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evolutionary situation explains why there is a tremendous diversity of blaCTX-M genotypes 
isolated from food animals in China (figure 2.4). The prevalence of blaCTX-M-55 in China has 
grown significantly in recent years in both animal (Rao et al., 2014) and human populations 
(Xia et al., 2014),  and it has been suggested that blaCTX-M-55 in human isolates arose from 
food animal sources  (Zhang et al., 2014). Isolates of human and food animal origin share 
dominant blaCTX-M genotypes (figure 2.3 and 2.4), suggesting that there is clonal or horizontal 
exchange of blaCTX-M between these settings. Due to rising demands, worldwide antibiotic 
use in food animals is projected to rise by 67% by 2030, therefore the role of food animals as 
a source of AMR genes will become more prominent (Van Boeckel et al., 2015). 
 
2.5.4 Role of the natural environment in dissemination of ESBLs 
The natural environment as a reservoir of ESBL genes is inextricably linked to human and 
animal reservoirs (Wellington et al., 2013; Woerther et al., 2013). The origin of CTX-M 
enzymes can be traced back to Kluyvera spp, which normally inhabit the rhizosphere, so 
environmental sources play an important role in the dissemination of blaCTX-M.  
ESBL-producing bacteria have been found in sewage (Yang et al., 2012), rivers downstream 
of wastewater treatment facilities  (Amos et al., 2014), urban freshwater (Dhanji, Murphy, et 
al., 2011; Bajaj et al., 2015; Azam, Jan and Haq, 2016) and marine environments (Maravić et 
al., 2015). Furthermore, resistant organisms have been found in several agricultural settings 
(Hammerum et al., 2014),(Randall et al., 2014),(Laube et al., 2014).  
 
Pollution of the environment with Enterobacteriaceae from human and animal waste is an 
issue in developing and developed countries. However, the poor standards of sanitation, and 
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contamination of drinking water supplies in the developing world allows increased cycling of 
CTX-M-producing E.coli between humans and the environment, (Hawkey, 2015). This 
explains our finding of a significant upward trend in ESBL carriage rates in developing 
countries (figure 2.2), notably in India, where ESBL carriage rates are amongst the highest in 
the world (Chen et al., 2011). Moreover, the environmental-human exchange of AMR genes 
is highly relevant to the spread of other faecally-carried genes such as blaNDM-1 (Walsh et al., 
2011).  
 
The presence of resistant genes in an environment is closely related to anthropogenic 
activities. For example, the prevalence of class I integrons carrying resistance genes in 
sewage sludge, pig slurry and textile mill effluent is significantly higher than levels found in 
fallowed soil. The common practice of using animal manure as fertiliser creates 
opportunities for species of Enterobacteriaceae to capture novel resistance genes on mobile 
genetic elements from soil bacteria (Wellington et al., 2013). More recently, a 
metagenomics approach was used to assess the AMR gene content across human, 
environmental and animal microbiomes in two developing regions in South America, and 
showed that mobile genetic elements played a significant role in the transfer of ESBLs 
(notably blaTEM-1) between different resistomes (Pehrsson et al., 2016). 
 
Environmental contamination with fluoroquinolones is especially worrisome, as these are 
known to persist in rivers and soil, and have the ability to select bacteria bearing class I 
integrons which carry resistance cassettes, including  qnr genes and blaCTX-M  genes 
(Wellington et al., 2013). In India, high levels of ciprofloxacin in the waste water effluents of 
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pharmaceutical factories and in nearby sources of drinking water is a serious issue which is 
likely to be a major contributory factor in the emergence and spread of blaCTX-M in human 
populations and in the environment (Fick et al., 2009). 
 
2.5.5 Role of poor sanitation in developing countries 
There is increasing community prevalence of ESBL-producing Enterobacteriaceae worldwide 
(figure 2.1), especially CTX-M-15, which is reflected by much higher faecal carriage rates in 
Asia compared to Europe and North America (Woerther et al., 2013). Individuals with ethnic 
origins in the Middle East or South Asia have significantly higher carriage rates of CTX-M-15 
producing E.coli compared with Europeans, which is likely due to the high frequency of 
travel to these areas amongst particular ethnic groups (Wickramasinghe et al., 2012). 
Prospective cohort studies have shown that travellers from Western countries visiting 
countries with high prevalence of ESBL producing bacteria are likely to become 
asymptomatic carriers: 75% of those travelling to Southern Asia acquired ESBL-producing 
organisms (Arcilla et al., 2017). 
 
Access to improved sanitation facilities as defined by WHO/UNICEF is an important indicator 
of social and economic development, and is important in reducing the spread of diarrhoeal 
diseases ( http://data.worldbank.org/indicator/SH.STA.ACSN). It is likely that such access is 
also paramount in controlling the spread of ESBLs. Improving levels of sanitation worldwide 




Figure 2.5 shows that there is an association between access to basic sanitation and rates of 
ESBL-producing Enterobacteriaceae by country. However, it must be noted that confounding 
factors could easily be implicated in this relationship. For example, more developed 
countries such as the UK, with high levels of access to basic sanitation, tend to have good 
standards of human sewage treatment, regulations limiting environmental pollution in 
industry and agriculture, and are good at limiting the use of antibiotics in humans and 
animals. All these factors will contribute to lower levels of ESBL-producing organisms.  
 
India is likely to be where blaCTX-M-15 originated (Ensor et al., 2006) and is the most common 
ESBL worldwide. Despite gradual improvements in India, access to basic sanitation still falls 
below 40% (figure 2.5). Poor access to latrines in India, combined with high population 
density and increasing human migration, have made this region a key epicentre of ESBL 
evolution, and a source for the worldwide spread of blaCTX-M-15. 
 
 
2.5.6 Prominent global changes in CTX-M epidemiology: the fall of blaCTX-M-2 and the 
emergence of blaCTX-M-27 
The distribution of CTX-M variants in particular geographical regions is not always easily 
attributed to human migration. Given historical and cultural links between Spain/Portugal 
with South America, it follows that CTX-M variants in these regions should be similar, due to 
frequent migration between these areas. However, where blaCTX-M-2 has been the main 
genotype in South America until the recent spread of blaCTX-M-15, blaCTX-M-2 has never gained a 
foothold in Spain or Portugal (Livermore et al., 2006). One explanation for this phenomenon 
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is that blaCTX-M-2 evolved in South America, was probably imported to Western Europe on 
multiple occasions, but never had the successful evolutionary characteristics to compete 
with the dominant genotypes in Europe. Outside of South America, the only regions showing 
a predominance of blaCTX-M-2, before 2004, were Japan (Yagi et al., 2000) and Israel 
(Karfunkel et al., 2013). It is clear that blaCTX-M-2 is somehow evolutionarily ‘less fit’ than its 
counterparts blaCTX-M-14 and blaCTX-M-15, as these two genotypes have started to overtake 
blaCTX-M-2 in all regions where it was previously the main CTX-M variant (see figure 2.3). 
 
There is increasing evidence to suggest that blaCTX-M-27, a single nucleotide variant of blaCTX-M-
14, has begun to out-compete other blaCTX-M genotypes globally (figure 2.3). First isolated 
from a clinical E.coli in France (Bonnet et al., 2003), blaCTX-M-27 is now found worldwide, 
recently gaining ground in Japan, China, South East Asia, North America, and in Europe 
(Doumith et al., 2012; Castanheira et al., 2013; Denisuik et al., 2013; Biedenbach et al., 2014; 
Micenková et al., 2014; Matsumura et al., 2015; Vlieghe et al., 2015; Zhong et al., 2015; 
Birgy et al., 2016) (see figure 2.3). The cause of this rise is unclear: CTX-M-27 has a higher 
MIC to ceftazidime compared with CTX-M-14, so use of ceftazidime would theoretically 
select for blaCTX-M-27 (Kuroda et al., 2012). E.coli clones producing CTX-M-27 may also be 
more transmissible in a nosocomial environment, when compared to CTX-M-15-producers 
(Adler et al., 2012).  
 
As discussed above, there is genetic exchange and/or clonal exchange of E. coli of animal or 
human origin between humans, animals and the environment. The presence of blaCTX-M-27 in 
food animal isolates from China in all three time periods suggests a stable reservoir for 
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blaCTX-M-27 in this ecological niche (figure 2.4). Indeed, blaCTX-M-27 identified from E.coli from 
food animals in a multicentre Chinese study represented 12% of bla-CTX-M variants 
detected (notably in ducks) (Zheng et al., 2012), and blaCTX-M-27 also dominates ESBL-
producing Salmonella enterica serotypes in China (Zhang et al., 2016). In Vietnam as in 
China, where close proximity of animals and humans is common, blaCTX-M-27 is the most 
common blaCTX-M genotype (Biedenbach et al., 2014), which could be due to human 
transmission from animal sources.  
 
Clonal spread of E.coli ST131 in humans has certainly played a role in the dissemination of 
blaCTX-M-27 in Japan (Yano et al., 2013; Osawa et al., 2015), China (Zhong et al., 2015), France 
(Blanc et al., 2014), Portugal (Rodrigues et al., 2016), Germany (Valenza et al., 2015) ,and the 
Czech Republic (Micenková et al., 2014). Moreover, E.coli ST131 isolates producing CTX-M-
27 have been reported from companion animals in Japan (Harada, Nakai and Kataoka, 2012), 
from wild birds in Czech Republic (Tausova et al., 2012), and from freshwater in Switzerland 
(Zurfluh et al., 2013).  
 
However, ST131 CTX-M-27-producing isolates from South Korea  and Japan did not belong to 
the H30Rx sub-clone (Matsumura et al., 2015; Kim et al., 2016). Rather, Matsumura and 
colleagues found that blaCTX-M-27 isolates were significantly associated with the H30R sub-
clone (Matsumura et al., 2015). They also suggested that although blaCTX-M-27 is a single 
nucleotide variant of blaCTX-M-14, blaCTX-M-27 is unlikely to have evolved by point mutation from 
blaCTX-M-14 in Japan, as the genetic surroundings and virulence profiles of blaCTX-M-27 versus 
blaCTX-M-14 are quite different (Matsumura et al., 2015). This suggests that separate 
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importations to Japan and/or separate bla-CTX-M capture events to E.coli clonal lineages 
occurred for blaCTX-M-27 and blaCTX-M-14. In contrast, it remains a possibility that blaCTX-M-27 did 
evolve from blaCTX-M-14 by point mutation in Japan, as the first cluster of CTX-M-27-producing 
isolates in the world was described in Japan (Kuroda et al., 2012). It is possible that the 
original blaCTX-M-14 progenitor has since been subject to out-competition and/or genetic 
rearrangement which might explain why it has not been detected in the more recent studies 
outlined above.  
 
The role of horizontal gene transfer in the spread of blaCTX-M-27 has very poor coverage in the 
literature. However, interestingly, published data suggests that in animal strains, blaCTX-M-27 is 
associated with a wide range of plasmid replicons in transconjugants including N, FIB, FII, I1, 
HI2, A/C, and P (Ma et al., 2012; Jiang et al., 2014; Zhang et al., 2016), whereas in studies 
with human isolates, blaCTX-M-27 has been found in E.coli ST131 strains associated with with 
F1A, FIB and FII replicons only (Kim et al., 2016; Nakane, Kawamura and Goto, 2016). Thus, 
one could speculate that blaCTX-M-27 has undergone transposition onto a IncF plasmid residing 
in E.coli ST131, similar to the IS26 mediated capture of blaCTX-M-15 described recently 
(Johnson et al., 2016). 
 
Understanding why certain blaCTX-M genotypes are more successful (e.g. blaCTX-M-15, blaCTX-M-
14, and blaCTX-M-27) than others (e.g. blaCTX-M-2), will support the development of more 





Infections with CTX-M-producing Enterobacteriaceae are of huge clinical importance, as 
increasing rates of ESBL-producers drive carbapenem prescribing, which in turn promotes 
the spread of potentially untreatable carbapenemase-producing Enterobacteriaceae (Geyer 
et al., 2015). Dealing with this situation requires constant monitoring of the global 
epidemiology of CTX-M genotypes, allowing early anticipation of emerging ESBL genes. 
Moreover, improving the global surveillance of AMR has been identified as a key 
intervention in addressing the rise of resistant bacteria (O’Neil, 2016).  
 
The data presented in this chapter has several limitations. Notably, in the early surveys of 
blaCTX-M, sample sizes were often small, and several studies, undertook only CTX-M grouping 
PCR. Furthermore, many studies do not report on the clonal relatedness of the strains they 
included, leading to bias by outbreaks. There is publication bias, e.g. in China, many studies 
describe CTX-M prevalence, whereas in Africa there are few studies. Therefore, the limited 
data from under-resourced countries is likely to represent the ‘tip of the iceberg’ in terms of 
percentage ESBL prevalence in these regions, leading to late detection of new genes. 
WHO/UNICEF data on access to improved sanitation facilities was utilised, which is defined 
as “one that hygienically separates human excreta from human contact.”(WHO, 2016) This 
includes pit latrines and flushing latrines, and it must be noted that the fate of this human 
waste is not recorded in this data and therefore the presence or effectiveness of onward 
sewage processing is not recorded. Therefore human exposure to human sewage (and 
therefore ESBL-producing bacteria) in many underdeveloped regions is likely to occur, even 
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if access to improved sanitation facilities is high, and such exposures are likely even with 
high standards of sewage treatment (Amos et al., 2014).  
 
This chapter has shown that CTX-M community faecal carriage rates are rising (Figure 2.1 
and 2.2), and this is more pronounced in developing countries, supporting previous studies 
(Woerther et al., 2010; Karanika et al., 2016). Therefore, there exists a vast human reservoir 
of blaCTX-M-producing strains, which provide a source of bacteria which often go onto cause 
antimicrobial-resistant infections. Equivalent ESBL reservoirs are present in the environment 
and in food producing animals, which constantly exchange clones and mobile genetic 
elements with the human reservoir. Transfer of blaCTX-M thus occurs by the spread of clonal 
lineages, epidemic plasmid spread, or via the movement of smaller genetic elements by 
transposition or transduction. Although these processes are usually studied in isolation, they 
do not occur in isolation. Rather, the concept of the “selfish gene” (Dawkins, 1976) should 
be applied: each individual blaCTX-M gene is opportunistic, using every possible mechanism to 
propagate itself. Therefore, the global success of blaCTX-M is due to a combination of all the 
mechanisms discussed above.   
 
There is little doubt that a combination of human factors has increased the propagation of 
blaCTX-M. Antibiotic overuse in humans and animals, increased global migration and 
population density, and contamination of the food chain and environment with human and 
animal waste promote AMR (Holmes et al., 2016). The evolution of highly successful lineages 
of CTX-M-producing bacteria is a critical factor. We have described the contribution of poor 
access to basic sanitation facilities in some countries as a risk factor for higher ESBL carriage. 
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Poor sanitation access in these countries, combined with poor standards of animal 
husbandry, unregulated wet food markets, and antibiotic overuse in humans and animals is 
dangerous, and provides opportunities for the evolution of novel AMR genes. 
 
Where possible, attempts must be made to mitigate these risks through preventative 
strategies, such as improving access to latrines in developing countries, better antimicrobial 
stewardship in humans and animals, environmental controls, and targeted evidence based 
ESBL screening strategies (O’Neil, 2016).  
 
The data presented in this chapter is not only of relevance to ESBL-producing 
Enterobacteriaceae. Bacteria carrying mcr-1 and/or carbapenemase genes are found in 
similar habitats to Enterobacteriaceae producing CTX-M, such as the human gut. Therefore, 
explanations for the trends observed in blaCTX-M epidemiology can be applied to these other 
faecally-carried AMR genes.  
 
This chapter has provided an up to date review and analysis of the global epidemiology of 
the blaCTX-M family, demonstrating a continued global rise in ESBL incidence. This has led to 
an inevitable rise in carbapenem use in humans with an associated rise in resistance. There 
have been dramatic regional shifts in the epidemiology of CTX-M-producing 
Enterobacteriaceae; but also remarkable stability in many regions. Both changes and 
stability in blaCTX-M genotypes in specific regions of the world seem to favour the highly 
successful blaCTX-M-15 and blaCTX-M-14 genes. Understanding global temporal trends in these 
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genotypes will help develop hypotheses as to why these changes occur, supporting 




Chapter 3: Volunteer recruitment, demographics, and CTX-
M-producing E. coli acquisition 
 
3.1 Introduction  
The global prevalence of CTX-M-producing E. coli (CTX-M-EC) is rising, thereby increasing the 
use of carbapenem antibiotics, and therefore acting as a driver for the emergence of 
carbapenemase-producing Enterobacteriaceae (CPE) (Hawkey, 2015). Anthropogenic factors 
such as low levels of basic sanitation, poor standards of animal husbandry in agriculture, and 
the overuse of antibiotics in animals and humans, all contribute to high prevalence of CTX-
M-EC in developing countries, especially in South Asia.  (Bevan, Jones and Hawkey, 2017).  
 
International travel plays a key role in the spread of antibiotic resistant bacteria carried in 
the human gut (Nordahl Petersen et al., 2015), and the acquisition of CTX-M-EC by travellers 
who visit countries with high levels of CTX-M- producers in the environment, is a well-
recognised phenomenon (Chapter 1, Section 1.7). In particular, travel to South Asia, which 
includes densely populated countries such as India and Bangladesh, presents the highest risk 
for acquisition of CTX-M-producing Enterobacteriaceae (Arcilla et al., 2017).  
 
Twenty-two studies investigating the acquisition of CTX-M-producing bacteria by travellers 
have been published, but none prospectively recruited volunteers from the UK (Chapter 1, 
Table 1.1). The work presented in this thesis is therefore the first study to assess CTX-M 
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acquisition in travellers returning to the UK.  The following chapter will outline volunteer 
recruitment and demographics, post travel survey data, and CTX-M-EC acquisition rate. 
 
3.2 Hypotheses 
1. The rate of acquisition of CTX-M-EC will be similar to previous studies with volunteers 
travelling from developed countries to South Asia.  
2. Risk factors known to be associated with CTX-M-EC acquisition will be identified from 
the post-travel questionnaires completed by volunteers.  
 
3.3 Methods 
3.1 Study Design and Ethical Approval 
The traveller study methodology was conceived after discussion and approval by South 
Birmingham Research Ethics Committee (REC) and presentation to the patient forum group 
at Heart of England NHS Foundation Trust. The REC-approved study documents which 
included advertisements, participant information sheets, consent forms, and questionnaires, 
are provided in appendix 2. A power calculation was not undertaken at the outset because 
the frequency of transfer of ESBL-EC plasmids in-vivo is unknown. Therefore, the number of 
volunteer isolates required to detect such an event could not be determined. 
 
 67 
3.2 Recruitment and Inclusion/Exclusion Criteria 
Healthy volunteers were recruited from the student and staff members of the University of 
Birmingham and Heart of England NHS Foundation Trust. The study was advertised using 
posters and entries in weekly departmental e-newsletters. Targeted recruitment, through 
group emails, and announcements before lectures, was aimed at medical elective students 
planning overseas travel. A Twitter campaign using University of Birmingham twitter account 
was also undertaken. Individuals planning travel to South Asia, who were interested in 
becoming study participants, contacted ERB by email or telephone, at which point they were 
excluded from taking part if they reported previous travel to South Asia in the previous three 
months, or if they had significant long-term chronic disease. For the purposes of this study, 
South Asia included India, Pakistan, Bangladesh, or Sri Lanka. Long term chronic disease 
which would lead to exclusion from the study included diabetes mellitus, inflammatory 
bowel disease, cancer, any immunosuppression or any other long-term systemic illness. 
Children or adults lacking mental capacity were also ineligible to take part in the study. 
Providing they did not meet any exclusion criteria, the participant information sheet 
(appendix 2) was then sent to the individual by email for consideration. A meeting was then 
arranged with the participant to provide further information if required, and to sign the 
study consent form and to complete the pre-travel questionnaire (appendix 2). 
 
3.3 Laboratory Methodology: Sample Collection, Culture and Identification 
After giving consent to take part in the study, volunteers were given stool sample collection 
containers and transparent specimen bags. Study participants were allocated a number to 
identify them and allow pseudo-anonymization, and each sample was given a unique 
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number which would allow determination of the sample type (pre or post travel and sample 
number). Volunteers were asked to provide at least 5g of sample (filling container half way) 
and were asked to provide a specimen as close to the time of sample submission as possible. 
Volunteers were then met in person by ERB, and samples were stored for no more than 24h 
hours at 4°C.  
 
The following culture-based ESBL isolation strategies were then undertaken: (1) A sterile 
swab was used to inoculate a faecal sample onto oxoid ESBL brilliance agar which was 
incubated at 37°C for 48 hours. Plates were checked and moved to 4°C if growth was seen at 
24 hours; (2) Additional chromogenic agar (oxoid UTI brilliance agar) supplemented with a 
cefpodoxime disc (10µg/ml) was inoculated with serial dilutions of stool culture (x10, x100, 
x1000, x10000) to allow isolation of single colonies after 24 hours incubation at 37°C; (3) 
Brain heart infusion (BHI) broth supplemented with a cefpodoxime disc (10µg/ml) was also 
inoculated with a sterile swab loaded with faeces, incubated at 37°C for 24 hours. A 10µl 
loop of the overnight broth was then sub-cultured onto a fresh UTI chromogenic agar plate 
supplemented with a cefpodoxime disc and incubated for a further 24 hours. Resistance to 
cefpodoxime is a widely used screening tool for ESBL producers in clinical laboratories (Gibb 
and Crichton, 2000). 
 
Putative ESBL-EC strains were identified as blue or pink colonies on ESBL agar, and pink or 
clear colonies within the cefpodoxime disc zone (or outside the zone in pre-travel samples) 
on UTI media before and after broth enrichment. After culture, faecal samples were stored 
at -80°C.   
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Each colony pick (appendix 1) subculture was confirmed to be E.coli using matrix-assisted 
laser desorption ionisation time-of-flight mass spectroscopy (MALDI-TOF MS). A bacterial 
colony was touched with a sterile toothpick which was then used to produce a smear on the 
polished MALDI-TOF MS target. A solution of matrix was applied to each smear on the target 
and allowed to dry. MALDI-TOF MS organism scores (based on degree of match to the 
organism mass spectral database) of >2.0 provided identification to species level. If the score 
was <2.0, the MALDI-TOF MS method was repeated for that isolate. After identification, 
isolates were stored at -80°C on protect beads. Sweeps from ESBL agar and UTI media were 
also taken and saved, as a representation of the 3GC-resistant population cultured. 
 
3.4 Identification of ESBL genes 
Primers for multiplex PCR were used to identify the three most common CTX-M groups: 
Group 1, group 2 and group 9 (Dallenne et al., 2010). PCRs were only carried out on isolates 
which had either grown on ESBL agar, or from within the zones of cefpodoxime on non-
selective UTI agar. Positive control organisms for each CTX-M group were utilised which had 
been previously confirmed as encoding the specific blaCTX-M group after Sanger sequencing. 
 
3.4.1 CTX-M grouping PCR 
Crude cell lysates for PCR reactions were obtained by suspending a colony in 200μl in 
molecular grade water (mH20) and heating to 95°C for 15 minutes. After this point the PCR 
constituents were prepared on ice. The total volume for each PCR reaction constituted:  4μl 
multiplexed primers (4 x 0.5μl forward, 4x 0.5μl reverse), 12.5μl mytaq redmix, 3μl cell 
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lysate, and 5.5μl mH20. Reactions were run on a Veriti PCR thermal cycler using the 
following conditions: 95°C for 1 min, followed by 30 cycles of: 95°C 15 sec, 58°C 15 sec, and 
72°C 10 sec.  
 
3.4.2 Agarose gel electrophoresis 
Agarose gel (1%) was prepared by suspending 1g agarose in 100mls in 0.5M tris-borate EDTA 
(TBE) buffer and boiling until all agarose was dissolved. The molten agarose was allowed to 
cool for 3 minutes before adding  5μl Midori Green (0.05μl/ml). The agarose was mixed 
briefly and then allowed to set in a gel tray with comb. PCR products were loaded directly 
into the wells of the agarose gel (12μl per well) and a 1kb DNA sizing ladder was added at 
the start and end of the test samples. Gels were run at 150V for 40 minutes and images were 
viewed and edited using a UV trans-illuminator and GeneSys software. Remaining PCR 




3.4.1 Recruitment of volunteers 
3.4.1.1 Participant characteristics 
Eighty individuals responded to study advertisements. Respondents were sent an email 
providing further information about the study, including the Participant Information Sheet 
(PIS) (appendix 2). Subsequently, 23/80 (28.8%) did not respond after the PIS was provided 
(Table 3.1).   
 
3.4.1.2 Volunteer drop-outs 
Twenty-three volunteers provided informed consent to take part in the study (Table 3.1). 
After consent was provided, each volunteer was allocated a number in chronological order 
of recruitment. Four volunteers (17%) withdrew from the study before providing samples 
(Figure 3.1). Of the volunteers who dropped out, 3/4 provided written informed consent to 
take part, but failed to respond after repeated reasonable efforts to contact them after the 
initial meeting (volunteers 2, 11, and 14). These included emails and answerphone 
messages. The remaining participant dropped out after his trip to Bangladesh was cancelled 
(volunteer 13).   
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Table 3.1 Fate of 80 initial expressions of interest in enrolling in the study 
 
Outcome after initial Enquiry and provision of Participant Information Sheet* 
Frequency 
(%) 
No response to follow up email  38 (47.5) 
Previous travel to Indian subcontinent within preceding 4 months 7 (8.8) 
Exclusion due to medical history 3 (3.8) 
Unwilling to provide samples  7 (8.8) 
Unable to deliver samples 2 (2.5) 
Provided Informed Consent 23 (28.8) 
TOTAL 80 (100.0) 






Figure 3.1. CTX-M positivity rate and fate of twenty-three volunteers who provided informed consent to take 
part in the study 
  
23 volunteers provided 
informed consent
19 volunteers screened for 
bla-CTX-M
18 CTX-M negative 
volunteers BEFORE travel
TRAVEL
16/18 (89%) volunteers 
CTX-M positive AFTER 
travel
4 drop outs before sample collection
1 CTX-M positive pre-travel excluded
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3.4.2 Volunteer demographics 
The participant demographic data for volunteers who provided pre and post travel faecal 
samples is displayed in Table 3.2. The mean and median age of volunteers was 35 and 30 
years, respectively. The youngest volunteer was 21, and the oldest, 67. 10/19 were male; 
9/19 female. In response to the volunteer pre-travel questionnaire (appendix 2). With 
respect to ethnicity, 58% (11/19) identified as ‘White/British’, while 32% (6/19) identified as 
‘Indian’ or ‘British Pakistani.’ Ethnicity was self-reported and in accordance with the UK 
Office for National Statistics (ONS). 
 
All participants reported a travel history outside the UK in the previous 2 years (Table 3.2). In 
13/19 (68%) of volunteers, locations of previous travel included countries with a significant 
risk (>18% risk) of ESBL-EC acquisition post travel, as reported by Arcilla and colleagues 
(Arcilla et al., 2017). 5/19 had travelled to India in the past 2 years which carries a very high 
risk of acquisition: up to 89% (Arcilla et al., 2017)(Table 3.2).  
 
In terms of past medical history, those with significant chronic systemic illnesses, were 
excluded from the study as outlined above. Most of the volunteers had no previous medical 
history nor did they take any medications. We did include 4 participants who had relatively 
minor, controlled or treated conditions which included hay-fever, hypertension, kidney 





Table 3.2. Pre-travel volunteer demographic data 
Volunteer Age Sex Ethnicity* 2 year travel history prior to entry into study^ Medical history/medications 
1 38 M Indian USA Nil 
3 22 M White British Australia, Italy, Spain Nil 
4 23 M White British Spain, Croatia, Italy, USA, Malta, Australia, Bulgaria, Iceland  Hayfever/on desensitisation treatment 
5 67 F White British Spain, Cuba, Costa Rica, France, USA, Burma, Mexico Nil 
6 31 M Mxed British Greece, India, Morocco, Lithuania, Netherlands, Germany Nil 
7 22 M White British Greece Nil 
8 53 M Indian India (Jan 2014), USA, China (2014), Italy, Slovenia, France Hypertension, kidney stones 
9 30 F White British Portugal, Italy, Poland, Greece, Vietnam, Cambodia, Thailand (Dec 2013-Jan 2014 Nil 
10 29 M White British Portugal, Italy, Poland, Greece, Vietnam, Cambodia, Thailand (Dec 2013-Jan 2014 Nil 
12 29 M White British USA, Guinea (Mar 2015), Albania/Greece, Ukraine Nil 
15 43 F Italian India, Kenya, Portugal, Italy Nil 
16 21 M White British Spain, Greece mild asthma 
17 53 F Indian USA, Japan, Vietnam/Cambodia (June 2015), China (July 2016), Turkey Nil 
18 23 F White British Spain, Portugal, Vietnam, Cambodia Nil 
19 22 F White British Cambodia, Vietnam, New Zealand, France, Spain, Croatia, Italy Nil 
20 34 F Indian India, 2015 Previous TB, treated 
21 29 F British Pakistani Morocco, 2015 Nil 
22 56 F White British USA, Belgium, Spain Nil 
23 34 M Indian India, 4 weeks, 1 year previous Nil 
*based on ONS classification; ^Countries in bold are high risk for acquisition (>18%); those underlined have a very high risk of acquisition of ESBL-E (75%) (Arcilla et al 2017). 
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3.4.3 Volunteer travel-related meta-data 
Volunteers completed a post travel survey on return to the UK (appendix 2). The primary 
destinations visited by volunteers were India (68%; 13/19;) and Sri Lanka (31%; 6/19), and 
the mean travel duration was 27 days (median 21 days). A number of factors were reported 
by volunteers which are known to be risk factors for acquisition of ESBL-producing 
Enterobacteriaceae (ESBL-E) (Arcilla et al., 2017; Peirano et al., 2017). These included 
symptoms of diarrhoea during the trip (63%; 12/19), taking antibiotics (26%; 5/19), staying in 
a hostel or guesthouse/B&B (47%; 9/19), and consumption of food from street vendors 
(36%; 7/19). Moreover, 18/19 volunteers travelled for non-business reasons, which is also a 
risk factor for ESBL-EC acquisition (Peirano et al., 2017) (Table 3.3).  
 
3.4.4 Pre-travel sample collection 
After screening volunteer stool samples using selective culture and PCR, 18/19 were blaCTX-M 
negative before travel (Table 3.4). Volunteer 23, who had travelled to India almost exactly 4 
months prior to his recruitment to the study, was found to be carrying CTX-M-producing E. 
coli (Group 1 CTX-M) (Table 3.4). This was not an unexpected finding, but as volunteer 23 
was on the ‘borderline’ of exclusion criteria, a decision was made to go ahead and recruit 
this individual and check for pre-travel CTX-M-EC. 
 
Table 3.3. Travel related demographic data  




Duration Accommodation Diet Illnesses while 
away 
Antibiotic use 
1 India and UAE 
(transit only) 
N/A 0 21 family home food at hotels, home 
and street market, tap 
water 
none amoxicillin 5/7 for CAP same 
week as sample 1e submission 




food, bottled and 
spring water 
Severe D&V Omidazole/olfloxacin, 5 days 
4 Sri Lanka Columbo 0 30 hostel restaurants, bottled 
water only 
48hrs D&V None 
5 Uzbekistan 
and India* 
N/A 1 14 hotels bottled water only D&V  amoxicillin in Uzbek. 
6 India N/A 1 10 hotel and family 
home 
restaurants, UV 





7 India N/A 20 14 hotel restaurants, bottled 
water 
mild diarrhoea none 
8 India and 
Qatar (3 days) 
N/A 1 23 home, hotels restaurants, bottled 
water 
diarrhoea Norfloxacin/Tinidazole 400/300 
BD 3 days for diarrhoea 
9 Sri Lanka  and 
India (transit 
only) 
N/A 1 21 B&B, hotels restaurants, bottled 
water 
D&V none 
10 Sri Lanka  and 
India (transit 
only) 
N/A 1 21 B&B, hotels restaurants, bottled 
water 
none none 
12 India N/A 1 21 B&B, hotels restaurants, street 
food, bottled water 
mild diarrhoea none 
15 India, Italy, 
Greece^ 
N/A 1 35 hotels restaurants, bottled 
water 
mild diarrhoea none 
16 India Bangalore 3 56 hotels, hostels, tent hotels, street food, 
bottled water with ice 
D&V none 
Volunteers who travelled together (2 pairs) are boxed in dark grey. Risk factors associated with CTX-M acquisition are underlined. 
 
 
Table 3.3. Continued.  




Duration Accommodation Diet Illnesses while 
away 
Antibiotic use  
17 India and Italy N/A 3 10 hotels restaurants, bottled 
water 
none none 
18 Sri Lanka and 
China 
Galle 1 (vol 19) 56 private homes, 
hotels, hostels 
restaurants, street 
food, bottled water 
none none 
19 Sri Lanka and 
China 
Galle 1 (vol 18) 56 private homes, 
hotels, hostels 
restaurants, street 
food, bottled water 
Chest infection, 
no admission 
Yes, unsure name of drug 
20 India  N/A 1 21 family home tap water mild diarrhoea amoxicillin for LRTI in UK, 4 
days before travel 
21 Pakistan and 
Turkey 
N/A 4 21 family home bottled and tap water diarrhoea none 
22 Sri Lanka  N/A 1 18 hotels. 
Guesthouses 
markets, bottled and 
tap water 
mild cold none 
23 India 
 
1 30 home home food, street 
food, bottled water 
none none 




















1 India No Yes 15  NBT, SV 1-3 weeks 
3 India No Yes  15 
Acc, NBT, Abx, 
SV 
> 9 months 
4 SL  No Yes 14 and 15 Acc, NBT, G > 5 months 
5 India No Yes 15 NBT, G, Abx > 12 months 
6 India No Yes 15 NBT, G 6 weeks 
7 India No Yes 15 NBT, G 2-4 months 
8 India No Yes 15 NBT, G, Abx > 11 months 
9 SL & India  No Yes 15 Acc, NBT, G > 7 months 
10 SL & India No No N/A Acc, NBT, G N/A 
12 India No Yes 15 
Acc, NBT, G, 
SV 
2-4 months 
15 India No yes 15 G >1 week 
16 India No yes 14 and 15 
Acc, NBT, G, 
SV 
>6 months 
17 India No Yes  15 NBT 3-6 weeks 
18 SL & China No No N/A 
Acc, NBT, G, 
SV 
N/A 
19 SL & China No Yes 14 
Acc, NBT, Abx, 
SV 
>14 days 
20 India No Yes 15 NBT, G 3-4 months 
21 Pakistan No Yes 15 NBT, G 1-2 weeks 
22 SL No Yes 15 Acc, NBT  1-3 weeks 
SL, Sri Lanka. Light shading: lack of CTX-M by culture, PCR and WGS. Dark shading: blaCTX-M detected. Risk 
factors for acquisition: Acc, accommodation was hostel, B&B, or guesthouse; NBT, non-business travel; G, 
gastroenteritis symptoms; SV, street vendor food consumption; Abx, antibiotic consumption during travel. 
Duration of carriage is marked in red and italicized where a ‘CTX-M free’ follow-up faecal sample could not be 
obtained. *Other destinations during the same tip with a low blaCTX-M community carriage prevalence are not 
included in this column e.g. Countries in Europe. 
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3.4.5 Travellers to South Asia have a high CTX-M-EC acquisition rate 
3.4.5.1 Results of selective stool culture and CTX-M grouping PCRs 
Putative E. coli colonies were picked from selective chromogenic media (Figure 3.2) and 
identified using MALDI-TOF. ESBL oxoid agar has a shelf life of only 14 days, therefore on 
receipt, each pack was checked with a positive (K. pneumoniae producing ATCC 700603), and 
a negative control bacterium (E. coli ATCC 10798).  
 
CTX-M-grouping PCRs were used to confirm the presence of blaCTX-M genes for colonies 
growing on ESBL-screening plates. Figure 3.3 is a representative example of blaCTX-M grouping 
PCR after agarose gel electrophoresis. In this example, four isolates from a volunteer 1 post 
travel faecal sample (sample 1e) are displayed which did not contain CTX-M-EC. In addition, 
four isolates each from volunteer 3 (sample 3e, post travel) and volunteer 4 (sample 4e, post 
travel) are displayed, all of which have a band at 688bp which is consistent with the 
presence of group 1 CTX-M (Figure 3.3). Ultimately, WGS was used to confirm the resistance 
mechanism responsible for the phenotype detected using the selective culture of faecal 
samples (Chapter 4). 
 
The culture-based screening approach yielded 236 putative ESBL-producing E. coli isolates 
from 17 volunteers (16 post travel, 1 pre-travel) (Figure 3.4). After WGS and identification of 
resistance genes, 86% (203/236) of culture positive E. coli were CTX-M grouping PCR 




In the case of 8 isolates from 2 volunteers, CTX-M grouping PCR was positive, but analysis of 
draft WGS assemblies did not reveal any blaCTX-M genes (Figure 3.4). These isolates were 3 
ST10s from volunteer 7, 3 ST648s from volunteer 7, and 2 isolates from volunteer 20 with no 
ST assigned. It is likely that plasmid loss occurred, after the initial PCR, as repeat grouping 
PCRs on the same isolates were negative for blaCTX-M genes. An alternative explanation is 
that contamination occurred on the first occasion PCR was done for these isolates, resulting 
in false positives.  
 
In the case of 14% (33/236) of culture positive isolates on selective media which were 
grouping PCR negative, WGS was used to determine the resistance genes leading to growth 
on cephalosporin-contianing agar. Seventeen isolates were AmpC enzyme producers, 2 were 
bla-SHV-12-producers, and 14 had no CTX-M or AmpC genes, after the analysis of WGS 








 A          B 
 
Figure 3.2. Representative examples of ESBL screening media. A: ESBL chromogenic media with faecal sample 
3e with positive control visible in green (Klebsiella pneumoniae ATCC 700603) and B: Chromogenic UTI media 
plus addition of cefpodoxime disc, also sample 3e cultured with putative ESBL-E. coli (pink colonies) within the 








Figure 3.3. Representative example of CTX-M grouping PCR products after agarose gel electrophoresis. L: 1kB 




























4% (8/203) bla-CTX-M lost
<1% (1/203) failed assembly
52% (17/33) AmpC: 9 DHA-1, 7 
CMY-60, 1 CMY-841 
6% (2/33) bla SHV-12
42% (14/33) No ESBL or AmpC
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3.4.5.2 blaCTX-M acquisition rate 
After travel, blaCTX-M had been acquired by 16/18 (89%) volunteers (Figure 3.1). Most 
volunteers acquired CTX-M-15-producing E. coli after travel to India, (75%; 12/16), while the 
remaining 4 volunteers who acquired CTX-M-EC travelled to Sri Lanka (volunteers 4 and 22), 
Sri Lanka and China (volunteer 19), and Pakistan (volunteer 21) (Table 3.4). Two volunteers 
acquired E. coli producing both CTX-M-14 and CTX-M-15, and one volunteer acquired only 
CTX-M-14 (Table 3.4). All 18 volunteers had one or more of the following risk factors for CTX-
M-EC acquisition: staying at a hostel, B&B, or guesthouse; travel for non-business reasons; 
symptoms of gastroenteritis during travel; consuming food from a street vendor; and/or 
antibiotic consumption during travel (Table 3.4). This study did not set out to, or achieve, 
sufficient study volunteer numbers to carry out an analysis as to whether any risk factor was 












3.5.1 Recruitment of volunteers 
This is the first prospective study recruiting volunteers from the UK to determine the rate of 
acquisition of CTX-M-EC in the faecal microbiome after travel. Eighty individuals responded 
to our study advertisements, but only 28.8%, (23/80) were recruited to the study. Nearly 
half of the initial advertisement respondents (47.5%; 38/80) failed to reply to ERB, after 
provision of the participant information sheet (PIS) (appendix 2) via email. The main 
explanation for this poor response after full details of the study were provided is that the 
initial advertisement (appendix 2), does not state that volunteers are required to provide 
faecal samples, whereas the PIS clearly states the requirements of multiple faecal samples at 
several time points, without any financial reimbursement. The population targeted by the 
advertising campaign are full time professionals or students working in the NHS or at the 
University of Birmingham, and therefore it can be appreciated that these individuals may not 
be expected to have enough time to devote to providing and delivering faecal samples to 
ERB.   
 
Lecky and colleagues described the barriers facing successfully recruiting healthy volunteers 
for faecal sample collection in the UK (Lecky et al., 2017).  Lecky et al reported from a large 
population based general practice faecal collection study, where of 58337 contacted 
persons, only 3.9% returned a questionnaire and stool sample, but their sample return rate 
for interested individuals was 67.7% (Lecky et al., 2017). Therefore, our success rate of 
28.8% (23/80) does not compare favourably with the paper by Lecky et al, although the 
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information provided on our advertisements did not state that faecal sample collection was 
required, which is likely to be an important driver for non-participation (McNulty et al., 
2018). Although, beyond the resources available for the present study, a small gift voucher 
incentive (e.g. £5) would be a potential motivating factor for recruitment, particularly among 
the university student population (Lecky et al., 2017). 
 
Our attrition rate of 4/23 (17%) after volunteer consent and recruitment is lower than the 
reported rate of 33.3% in the aforementioned study, (Lecky et al., 2017). This may reflect the 
young, relatively enthusiastic group of volunteers, who were contacted by email and text 
message as reminders to provide samples. An improvement on this approach may have been 
more acceptable to provide volunteers with a larger ‘whole stool’ collection pot, rather than 
the 20ml stool container with mini-scoop, therefore providing a less unpleasant faecal 
collection method. In 3/4 cases, the volunteer drop-outs did not contact ERB stating a wish 
to withdraw from the study. Withdrawal was implied through lack of response to multiple 
emails and text messages to determine the wishes of the volunteer in question.   
 
3.5.2 Volunteer demographics 
Ethnicity is an important factor to illicit in prospective traveller studies of this kind, because 
individuals of Middle Eastern or South Asian (MESA) origin, are known to have a higher rate 
of ESBL-EC compared to individuals of European origin, as evidenced by a study from 
Birmingham, UK (Wickramasinghe et al., 2012). In general practice populations, the MESA 
group had 22.8% ESBL-EC faecal carriage compared with 8.1% carriage in the European 
group. In the present study, however, we did not exclude MESA-origin participants. This 
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would be ethically questionable, and furthermore, individuals of South Asian origin make up 
a large population of Birmingham, and 32% of volunteers in our study. 
 
A potential limitation of the study is a degree of selection bias in that our study population is 
not representative of the population as a whole. The study population are young (mean age 
35) and given the recruitment sites – well educated – all volunteers in this study were at 
least previous recipients of a bachelor’s degree or were current undergraduate students. 
Recruiting a more representative sample including different age groups, socioeconomic 
groups, and ethnicities would require extensive resources outside the capabilities of our 
study. Nevertheless, our main study outcomes are broadly in concordance with other large 
traveller studies, which will be described in due course.  
 
3.5.3 Sample collection 
3.5.3.1 Pre-travel participant exclusion 
It can be seen that our study exclusion criteria were effective in ruling out participants based 
on a previous travel history to the Indian subcontinent, as only 1/19 volunteers carried CTX-
M-EC before travel. This person had travelled to India 4 months prior to the pre-travel 
sample submission, which is the likely source of the CTX-M-EC detected. In the UK, previous 
travel to high endemicity regions is a risk factor for ESBL faecal carriage 
(McNulty et al., 2018).  
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3.5.3.2 Faecal sample collection 
A separate sterile swab loaded with faeces was used to inoculate culture plates and BHI 
broth for enrichment. Sterile swabs were confirmed to carry approximately 0.5g of faecal 
material, however, this varies according to the water content of the sample. Therefore, 
estimating the E. coli cfu/ml in any faecal sample was not possible. In addition, a previous 
study suggests that stool consistency is related to gut composition and microbial richness 
(Vandeputte et al., 2015). Stool consistency was not recorded in the present study, and this 
is difficult to assess once samples are compressed in a 10ml faecal sample container. 
Therefore, no attempt was made to estimate the E. coli abundance (cfu/ml) in this study. 
 
3.5.4 Volunteer post travel- related meta-data 
Arcilla and colleagues identified several risk factors for ESBL-E acquisition using multi-
variable logistic regression. These included antibiotic consumption during travel, travellers’ 
diarrhoea, consumption of food from street vendors, and in South Asia, eating food daily at a 
hostel or guesthouse (Arcilla et al., 2017). 
 
Travelling for ‘non-business’ reasons (95%; 18/19) has also been identified as a risk factor for 
ESBL-EC acquisition (Peirano et al., 2017). Although not known to be a risk factor for CTX-M-
E acquisition, 5/19 volunteers were medical students who spent time during their trip 
working in hospitals. There is therefore a possibility that these five individuals may have 




3.5.5 Travellers to South Asia have a high CTX-M-EC acquisition rate 
This study has demonstrated an ESBL-EC acquisition rate of 89% (Figure 3.1 and Table3.4), 
which is in concordance with previous studies. The largest traveller study to date which 
included 2001 healthy volunteers (the COMBAT study) found that the country visited with 
the highest ESBL-EC acquisition rate was India: 89% (70/79) of those who travelled from the 
Netherlands to India acquired ESBL-producing E. coli (Arcilla et al., 2017). Other traveller 
studies have also shown high acquisition rates of ESBL-producing Enterobacteriaceae in 
those who visit the Indian subcontinent: prospective studies report acquisition rates of 73% 
(66/90 participants) (Peirano et al., 2017); 49% (30/61) (Vading et al., 2016); 85% (53/62) 
(Ruppé et al., 2015); 46% (28/61) (Kantele et al., 2015); and 87% (59/68) (Kuenzli et al., 
2014).  After WGS and bioinformatic screening of contigs, none of our post travel isolates 
contained carbapenemase genes. This is in keeping with the COMBAT study which reported 
the rate of CPE acquisition in returning travellers as <1% (Arcilla et al., 2017). 
 
Specific blaCTX-M genotypes are often strongly associated with specific regions, in particular, 
CTX-M-producers in India are almost entirely comprised of blaCTX-M-15, whereas in China, 
blaCTX-M-14 is the predominant genotype (Bevan, Jones and Hawkey, 2017). Therefore, the 
high acquisition rate of CTX-M-15-producing E. coli is unsurprising, as most volunteers 
travelled to India. Volunteers 4 and 19 who acquired blaCTX-M-14 travelled to China and/or Sri 
Lanka, where blaCTX-M-14- producing E. coli are common (Hawkey, 2008; Tillekeratne et al., 
2016). However, volunteer 16 only travelled to India, where blaCTX-M-14 is a rare genotype, 
but this individual travelled widely (Kerala, Karnataka, New Delhi, and Uttarakhand), and 
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also worked in a Bengaluru hospital as a volunteer for 4 weeks, providing opportunities for 
acquisition of what is an unusual blaCTX-M genotype in India.  
 
The results of our selective culture-based screening showed that this was a sensitive 
method, sometimes detecting isolates with mechanisms conferring 3GC resistance, other 
than CTX-M production (Figure 3.4). In the case of 14 isolates, we did not detect any ESBL or 
AmpC genes, which suggests that either these E. coli grew on selective media which failed to 
suppress their growth for some reason, or the isolates in question have an alternative 
resistance mechanism, which was not detected using the resistance-gene finder. 
 
We used CTX-M grouping PCRs to confirm the presence or absence of blaCTX-M in all our 
isolates which were culture positive on selective media for ESBL-producing E. coli. Our 
approach did have some limitations. The PCR primers used in these experiments did not 
include group 8/25 CTX-M. The lack of coverage of group 8/25 CTX-M producers in the PCR 
screening stage was mitigated by the sequencing (WGS) of all culture-positive isolates 
(putative ESBL producers) which were CTX-M-negative after grouping PCR. Therefore, rarer 
CTX-M genes or other resistance mechanisms could be detected after WGS. We did not find 
any blaCTX-M genotypes other than CTX-M-14 and CTX-M-15, which is unsurprising, as these 
are the genotypes prevalent in the countries visited by our volunteers (Tillekeratne et al., 
2016; Bevan, Jones and Hawkey, 2017).  
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3.6 Conclusion 
A prospective observational cohort study was undertaken, recruiting persons travelling from 
the UK to South Asia. Twenty-three participants were recruited and retained for follow-up, 
exceeding the original target of twenty.  
 
Although there may be a degree of selection bias in terms of the demographic and socio-
economic groups recruited, this is a difficult hurdle to overcome – as individuals who make 
long haul trips to South Asia tend to be well educated and/or have above average disposable 
income. Furthermore, the acquisition rate of CTX-M-EC, and the CTX-M genotypes in 
returning travellers, correlated closely with data from previous studies.  
 
This chapter has outlined volunteer recruitment, demographics, and CTX-M-EC acquisition. 
The following chapters will focus on the dynamics of CTX-M-EC acquisition, with particular 
focus on the E. coli clones acquired after travel (Chapter 4) and characterisation of the blaCTX-









Chapter 4: The molecular dynamics of acquisition of CTX-M-
producing E. coli and relationship to non-CTX-M E. coli 
 
4. 1 Introduction  
In the present study, a high acquisition rate of CTX-M-producing Enterobacteriaceae was 
found (89%), for individuals who returned to the UK from South Asia. In a larger cohort of 
volunteers, Arcilla and colleagues also found that 89% (70/79) individuals returning to The 
Netherlands from India, also acquired CTX-M-producing Enterobacteriaceae (Arcilla et al., 
2017). Acquisition rates by world region, and risk factors for acquisition have been 
investigated previously (Chapter 1, section 1.7.), however, the dynamics of acquisition of 
CTX-M-producers and non-producers in travellers is not well understood.  
 
The aim of this chapter is to investigate the acquisition and Loss of CTX-M-producing and 
non-producing E. coli in the faecal microbiome of travellers to South Asia. Whole genome 
sequencing (WGS) was used to type strains before and after travel, providing an insight into 
the changing populations of E. coli, including the role of non-CTX-M, cephalosporin sensitive 




1. Acquisition of CTX-M-E. coli is due to multiple acquisition events which leads to colonisation with 
multiple E. coli clones after travel 
2. CTX-M-EC are maintained in the faecal microbiome after return to the UK 
3. CTX-M-EC do not displace non-CTX-M E. coli which were present before travel 
4. Non-CTX-M strains persist as a minority population in the faecal microbiome, despite CTX-M-EC 
acquisition 





The methodology for faecal sample collection, culture, and isolate identification is outlined 
in chapter 3. PCR was used as a screening method before putative ESBL producers were 
subjected to WGS. Primers for multiplex PCR were used to identify the three most common 
CTX-M groups: group 1, group 2, and group 9. PCR was carried out only on isolates which 
had grown either on ESBL agar or from within the zones of cefpodoxime on nonselective UTI 
agar. PCR amplimers were visualized using 1% agarose gel electrophoresis, as described in 
chapter 3. 
 
4.3.1 Tooth-picking experiments 
In order to characterise the cefotaxime-sensitive population of E. coli within stool samples 
containing CTX-M-positive post travel E. coli, a selection of post-travel stool samples were 
subjected to tooth-picking experiments. As outlined in chapter 3, Oxoid UTI brilliance agar 
was used to culture E. coli (pink colonies) directly from stool samples. After checking for the 
presence of blaCTX-M using PCR, tooth-picking experiments were undertaken. A sterile wire 
was used to pick individual putative E. coli colonies (pink colonies) from the chromogenic 
plate. Each colony was then lightly ‘scored’ (2-3mm) onto antibiotic free LB agar, and to LB 
agar containing cefotaxime (4µg/ml). The wire was flamed between each colony pick. 100 
colonies were picked from each faecal sample tested. Isolates which grew on the antibiotic-
free plate but failed to grow on the cefotaxime plate were enumerated and sweeps of this 
cefotaxime-sensitive population were stored at -80⁰C for each stool sample tested. 
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4.3.2 Whole genome sequencing  
Automated DNA extraction and whole-genome sequencing were undertaken by MicrobesNG 
at the University of Birmingham. Sequencing was performed using HiSeq 2500 with 250-bp 
paired-end reads. QC was performed using QUAST (Gurevich et al., 2013). All isolates were 
assembled using SPAdes (Bankevich et al., 2012) and annotated using Prokka (Seemann, 
2014).  
 
4.3.3 Bioinformatic analyses 
Downstream bioinformatics analysis after illumina sequencing was undertaken using the 
Cloud Infrastructure for Microbial Bioinformatics (CLIMB). This is a cloud based computing 
network for the processing storage and analysis of large genome datasets (Connor et al., 
2016). All analysis using illumina reads and contig files was undertaken using command-line 
based software. 
 
All sequenced E. coli isolates were subjected to analysis, by determining the multi locus 
sequence type (MLST) (Maiden et al., 1998) and determining the antimicrobial resistance 
(AMR) genes present in each strain. The E. coli Achtman MLST scheme 
(enterobase.warwick.ac.uk/species/ecoli/) of each strain was determined by inputting contig 
files and running the mlst program, (github.com/tseemann/mlst)  (Seemann, 2017b). AMR 
gene sequences were found using each strain contig file using abricate, which uses the AMR 
databases CARD and Resfinder (github.com/tseemann/abricate) (Seemann, 2017a).   
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4.3.4 Identifying E.coli clones from WGS data 
Illumina sequence reads (fq files) and assembled draft genomes (fasta files) were used to 
determine the phylogenetic relationships of selected strains. In addition to obtaining the 
MLST of each E. coli strain in the study, a core genome alignment of all strains was also 
undertaken, using Parsnp, from the harvest suite of bioinformatics tools. Parsnp is useful in 
aligning large numbers of similar strains using core regions of similarity between strains 
(Treangen et al., 2014). 
 
Higher resolution SNP typing was undertaken to ascertain the relationship between identical 
STs (i.e. the number of SNPs between E. coli strains). SNP typing was undertaken using a 
pipeline of individual programs. Firstly, snippy was used to find SNPs between a chosen 
reference genome and a set of sequence reads, thus creating a core genome SNP alignment, 
as described, github.com/tseemann/snippy (Seemann, 2017c). Using the output from 
snippy, a maximum likihood phylogenetic tree, with bootstrapping, was generated using 
MEGA (run on Mac OS Sierra), (Kumar, Stecher and Tamura, 2016). A MEGA computation 
would usually take approximately 4 hours for a phylogeny consisting of 40 E. coli sequences. 
Finally, SNP distances between each isolate in the phylogeny were determined using snp-
dists, which produces an output in the form of a table matrix (github.com/tseemann/snp-
dists) (Seemann, 2017d). Outputs were displayed using phandango (Hadfield et al., 2017). 
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4.3.5 Determining resistance gene content of E. coli strains 
Resistance gene finder (cge.cbs.dtu.dk/services/ResFinder/) was used to determine the AMR 
gene content of strains: the draft WGS genomes were run against the ResFinder database 
(Zankari et al., 2012).  
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4.4 Results  
4.4.1 Travellers to South Asia have a high CTX-M-EC acquisition rate 
A breakdown of faecal culture and blaCTX-M PCR results are covered in chapter 3. Post-travel, 
blaCTX-M had been acquired by 16/18 (89%) volunteers (Chapter 3, Table 3.4).  
After WGS and bioinformatic screening of contigs using ResFinder, none of our post travel 
isolates contained carbapenemase genes. 
 
4.4.2 CTX-M-EC acquisition is Polyclonal 
CTX-M-producing E. coli acquired during travel came from a wide range of sequence types 
(STs) and phylogenetic groups (Figure 4.1). Among volunteers in our study we found 11/15 
(73%) acquired CTX-M-EC belonging to phylogenetic group (PG) A. Other common PGs were 
PG-D (6/15 volunteers, 40%), PG-B2 (5/15, 33%), and PG-B1 (4/15, 27%). PG-B2 comprised of 
ST131 in 4/5 volunteers, and ST1193 in 1/5 volunteers (Figure 4.1). 
 
For volunteers acquiring CTX-M-EC, gut colonisation with CTX-M-EC was often polyclonal 
(8/15 volunteers with sequenced E. coli had >1 MLST producing CTX-M). (Table 4.1 and Table 
S1, appendix 1). The mean number of acquired E. coli STs per volunteer was 3 (median 3, 
range 1-9). 7/15 travellers had >3 E. coli ST with blaCTX-M. Taking the number of volunteers 
with WGS data as the denominator, the commonest ST among CTX-M-producing E. coli was 




Figure 4.1. Phylogenetic relationships of pre- and post-travel E. coli strains. Displays the phylogenetic groups, majority MLST types, and 
presence of blaCTX-M before and after travel top South Asia. Four hundred eighty-three E. coli strains from 15 volunteers. *white bars indicate 
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Table 4.1. Pre- and post-travel E. coli from each volunteer indicating CTX-M-EC, non-CTX-M-EC, and tooth-picked strains. 
Volunteer 
Number of faecal 
samples 
E. coli MLST after illumina sequencing 
Pre-travel Post-travel Pre-travel Post travel ST of non-CTX-M-EC from tooth-picking experiment 
1 2 4 131 349, 394, 69, 131  
3 3 6 69, 941, 2008 43, 38, 1193, 405 2076, 617, 46 (3 cols sample 3a), 224 (1 col from 3b), 10 (2 cols from 3f) 
4 2 5 10 2732, 69, 648  
5 1 10 452 38, 405, 131, 48, 10, 6338, 88, 3478  
6 3 4 69, 73 450, 8095, 2221, 73  
7 3 6 10, 69 10, 6438, 43, 200, 3036, 69  
8 2 7 69, 1163, 2712, 10 448, 10, 648, 131, 38 *38 (1 col from 8g) 
9 3 6 69, 3727, NT 4, 200, 2617 *2617 (1 col 9f) 
10 3 4 354 642, 200, 34, 10  
12 2 8 1314, 10, 752, 770 43, 1276, 189, 5919, 216  349 (1 col from 12e) 
15 2 3 210, 10 167, 52, 10  
16 2 5 349 38, 227, 131  
17 2 3 NT, 131 450, 43, 131 206 (1 col from 17a) 
19 2 1 10 43 7174 (1 col from 19a) 
20 2 6 10,452, NT 6438, 162, 131, 226, 405, 10 2797 (1 col 20a), *10 (1 col 20b) 
22 2 3 2619 226, 607, 2967, 7174  
Blue rows indicate where there is data from tooth-picking experiments 
*ST2617, non-CTX-M-EC, in faecal sample 9f, is not the same strain as the CTX-M-producing ST2617, also from volunteer 9 faeces (determined by SNP 
typing). 
For STs, black font indicates non-CTX-M; red font indicated CTX-M-15; blue font indicates CTX-M-14. Text in parentheses indicates the number 
of tooth-picked colonies which were sequenced. NT, non-typeable. 
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4.4.3 CTX-M-EC clones are maintained after travel 
The mean duration of carriage of CTX-M-EC was 113 days, with a median of 60 days. This 
carriage duration must be considered to be an underestimate, because 8/16 volunteers 
remained CTX-M-EC carriers at the last faecal sampling point. 46% (6/13) volunteers were 
known to CTX-M-EC positive at 6 months after travel. E. coli STs with blaCTX-M which were 
carried the longest in this study were ST131 (PG-B2) (11 months, volunteer 8), ST405 (PG-D) 
(9 months, volunteer 3), and ST648 (PG-B1) (8 months, volunteer 8). Considering all strains 
which colonised the faecal microbiome for the longest duration, there was no predominance 
of any particular ST or PG.  
 
Eight volunteers provided stool samples at two or more time points after travel. Of these, 
8/8 volunteers carried CTX-EC of the same ST in stool samples at different time points (Table 
4.2). Using SNP typing, in 8/8 volunteers the isolates found in separate faecal samples are 
<10 SNPs apart, suggesting stable colonisation with the same strain over several months 
(Table 4.2). Four volunteers had post travel CTX-M-EC isolates which were indistinguishable 
(0 SNPs) between separate post travel faecal samples collected at different time points: 





Table 4.2. SNP typing of Post travel CTX-M-EC. 
Strain (preceding number is 
volunteer number) 
Sample collection point (days post 
travel) 
MLST 
3b3 7 1193* 3b4 11930 









































5c4 28 days 4648 
5e3 91 days 38
6 
5e4 386 






























































































*indicates reference strain for SNP comparisons for any given volunteer. SNPs are displayed as super-script 
after the ST; 




4.4.4 E. coli without CTX-M acquired during travel co-colonise the GI tract alongside 
CTX-M acquired strains after travel 
The aim of this experiment was to determine whether faecal samples containing CTX-M-EC 
co-colonise the faecal microbiome with CTX-M non-producers. Tooth-picking experiments 
were undertaken for faecal samples from eight volunteers who were known to have 
acquired CTX-M-EC.  
 
Data from tooth-picking 100 colonies per faecal sample, followed by spotting on to plain LB 
agar, followed by onto cefotaxime-containing agar, is displayed in Table 4.1 and Figure 4.2. 
In 3/4 volunteers, for whom we collected tooth-picking data on multiple faecal samples, the 
proportion of cefotaxime-resistant strains diminishes over time (Figure 4.2). In 7/7 cases 
where non-CTX-M tooth-picked isolates were sequenced, we found unique non-CTX-M-
















4.4.5 Resident E. coli Persist as a minority population in the faecal microbiome 
For seventeen volunteers, non-CTX-M-EC populations were sequenced before and after 
travel. In the case of seven volunteers who had acquired and then lost CTX-M-EC, we 
detected the same non-CTX-M-EC MLSTs before and after travel. We used SNP typing to 
clarify whether these strains were the same clonal lineage of non-CTX-M-EC before versus 
after travel. In 5/7 volunteers we found near-indistinguishable strains (<20 SNPs) before 















Table 4.3. SNP comparisons of pre and post travel non-CTX-M E. coli for volunteers with the same MLSTs 




point+ (days pre or 
post travel) 
MLST 
1_1a    
10 days pre 
131* 
1_1b    1315 
1_1c 1311 
1_1d    13119 
1_2a    
5 days pre 
13117 
1_2b    13118 
1_2c    1316 
1_e_1   
122 days post 
1313 
1_e_2   1316 
1_e_3   1312 
6_1c     
42 days pre 
7317 
6_1e     7314 
6_2a     











6_3e     7320 
6_3f     7388 
6c2 









Green shading: pre-travel; orange: post travel. 
*indicates reference strain for SNP comparisons for any given volunteer. SNPs are displayed as super-script 
after the ST 
+Sample collection point only includes faecal samples where the E. coli sequence type displayed for that 





Table 4.3. (Continued). SNP comparisons of pre and post travel non-CTX-M E. coli for 
volunteers with the same MLSTs before vs. after travel. 
  
Sample collection 




60 days pre 
10* 
7_1b     102 
7_1c     102 
7_1d     101 
7_1e     100 
7_1f     105 
7_3b     
7 days pre 
102 
7_3c     103 
7_3d     104 
7_3e     102 
7_3f     102 
7a1     5 days post 1018143 
7b1 



























Green shading: pre-travel; orange: post travel.  
*indicates reference strain for SNP comparisons for any given volunteer. SNPs are displayed as super-script 
after the ST. +Sample collection point only includes faecal samples where the E. coli sequence type displayed 




Table 4.3. (Continued). SNP comparisons of pre and post travel non-CTX-M E. coli for 
volunteers with the same MLSTs before vs. after travel. 
  
Sample collection 

















17_2a    
3 days pre 
131* 
17_2b    13118 
17_2c    13112 
17_2d    13111 
17_2e    13127 
17_2f    1318 
17c1 
84 days post 
13116 
17c2    13129 
17c3    13117 
17c4    13145 
20_1b 
10 days pre 
1013568 
20_1c 1013553 
20_2a 4 days pre 1014956 
20bpp   42 days post travel 10* 
20f1 120 days post 1010 
20g1 





Green shading: pre-travel; orange: post travel.  
*indicates reference strain for SNP comparisons for any given volunteer. SNPs are displayed as super-script 
after the ST 
+Sample collection point only includes faecal samples where the E. coli sequence type displayed for that 







4.4.6 Co-travelling spouses share non-CTX-M E. coli ST200 
Volunteers 9 and 10 are spouses who travelled to Sri Lanka and India together. Table 4.4 
shows the relatedness of four ST200 strains isolated from faecal samples from both of these 
volunteers. As can be seen from the SNP matrix these strains are indistinguishable between 
volunteer 9 and 10, with zero SNPs between isolate 9a2 and 10a1.  
 
4.4.7 Rise in overall number of different AMR genes after travel  
Figure 4.3 a-h displays AMR gene presence for fifteen volunteers with WGS data. After 
travel, E. coli in the microbiome carry a greater abundance of antimicrobial resistance genes 
compared to before travel (11/15 volunteers had increased abundance of AMR genes in 
post-travel faecal samples compared to pre-travel samples) (Figure 4.3 a-h). 
 
It is notable that volunteer 6 pre-travel E. coli contained no detectable AMR genes encoded 
by the two E. coli clones detected in pre-travel faecal samples (ST69 and ST73), compared to 
post travel E. coli (Figure 4.3 d). During the first 6 weeks of post-travel sampling for 
volunteer 6, antibiotic resistance genes to seven antibiotics were encoded by post travel E. 
coli (clones ST450, ST2221 and a clone with no ST assigned).  
 
Several other volunteers only carried one class of AMR gene pre-travel (tetracycline 







Table 4.4. SNP distance matrix of faecal ST200 E. coli from volunteer 9 and 10. 
 
 9a2* 10a1 10b1 10b2 
9a2* 0 0 1 7 
10a1 0 0 1 7 
10b1 1 1 0 8 
10b2 7 7 8 0 












































Figure 4.3h. AMR gene profile of pre and post-travel E. coli for volunteers 20 and 22.  
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4.5 Discussion 
4.5.1 CTX-M-EC acquisition is polyclonal 
CTX-M-producing E. coli acquired during travel came from a wide range of sequence types 
(STs) and phylogenetic groups, in keeping with previous studies (Weisenberg et al., 2012; 
Paltansing et al., 2013; Kuenzli et al., 2014; Pires et al., 2016; Vading et al., 2016). 
 
The pattern of E. coli PG group acquisition in the present study (Figure 4.1) are in keeping 
with previously published work which found a predominance of PG-A in travel-acquired 
strains (Valverde et al., 2015; Pires et al., 2016). Moreover, CTX-M-EC belonging to  PG-A, 
PG-D, and PG-B1 are commonly acquired after travel (Pires et al., 2016). In terms of E. coli 
pathogenicity, PG-B2 and PG-D tend to be extra-intestinal pathogenic E. coli (ExPEC), 
particularly urinary sepsis and bacteraemia, whereas PG-A and PG-B1 usually lack the 
required pathogenicity genes required for successful extra-intestinal virulence in humans 
(Boyd and Hartl, 1998).  
 
For each volunteer who acquired CTX-M-EC, the acquisition of >ST was common (8/15 
volunteers). The most common STs were ST131, ST38, ST10, and ST43. Limited data suggests 
that the prevalence of ST131 isolates in Indian CTX-M-EC clinical isolates varies between 9-
25% (Hussain et al., 2012; Roy et al., 2015; Ranjan et al., 2017). However, apart from the 
present study (Bevan et al., 2018), no studies to date have surveyed faecal carriage of E. coli 
in India.  
 
 122 
Relatively few studies have assessed the E. coli MLSTs from the human microbiome 
identified after travel, but all found there to be a wide range of ESBL-producing E. coli MLSTs 
acquired through travel, (Weisenberg et al., 2012; Paltansing et al., 2013; Kuenzli et al., 
2014; Pires et al., 2016; Vading et al., 2016). Pires and colleagues showed that travel from 
Switzerland to India results in polyclonal colonisation with CTX-M-producing E. coli with a 
mean of 2 STs and a range of 1-5 (Pires et al., 2016). In addition, Kuenzli et al found that in a 
representative population of 34 CTX-M-EC acquired after travel to India, there were 24 
different STs (Kuenzli et al., 2014).   
 
Pires and colleagues stated that re-colonisation after travel with a pre travel ST648 clone 
occurred (Pires et al., 2016), but unlike the present study, they did not undertake SNP typing 
to confirm presence of an indistinguishable strain (Bevan et al., 2018). In the current study, 
in post travel faecal samples in at least 4 volunteers, we were able to detect the same non-
CTX-M E. coli clones which had been present before travel, and before CTX-M-EC acquisition. 
The strains found after travel were almost identical (< 10 SNPs) from the pre-travel strains, 
therefore the re-acquisition of E. coli from the ‘home’ UK environment can be ruled out. 
Therefore, the pre-travel E. coli are not replaced by acquired CTX-M-EC strains, rather there 
is co-colonisation with acquired E. coli and pre-travel pre-existing E. coli. The loss of CTX-M-
EC after travel, albeit sometimes up to a year post travel, may be due to the competition 
from pre-existing non-CTX-M E. coli.  
 
Although Arcilla and colleagues conducted the largest prospective traveller study, which 
included >1000 volunteers, their focus was on risk of acquisition and onward transmission of 
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CTX-M-EC, and they did not analyse the clonal relationships between Enterobacteriaceae 
acquired by travellers (Arcilla et al., 2017). 
 
The commonest STs among the volunteer cohort after travel, with CTX-M-producing E. coli, 
were ST131, ST38, ST10, and ST43. These E. coli strains were colonisers of the faecal 
microbiome and were not infecting strains. It is notable that the E. coli STs acquired by seven 
volunteers were either ST131 or ST38 (Figure 4.1). E. coli ST131 (part of PG B2) and to a 
lesser extent, ST38 (part of PG D) are known to be common causes of ESBL-producing-ExPEC 
infection in humans, shown to cause bacteraemia in recent surveys (Roer et al., 2017; Harris 
et al., 2018)( see also Chapter 2, section 2.5.2).   
 
The volunteers in this study were healthy, and all participants denied any illness on the days 
of faecal sampling. Volunteers were not followed up to determine the incidence of ExPEC 
infection in our cohort, but given that the participants were young, healthy individuals, 
ExPEC infection is likely to have been low or absent. Further work in this area would involve 
screening travel acquired CTX-M-EC for pathogenicity genes to give an indication of the 
clinical significance of these strains, in terms of their potential to cause ExPEC infection. 
 
 
4.5.2 CTX-M-EC clones are maintained in the faecal microbiome after travel 
The median duration of carriage of CTX-M-EC was 60 days, with 46% of volunteers (6/13) 
known to be CTX-M-EC positive at 6 months after travel. Volunteer 8 carried CTX-M-EC for 
the longest (11 months). However, a limitation of the carriage-data in this study is that 50% 
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of volunteers with CTX-M-EC were still colonised at the final sampling point. Therefore, the 
duration of carriage in 50% of volunteers was not determined, and the overall mean carriage 
duration is an underestimate.  
 
Arcilla and colleagues found 11.3% were still colonised with ESBL-producing 
Enterobacteriaceae at 12 months post travel, with a median post travel duration of 
colonisation of 30 days, but did not report a subgroup analysis on the duration of carriage 
for 79 travellers who went to India (Arcilla et al., 2017). Correlating with this study, Pires 
reported a 40% colonisation rate (6/15 travellers), 6 months after returning from India (Pires 
et al., 2016). In addition, Ruppe et al found that 7.2% (8/111) of ESBL-carriage positive 
travellers were still carriers at 6 months after travel to Asia (Ruppé et al., 2015). Moreover, 
Ruppe et al reported that travel to Asia is significantly associated with a longer duration of 
carriage compared to travel to Africa or Latin America (Ruppé et al., 2015). A more recent 
Canadian study which found that of 70 travellers to the Indian subcontinent who acquired 
ESBL-producing E. coli, 21% (15/70) were still colonised after return to Canada (Peirano et 
al., 2017).  
 
Volunteer 5 is particularly notable as having first travelled to Uzbekistan with return to the 
UK, followed by a second excursion to India, and then return to the UK. Putting the post 
travel CTX-M-EC-containing faecal samples into perspective, Sample 5.2 was collected 4 days 
after return from Uzbekistan (sample with isolate ST38), sample 5a1 was collected 5 weeks 
after the Uzbekistan trip and 3 days after the volunteer returned from India (sample ST48), 
and sample 5e4 was collected 12 weeks after the travel to India (sample with ST38). The 
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ST38 isolates in faecal samples 5.2 and 5e4 is only 6 SNPs apart, suggesting that the same 
CTX-M-EC strain remained as a coloniser within the faecal microbiome in the home 
environment post Uzbekistan, during the trip to India, and again stably maintained on return 
to the UK (Table 4.2 and Figure 4.3c). 
 
Given the diversity within E. coli, it is not surprising that we also found colonisation with 
completely different strains of the same MLST group. For volunteer 8 ST10 isolates (Table 
4.3), closely related CTX-M-EC are carried for 2-8 weeks after travel, but in addition there is a 
second ST10 population detected at 8 weeks post travel which is unrelated to the ST10 
detected in earlier post travel samples (13323 SNPs apart) (Table 4.3). 
 
4.5.3 E. coli without CTX-M acquired during travel co-colonise the GI tract alongside 
CTX-M-EC after travel 
The proportion of cefotaxime-resistant E. coli in faecal samples known to contain CTX-M-EC, 
varied considerably between volunteers, and at different time points for the same volunteer 
(Figure 4.2). Picking 100 colonies per faecal sample allows the isolation for the major E. coli 
strains in the sample, as previously described (Hedges, Howe and Linton, 1977).  
 
In faecal samples collected from the same volunteer that were analysed using tooth-picking 
over time, the proportion of cefotaxime-resistant strains did not remain stable (Figure 4.2). 
In 3/4 volunteers, the proportion of cefotaxime-resistant strains diminishes over time, 
probably reflecting out competition from non-CTX-M-EC and lack of re-exposure to CTX-M-
EC through ingestion in the UK.  
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A limitation of the tooth-picking approach is that only 15 strains were sequenced from 8 
volunteers (in most cases one colony pick per volunteer). Therefore, the true diversity of 
non-CTX-M E. coli in faecal samples containing CTX-M-producers, could not be ascertained. 
However, the present study is the first to demonstrate co-colonisation of 3-GC- sensitive E. 
coli in the faecal microbiome containing CTX-M-producing strains (Bevan et al., 2018). There 
are 2 possibilities underlying this phenomenon: (1) Gut colonisation during travel includes 
CTX-M-producers and CTX-M non-producers; (2) The CTX-M non-producers were acquired 
after return to the UK and were detected in stool samples co-colonising with travel-acquired 
CTX-M-producers. It is also possible that both scenarios take place. However, in 7/7 tooth-
picking experiments, the 3-GC-sensitive E. coli STs detected were new – the STs were 
different from both the pre-travel CTX-M-free strains – and the post-travel CTX-M-
producers. Thus, our data suggests that travel results in acquisition of both CTX-M-
producers, and non-producers (Table 4.1). Sampling volunteers while overseas would be 
required to prove this hypothesis. No such study has been published to-date.   
 
4.5.4 Pre-travel resident E. coli persist as a minority population in the faecal 
microbiome  
The present study is the first to show that pre-travel resident E. coli persist as an 
undetectable minority population in the faecal microbiota of volunteers who have acquired 
CTX-M-EC. This is a novel finding: pre-travel non-CTX-M- E. coli are not completely displaced 
from the faecal microbiome, but are maintained as a minority population throughout travel, 
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and become detectable again as a majority population after travel. (Table 4.3) (Bevan et al., 
2018). 
 
A small number of studies have considered the E. coli clonal dynamics of travel-acquired 
strains over time (Paltansing et al., 2013; Pires et al., 2016; Vading et al., 2016). Pires found 
3/15 volunteers who were CTX-M-positive before travel, and in 1/3 cases, the ST648, CTX-M-
14-producing strain found before travel - was also detected at 3 months after travel – and 
was presumably the same pre-travel strain. Similarly, Vading used Rep-PCR to show that 4 
volunteers carried the same PG-B2 ESBL-producing Enterobacteriaceae before and after 
travel (Vading et al., 2016). Moreover, Paltansing showed that 4/7 volunteers who were CTX-
M-positive pre travel, had the same CTX-M-strain genotype and ST combination detected in 
faecal samples after travel (Paltansing et al., 2013). Based on the findings from Pires, Vading 
and Paltansing, it is reasonable to suggest that pre-travel CTX-M-EC often persist throughout 
the period of travel and are detectable in post travel faecal samples. However, unlike the 
present study, none of these studies did SNP-typing of strains, therefore definitive evidence 
of pre-travel strain persistence was not provided. 
 
4.5.5 Volunteer 9 and volunteer 10 share indistinguishable E. coli ST200 
Both volunteers 9 and 10 share the same ST200 strain, which is a pre-travel non-CTX-M-
producing E. coli. (Table 4.4).  
 
When an identical (0 SNPs distance) strain is found from two volunteer samples, the 
possibility of laboratory cross-contamination must be considered and ruled out. Cross 
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contamination in the laboratory, but also at the volunteer sample collection stage is a 
possibility for the samples in question because volunteers 9 and 10 were spouses, and 
probably used the same bathroom facilities. This is particularly the case for faecal samples 
9a and 10a which were submitted on the same day.  
 
However, indistinguishable ST200 strains were found at a later sampling point: 1 SNP 
between isolate 9a2 (5 days post travel faecal sample, volunteer 9) and 10b1 (30 days post 
travel faecal sample, volunteer 10). The same E. coli ST200 is present in different volunteer 
faecal samples, on different occasions, separated by in time. Therefore, there has probably 
been household transmission between volunteers 9 and 10. Such an occurrence has been 
described in the literature, most recently by Arcilla and colleagues who calculated a 12% risk 
of transmission of faecal E. coli between a returning traveller and a non-travelling household 
contact (Arcilla et al., 2017).   
 
4.5.6 Mechanism of blaCTX-M acquisition  
Typing of CTX-M-EC and non-CTX-M-EC before and after travel using MLST and SNP typing 
was used to ascertain whether HGT of blaCTX-M had occurred. After MLST of pre- and post-
travel E. coli for sixteen volunteers, 13/16 had different E. coli STs with blaCTX-M, to pre-travel 
non-CTX-M E. coli (Table 4.5). For 3/16 volunteers, pre-travel non-CTX-M-EC before travel 
and CTX-M-EC after travel had the same ST, ST10 (Table 4.5). This suggested that HGT of the 
blaCTX-M gene onto a pre-existing E. coli ST10 had occurred. In order to investigate this initial 
finding, SNP typing was used to assess the ST10 strain relatedness for each volunteer. Pre- 
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and post-travel ST10s for each of volunteer 7, 8, and 20 were >13,000 SNPs apart, indicating 
that these were not the same strain. Therefore, HGT of blaCTX-M was not detected (Table 4.5). 
 
 
Table 4.5. Investigating volunteer isolates for horizontal gene transfer.  
 
Volunteer Pre- and Post-travel MLST comparison SNP typing 
1 New ST post-travel with blaCTX-M N/A 
3 New ST post-travel with blaCTX-M N/A 
4 New ST post-travel with blaCTX-M N/A 
5 New ST post-travel with blaCTX-M N/A 
6 New ST post-travel with blaCTX-M N/A 
7* ST10 pre (no blaCTX-M) and post travel (with 
blaCTX-M) 
Pre vs. post-travelST10s 
>18,000 SNPs apart 
8* ST10 pre (no blaCTX-M) and post travel (with 
blaCTX-M) 
Pre vs. post-travelST10s 
>13,000-18,000 SNPs apart 
9 New ST post-travel with blaCTX-M N/A 
12 New ST post-travel with blaCTX-M N/A 
15 New ST post-travel with blaCTX-M N/A 
16 New ST post-travel with blaCTX-M N/A 
17 New ST post-travel with blaCTX-M N/A 
19 New ST post-travel with blaCTX-M N/A 
20* ST10 pre (no blaCTX-M) and post travel (with 
blaCTX-M) 
Pre vs. post-travel ST10s 
>13,000-15,000 SNPs apart 
21 New ST post-travel with blaCTX-M N/A 
22 New ST post-travel with blaCTX-M N/A 









In eight volunteers, multiple different STs with CTX-M-EC were acquired (Table 4.1), 
however, no cases were found where a plasmid sequence matched between strains of a 
different sequence type. Therefore, HGT was not detected occurring between different E. 
coli strains in post travel faecal samples.  
 
 
4.5.7 Rise in AMR gene frequency after travel  
After travel, there was a rise in overall antimicrobial resistant gene abundance, associated 
with blaCTX-M acquisition, which is usually due to carriage of multiple AMR genes on 
plasmids (Woodford et al., 2009). Investigation of post travel ESBL-producing (and 3GC-
resisitant) E. coli in a number of studies has determined antibiotic co-resistance to multiple 
antibiotics, predominantly, ciprofloxacin (Kennedy and Collignon, 2010; Tängdén et al., 2010; 
Ostholm-Balkhed et al., 2013; Paltansing et al., 2013; von Wintersdorff et al., 2014; Angelin 
et al., 2015; Lübbert et al., 2015; Barreto Miranda et al., 2016); gentamicin (Kennedy and 
Collignon, 2010; Tängdén et al., 2010; Ostholm-Balkhed et al., 2013; Paltansing et al., 2013; 
Angelin et al., 2015; Barreto Miranda et al., 2016); and co-trimoxazole (Paltansing et al., 
2013; Angelin et al., 2015; Lübbert et al., 2015; Barreto Miranda et al., 2016).  
 
Figure 4.3 a-h supports the SNP typing data (Table 4.2 and 4.3), demonstrating that pre-
travel non-CTX-M producers are not displaced, but are maintained in the faecal microbiome, 
and re-emerge as the dominant population after travel. This is shown in Figure 4.3 a-h for 
five volunteers: 1, 6, 15, 17, and 20. In all 5 cases, the pre-travel strain becomes dominant 
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again, after CTX-M-EC is lost. CTX-M-EC loss is accompanied by loss of multiple other AMR 
genes from E. coli in the faecal microbiome before the final faecal sampling point. 
 
Dissemination of CTX-M-EC is likely to occur via antibiotic co-selection, particularly in South 
Asia, where high levels of antibiotics are released into ground water during pharmaceutical 
production (Fick et al., 2009). Therefore, antibiotic co-selection provides a mechanism for 
propagation of blaCTX-M genes and any other genes present on the plasmid in question 
(Bevan, Jones and Hawkey, 2017). However, the role of antibiotic co-selection is not always 
involved in blaCTX-M dissemination, as exemplified by the CTX-M-14-producing ST2732 isolate 
carried by volunteer 4 after travel. This ST2732 strain only carried one resistance gene, 
blaCTX-M-14, which is a common phenomenon for this genotype (Cottell et al., 2011; P L Ho et 
al., 2011). Previous examples of blaCTX-M-14 carriage on a plasmid without other resistance 
genes includes the globally disseminated, epidemic plasmids: pCT (Cottell et al., 2011); and 
pHK01 (P L Ho et al., 2011).  
 
Beyond phenotypic studies of AMR in post travel E. coli isolates, only two studies were found 
which used molecular methods to determine the AMR gene content of isolates (von 
Wintersdorff et al., 2014; Bengtsson-Palme et al., 2015). A study recruiting healthy dutch 
travellers used a culture-independent PCR, applies directly to faecal samples, finding a 
statistically significant increased incidence of blaCTX-M, qnrB, and qnrS, after verses before 
travel  (von Wintersdorff et al., 2014). In keeping with our own data, tet genes were present 
at a high level both before, and after travel, suggesting continued exposure to tet-containing 
isolates at home, as well as during travel (von Wintersdorff et al., 2014).  
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A second study used shotgun metagenomic sequencing (illumina MiSeq) to assess the AMR 
gene content of the faecal microbiota before verses after travel (Bengtsson-Palme et al., 
2015). Bengtsson-Palme found a significant increase in abundance of resistance genes to 
sulphonamides, trimethoprim, and beta-lactams after travel (Bengtsson-Palme et al., 2015), 
thus providing support to the susceptibility testing undertaken in previous studies (described 
above) and the genotypic findings in the present study (Figure 4.3, a-h). 
Further work in the analysis of the AMR genes in strains would involve selecting 
representative strains for long read sequencing, to determine sequence of plasmids and/or 
large insertion sequences with multiple AMR genes. This would provide a picture of whether 




4.6 Conclusion  
This chapter has provided evidence that multiple CTX-M-EC clones are acquired by travellers, 
and that indistinguishable cefotaxime-sensitive strains (non-CTX-M-EC) are present before 
and after travel to the Indian subcontinent. Furthermore, the same CTX-M-EC strain 
colonises the human faecal microbiome, which is detectable up to 7 months after travel.  
 
Novel data has been provided on the dynamics of colonisation with CTX-M-EC and non-CTX-
M-EC after travel. The post travel faecal microbiome is made up of both cefotaxime-sensitive 
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and resistant E. coli populations (CTX-M-EC), indicating that non-CTX-M-EC are acquired 
alongside CTX-M-EC during travel. This is the first study to show that a minority population 
of pre-travel E. coli re-emerge as the dominant E. coli population after CTX-M-EC is lost. 
Further studies are needed in order to characterise the pre-travel non-CTX-M-EC.  
 
Travellers usually acquire multiple E. coli sequence types carrying blaCTX-M, and that the same 
E. coli clonal lineages are carried in the gut after return to the UK. The polyclonal CTX-M-
producing-E. coli acquisition suggests multiple acquisition events during travel, which is in 
keeping with exposure from contaminated food and water supplies with faecal bacteria. 
Carriage of the same CTX-M-EC clones - often for several months after return to the UK – 
shows that the acquired strains are not easily displaced and suggests the stable colonisation 
in the faecal microbiome in the absence of antibiotic selective pressure. 
 
Although the acquired CTX-M-EC are successful colonisers of the faecal microbiome, E. coli 
without CTX-M co-colonise the GI tract alongside CTX-M acquired strains within individual 
faecal samples collected after travel. The non-CTX-M E. coli in this situation are usually novel 
strains, not found before travel, which implies that travel-acquired strains are both CTX-M-
producers and non-producers. This would again be in keeping with multiple acquisition 
events of faecal bacteria during the period of travel. 
 
This chapter has confirmed that the most common mechanism of CTX-M-EC acquisition in 
healthy travellers is the acquisition of novel E. coli clones. Evidence is provided of the 
success of both CTX-M-EC in maintaining colonisation for several months after travel, and 
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also the success of pre-existing non-CTX-M host E. coli in remaining in the gut and emerging 
as the dominant E. coli population once the CTX-M-EC is lost.  
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Chapter 5: Plasmid identification and analysis 
 
5.1 Introduction  
5.1.1 Spread of blaCTX-M: the role of epidemic plasmids 
The transfer of bla-CTX-M genes on conjugative plasmids is fundamental to their evolution and 
global spread (Carattoli, 2013). Several studies have shown that plasmids of the IncF family 
are the predominant group which carry blaCTX-M-15 (Gonullu et al., 2008; Diestra et al., 2009; 
Marcadé et al., 2009; Dhanji, Doumith, et al., 2011; Lee et al., 2011) whereas bla-CTX-M-14 is 
carried on a variety of plasmid types including on IncF, especially in the far East, (P. L. Ho et 
al., 2012) and on IncK, predominantly in Western Europe (Cottell et al., 2011). Horizontal 
transfer of antimicrobial resistance plasmids by conjugation in Enterobacteriaceae occurs in 
the human gut, (Smith, 1969; Fernandez et al., 2007; Gona et al., 2014; Knudsen et al., 
2018), in animals (Cavaco et al., 2008) and in the environment (Amos et al., 2014; Pehrsson 
et al., 2016).  
 
The IncF family plasmids are narrow host range, being mainly restricted to 
Enterobacteriaceae, and contain a number of mechanisms e.g. addiction systems and post 
segregational killing machinery, favouring  plasmid  stability (Woodford et al., 2009). As a 
result, IncF plasmids are adapted to be stably maintained in commensal E. coli  the 




Identical plasmids which are found across genetically diverse strains have been termed 
‘epidemic plasmids,’(Carattoli, 2009) and their dissemination helps to explain some of the 
global trends in blaCTX-M epidemiology (see Chapter 2). Examples of epidemic plasmids 
include pCT (Cottell et al., 2011) and pHK01 (Ho et al., 2012) (which both carry bla-CTX-M-14), 
pC151a, (Lavollay et al., 2006) (which carries blaCTX-M-15) and the closely related plasmids, 
pEK516 and pEC_B24, (which also encode CTX-M-15) (Woodford et al., 2009; Smet et al., 
2010). In South China it has been proposed that a discrete group of blaCTX-M-15 epidemic 
plasmids are circulating which share significant homology to pKF3-94 — a Chinese reference 
plasmid isolated from K. pneumoniae — but are quite different from the pC151a-like 
plasmids described in Europe (Zhuo et al., 2013). An epidemic IncI1 plasmid carrying bla-CTX-
M-1 has also been shown to be highly prevalent across food animal isolates and human 
isolates (see figure 2) in the Netherlands, suggesting transmission of bla-CTX-M-1 via the food 
chain (de Been et al., 2014). Moreover, since the first description of bla-CTX-M-1 from a clinical 
isolate in Germany in 1989 (Bauernfeind, Grimm and Schweighart, 1990), bla-CTX-M-1 has 
maintained a significant presence in several countries in Western Europe since then (Chapter 
2, Figure 2.1 a-c). Globally, CTX-M-1 is less common, and therefore the ongoing persistence 
of this genotype in Europe could well be due to the spread of epidemic plasmids (de Been et 
al., 2014). 
 
One of the earliest reports of epidemic plasmid spread was the bla-CTX-M-3 IncL/M plasmid, 
pCTX-M-3, which disseminated bla-CTX-M-3 first in Poland (Gniadkowski et al., 1998), and then 
throughout Europe. The genotype blaCTX-M-15 differs from bla-CTX-M-3 by only one amino acid 
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substitution, but the different genetic surroundings of these genes in Europe suggests that 
the evolution and subsequent spread of blaCTX-M-3 from Poland occurred independently of 
the subsequent rise of blaCTX-M-15 in the other regions (Livermore et al., 2006). Interestingly, 
Inc L/M plasmids carrying blaCTX-M-3 in China and Australia share significant homology to 
pCTX-M-3, suggesting a common evolutionary origin (Zhu et al., 2009; Partridge et al., 2012).   
 
5.1.2 Other transferrable elements: insertion sequences, transposons and integrons 
Insertion sequences (IS), transposons and integrons have played a key role in the 
dissemination of blaCTX-M (Cantón, González-Alba and Galán, 2012). A diversity of genetic 
platforms for the expression of bla-CTX-M have been described (Zhao and Hu, 2012). 
 
Sequence ISEcp1 is the most common insertion element associated with bla-CTX-M genes and 
has been described as being associated with all bla-CTX-M variants and their spread (Zhao and 
Hu, 2012). ISEcp1 has two important characteristics: (1) It encodes a transposase, allowing 
mobilisation of the bla-CTX-M gene onto the particular plasmid; and (2) it acts as a strong 
promoter for the expression of blaCTX-M (Poirel, Decousser and Nordmann, 2003).  
 
The transposition element IS26 has also been important in the dissemination of group 1 and 
group 9 bla-CTX-M variants (Zhao and Hu, 2012). Ensor and colleagues investigated 130 ESBL-
producing E. coli and K. pneumoniae isolates collected 2003-2005 from three Indian 
hospitals. 73% of these isolates produced CTX-M-15, and in 31% of these, the insertion 
sequence IS26 was found within the ISEcp1 sequence, upstream of blaCTX-M-15 (Ensor et al., 
2006). However, in a collection of CTX-M-producing Enterobacteriaceae isolated in the late 
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1990s, IS26 was not found (Walsh, Toleman and Jones, 2007). Therefore, a specific event 
after 2000 led to capture of blaCTX-M-15 in India by IS26, which has been suggested as causing 
stable maintenance of blaCTX-M in the genepool thereafter (Ensor et al., 2006). Subsequently, 
IS26 has been found again in India (Shahid, 2010) and worldwide (Zhao and Hu, 2012). More 
recently, Johnson and colleagues investigated the role of IncF plasmids and IS26 in the 
context of the clonal E. coli sub-group ST131 H30-Rx, and fully assembled a series of 
plasmids (from isolates of American origin) using long-read sequencing. Their results suggest 
that plasmids from H30-S and H30-R sub-groups were highly similar compared to plasmids 
isolated from the later H30-Rx sub-group of ST131, except that only the H30-Rx group 
contained blaCTX-M-15 (Johnson et al., 2016). In contrast to the early studies from India (Karim 
et al., 2001; Walsh, Toleman and Jones, 2007), it was suggested that IS26, which was found 
in high copy number across all isolates, was involved in mediating transposition of blaCTX-M-15 
onto a common plasmid backbone (Johnson et al., 2016). 
 
It must be stressed that the selective pressure imparted by the use of 3GCs in humans, 
animals or the environment will increase the chance of the mobilisation of bla-CTX-M. 
Mobilisation of multi-drug resistant class I integrons, which are often associated with ISEcp1 
and ISCR1, (particularly with group 2 and group 9 CTX-M (Zhao and Hu, 2012), is particularly 
problematic because they often contain multi-drug resistance cassettes. These include 
blaCTX-M, but also genes encoding resistance to  clinically important antibiotics such as 
fluoroquinolones, chloramphenicol, aminoglycosides and trimethoprim (Cantón and Coque, 
2006). Therefore, the overuse of any antibiotic which is encoded within an MDR cassette, 
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provides evolutionary pressure for the maintenance of all the MDR genes in the gene pool, 
and will lead to increased spread of the associated plasmid.  
 
5.1.3 Role of bacteriophages in mobilising blaCTX-M 
In addition to the clear roles of plasmid conjugation and transposition, or movement of 
blaCTX-M genes via integration or transposition, the role of bacteriophage mediated 
transduction is also a key component of blaCTX-M transmission between bacteria and their 
local environment (van Schaik, 2015). Bacteriophages commonly carry antimicrobial 
resistance genes, and have been found to be associated with blaCTX-M variants which include 
bla-CTX-M-10, (Oliver et al., 2005) blaCTX-M-27, (Yang et al., 2017) and blaCTX-M-15 (Falgenhauer et 
al., 2014).  In addition, AMR genes were found to be more abundant in phage DNA versus 
bacterial DNA (Subirats et al., 2016). Moreover, in mice treated  with ciprofloxacin and 
amoxicillin, phage DNA was found to be more highly enriched with antimicrobial resistance 
genes to these antibiotics, compared to untreated mice (Modi SR, Lee H, Spina CS, 2013).  
 
There are clearly a number of different players involved in the transfer of blaCTX-M: this is 
likely to be a highly opportunistic process, influenced by the genetic composition of 
particular ESBL gene reservoirs and differential antibiotic selective pressure, thus leading to 
convergent evolution in different parts of the world. These differences at the level of 





1. The blaCTX-M genes from the CTX-M-EC colonising the faecal microbiome in returning 
travellers are primarily plasmid mediated, rather than chromosomal in origin; 
2. Travel acquired blaCTX-M-containing plasmids are more closely related to plasmids 
previously identified from South Asia, than to plasmids of UK-origin; 
3. The genetic context of blaCTX-M will be reflective of non-UK-type genetic contexts; 
4. The ISECp1-CTX-M spacer sequence will vary according to region of origin of the CTX-
M-EC isolate; 




5.3 Methods  
Short read Illumina sequencing (see section 4.3.2) was used in combination with long read 
MinION sequencing to maximise contig size prior to further bioinformatic analysis of plasmid 
sequences. 
 
5.3.1 MinION long read sequencing 
5.3.1.1 DNA extraction 
The cationic detergent, cetyl trimethylammonium bromide (cTAB) was used in conjunction 
with phenol-chloroform for isolation of genomic DNA (Ausubel et al., 2003). 
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A 5ml BHI broth was grown overnight at 37 degrees for each E. coli strain in question. 
Bacterial pellet was then resuspended in 567μl TE buffer. To achieve bacterial cell wall lysis, 
SDS 10% (30μl) and proteinase K 0.5% (100μg/ml) were then added before incubation for 1 
hour at 37 degrees. Then, NaCl (5M 100μl) was added to allow precipitation of cell wall 
material, denatured protein and polysaccharides. Next, cTAB/NaCl solution was added, 
followed by further incubation for 10 minutes at 65 degrees. Then, an equal volume of 
chloroform/isoamyl alcohol was added, mixed, and micro-centrifuged for 5 minutes. 
 
The aqueous supernatant, containing DNA, was then removed and added to 0.6 volume 
isopropanol, allowing precipitation of nucleic acid. The string-like DNA pellet can then be 
transferred to a clean universal with 70% EtOH using a sterile plastic loop. After washing in 
70% EtOH, the DNA pellet was re-suspended in 100μl TE buffer.  
 
5.3.1.2 MinION setup 
Following DNA extraction, library preparation was carried out using the Oxford Nanopore kit 
supplied with the MinION, and used the following reagents: FRM fragmentation mix, RBF 
running buffer, rapid ID adaptor mix, blunt TA ligase. The protocol was followed as per the 
MinION online guidance https://store.nanoporetech.com/kits-245/pcr-sequencing-kit.html.  
The 2016 Oxford Nanopore MinION was used which had 1D read capability. After library 
preparation, 16 μl of pooled DNA was added to the flow cell before starting an overnight 




5.3.2 Plasmid Characterisation  
5.3.2.1 Unicycler assembly 
Prior to performing a hybrid assembly using short read and long read data, fast5 files 
produced by the MinION were converted to fastq using Poretools, followed by Porechop to 
trim the raw reads.  
 
Unicycler was then used for the hybrid assembly of MinION reads combined with illumina 
reads (https://github.com/rrwick/Unicycler). Illumina reads for each isolate are mapped to a 
single MinION file consisting of all MinION reads concatenated. Unicycler is a pipeline which 
uses the SPAdes and Racon assemblers combined with Bowtie2 and Samtools for mapping 
and polishing.  
 
5.3.2.2 Transconjugant analysis and plasmid identification 
For the five transconjugants (4a2T, 12a3T, 12c1T, 12d2T, 12e1T), the putative plasmid contig 
was identified using BWA-MEM and Samtools. Each transconjugant (fasta file) was used as a 
reference on which to map the recipient-only (TG1) illumina reads. As the majority of the 
transconjugant assembly is made up of recipient genomic DNA, the plasmid DNA (the 
plasmid contig) from the donor was easily identified from regions of the reference which had 
zero reads mapped from TG1.  
 
5.3.2.3 Confirmation of circular plasmid sequences  
A feature of the unicycler hybrid assembly tool is that the assembly output is recognised as a 
circular DNA sequence, if such a sequence is produced from the assembly. In four cases 
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where unicycler confirmed that a circular sequence had been assembled, a confirmatory 
method was used to confirm this using the cloud-based galaxy platform (Afgan et al., 2015). 
The fasta file opened in a text editor, and 2.5kbp from each end of the sequence were 
concatenated, with the join highlighted. The concatenated sequence was then saved as a 
new fasta file, and annotated using prokka (Seemann, 2014). The illumina sequence reads 
for the isolate in question were mapped to the concatenated file using the BWA-MEM tool 
(Li and Durbin, 2010) and visualised using artemis (Rutherford et al., 2000). If the illumina 
reads were seen to cross the concatenation point, then the original sequence was confirmed 
to be circular. In the four cases where unicycler suggested that an assembly was circular, this 
was confirmed using this manual approach.  
 
 
5.3.2.4 Investigation of remaining blaCTX-M-containing contigs  
Contigs which were not circularised using the above approach but nevertheless carried 
blaCTX-M, were assessed as to whether they were of plasmid or of chromosomal origin.  
 
Several approaches were used to identify plasmid contigs. Initially, the blaCTX-M contigs were 
screened for ‘plasmid features.’ Plasmid features included: (1) presence of a plasmid 
replicon; (2) presence of plasmid transfer genes; or (3) presence of other AMR or metal-
resistance genes.  
 
Further interrogation of blaCTX-M contigs was carried out using the basic local alignment 
search tool (BLAST), provided by the National Center for Biotechnology Information (NCBI). If 
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the BLAST results matched to plasmid sequences, then the contig was confirmed as a 
plasmid fragment, however, if the BLAST results only matched to bacterial genomic DNA, 
then the contig in question was confirmed to be of chromosomal origin. The size of the 
contig was also used as an indication of plasmid or chromosomal origin: contigs >500kbp are 
more likely to be chromosomal, and this was confirmed using BLAST. Further confirmation 
that a contig was chromosomal was carried out by determining the genes present by 
annotation using RAST (Aziz et al., 2008; Overbeek et al., 2014; Brettin et al., 2015).  
 
5.3.2.5 Sequence comparisons 
BLAST was used to investigate which previously sequenced plasmids were homologous to 
the plasmids identified in the present study. The BLAST expect value (e-value), which is the 
number of BLAST hits expected to occur by chance, has a default value of 10. The e value 
used in this study was lowered to 1x10-6, increasing the likelihood that BLAST matches are 
due to a biological sequence alignment rather than a random chance occurrence. BLAST 
filters out low complexity regions by default, which includes highly repetitive regions. When 
searching for plasmid sequence matches using BLAST, the low complexity filter was disabled, 
because plasmid sequences are often made up of highly repetitive regions.  
 
Between 5-10 sequences were selected from BLAST results for presentation using BLAST ring 
image generator (BRIG) (Alikhan et al., 2011). Sequences were selected for comparison if (1) 
there was >50% coverage of the query sequence, and (2) the BLAST result contained 
metadata or annotation including the species and/or host and location of origin. BRIG 
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annotations for each query sequence were based on a tab-delimited file created using RAST 
annotation data (Aziz et al., 2008; Overbeek et al., 2014; Brettin et al., 2015).  
 
5.3.3 Investigating the genetic context of blaCTX-M 
The genetic surroundings of blaCTX-M were investigated using BLAST searches, Artemis 
(Rutherford et al., 2000) and Mauve (Darling, Mau and Perna, 2010). Thirty-five 
representative blaCTX-M contigs were selected for analysis of the blaCTX-M genetic context. 
Genbank files (gbk) were viewed in Mauve, where all open reading frames can be seen. If the 
gbk annotation was absent or non-specific, this was checked using RAST or BLAST data. 
Common genetic contexts were displayed using Mauve and additional coloured arrows.  
 
5.3.3.1 Investigating the ISECp1—blaCTX-M-15 spacer sequence 
Using the data generated in the aforementioned genetic context analysis, the non-coding 
spacer sequence between ISECp1 and blaCTX-M-15 was copied and saved as a new fasta file 
using Artemis (Rutherford et al., 2000). This was repeated for the 23 occurrences of 
‘ISECp1—blaCTX-M-15’ identified in the genetic context analysis. In addition, sequences 
containing blaCTX-M-15 in the NCBI Genbank database were also used, including isolates of UK 
and Indian origin, as well as those spacer sequences described in a previous traveller study 
(Dhanji, Patel, et al., 2011) (Section 5.4.4). In order to compare the spacer sequences, Mauve 
was used to line up the above sequences (Notredame, Higgins and Heringa, 2000).  
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5.3.4 Conjugation Experiments 
The ability of post travel E. coli strains to transfer blaCTX-M containing plasmids in vitro was 
determined in a series of experiments. Firstly, post travel CTX-M-producing E. coli (the 
potential donor) were subjected to overnight conjugation on filters with J53 E. coli (the 
potential recipient). Where a successful conjugation had occurred for a donor/recipient with 
overnight incubation, the conjugation frequency was determined with the same 
donor/recipient combination after incubation for 3 hours. 
 
5.3.4.1 Overnight conjugation 
The recipient strain used was TG1: a J53 E. coli derivative which was rifampicin resistant and 
non-lactose fermenting. All potential donor E. coli were first checked for rifampicin MIC, 
lactose fermenting status on MaConkey agar, and PCR for blaCTX-M. Only strains which were 
rifampicin susceptible (at 100µg/ml), lactose fermenting, and PCR positive for blaCTX-M, were 
put forward as candidate donor organisms for conjugation experiments. 
 
One post travel CTX-M-producing E.coli colony (donor strain) was inoculated into 10mls 
Luria-Bertani broth (LBB) supplemented with 4µg/ml cefotaxime and incubated overnight at 
37⁰C at 200rpm. A colony of TG1 was also cultured overnight in the same way using LBB 
supplemented with 100µg/ml rifampicin. 1ml was removed from each overnight culture and 
centrifuged at 13,000rpm for 3 minutes. The supernatant was then removed, and the pellet 
washed in fresh LBB. The bacterial pellets from donor and recipient strains were then 
suspended in 125µl and 1000µl of LBB, respectively. Next, to achieve a donor: recipient ratio 
of 8:1, 50µl of each of donor and recipient suspensions were mixed in an Eppendorf. The 
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donor/recipient mixture was then transferred to a sterile nylon filter which had been placed 
in the centre of an antibiotic-free LB agar plate. These conjugation plates were incubated 
overnight at 37⁰C.   
 
After overnight incubation, sterile filters were vortexed in 1ml of fresh LBB, so that all 
bacterial culture was re-suspended. Serial 10-fold dilutions of this re-suspension were made 
in Eppendorfs up to x1000. 100µl of each dilution was then spread to LB agar plates 
containing rifampicin (100μg/ml and cefotaxime 4 μg/ml) and incubated overnight at 37⁰C. 
Negative control plates were also made up using agar containing rifampicin (100μg/ml) and 
cefotaxime (4 μg/ml). The negative controls were made from the original donor and 
recipient LB broths after serial dilution up to x1000. If a potential donor isolate failed to lead 
to transconjugants growth, the experiment was repeated a second time for that particular 
donor isolate.  
  
5.3.4.2 Experiments to determine conjugation frequency  
For the determination of conjugation frequency, a colony of fresh overnight culture of the 
donor and recipient E. coli were incubated in LBB at at 37⁰C at 200rpm until each broth had 
reached OD 0.6, measured using a spectrophotometer. Each donor/recipient mixture was 
made using an 8:1 ratio and transferred to a sterile filter on antibiotic-free LB agar. These 
conjugation plates were incubated for 3 hours at 37⁰C. Next, growth from filters was re-
suspended, and 10-fold dilutions were made and spread to LB agar containing rifampicin 
(100μg/ml) and cefotaxime (4 μg/ml) as in Section 5.3.4.1.  In order to determine 
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conjugation frequency, viable count plates of the donor isolate were determined by 
spreading serial dilutions of the original broths up to x10,000 and colony counting.  
 
Conjugation Frequency =  
    Median Number of Transconjugants 
Median Number of Recipients x  Donor Viable Count/Recipient viable count Recipient Viable Count 
 
Each donor which successfully conjugated overnight, was subjected to 3 separate replicate 
conjugation frequency experiments, with a mean value used to calculate standard deviation 
and 95% confidence intervals. 
 
5.3.5 Pulsed-field gel electrophoresis 
Pulsed-field gel electrophoresis was used as a tool to confirm plasmid transfer to recipient E. 
coli after conjugation experiments.  
 
Isolates were sub-cultured from -80 bead stock onto isosensitest agar plates and incubated 
aerobically overnight at 37°C. Whole plates were scraped off with a sterile cotton swab and 
the culture was thoroughly suspended in 2mls tris-EDTA (TE) buffer (100mM tris, 100mM 
EDTA). Molten 1% low melting point agarose (LMPA) was made up by dissolving 1g LMPA in 
100mls 0.5M TE buffer and heating in a microwave until fully dissolved. Molten LMPA was 
then immediately transferred to a water bath pre-heated to 55°C to prevent premature 
setting. PFGE plug moulds were inverted and placed on the adhesive tape, forming a 
temporary seal. 400µl of cell suspension was transferred to a sterile 1.5ml Eppendorf for 
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each isolate, within the 55°C water bath. 20 µl of Proteinase K (20mg/ml stock) was added to 
each Eppendorf and mixed carefully by gentle pipetting. 400µl of melted LMP was then 
added to the cell suspension/proteinase K mixture, (final concentration proteinase K, 
0.5mg/ml). Plug moulds were then filled with the molten mixture containing cell suspension, 
proteinase K, and LMPA. Five plugs were made for each isolate. Plugs were left to set for 20 
minutes at room temperature. 
 
Cell lysis buffer (250mls) was prepared using 125mls of TE buffer (100mM tris, 100mM 
EDTA), 100mls SDW, and 25mls 10% sarcosyl, and adjusted to pH 8.0. 400µl proteinase K 
stock solution (20mg/ml) was added to 80mls of cell lysis buffer (final concentration 
proteinase K, 0.1mg/ml). 5mls of cell lysis buffer was transferred to a sterile universal for 
each isolate. Excess agarose from the top of plugs was trimmed off with a scalpel. A sterile 
plastic loop was used to push five plugs (per isolate) into each universal containing. Plugs 
were incubated with cell lysis buffer at 50 rpm in a 55⁰C water bath for 90 minutes. 
Lysis buffer was drained from universals using a sterile fine-tipped pastette, without 
damaging agarose plugs. 10mls of pre-warmed SDW (55⁰C) was added to each universal 
which was incubated at 50 rpm in a 55⁰C water bath for 15 minutes. The SDW was removed 
and the plug washing step was repeated again with fresh SDW. The 15-minute washing steps 
were repeated for four times more using TE buffer (10 mM Tris:1 mM EDTA, pH 8.0) which 
had been pre-heated to 55⁰C. 
 
S1 nuclease buffer (100mls) was made up using 300mM sodium acetate, 10mM zinc acetate, 
and 50% glycerol w/v). 1ml S1 nuclease buffer was added to a sterile universal for each 
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isolate (5 plugs per isolate). 2.5µl of S1 nuclease 100 U/µl was added to each universal 
containing 1ml of S1 nuclease buffer, (final concentration S1 nuclease, 0.25 U/µl). Isolate 
plugs were added to each universal and incubated at 4⁰C for five days.  
 
1g PFGE-grade agarose was dissolved by boiling in a microwave in 110mls 0.5 M TBE buffer 
(approx. 1% gel). This was allowed to set at room temperature in a gel tray. Agarose plugs 
were removed from S1 nuclease universal containers and were cut to an appropriate size 
using a scalpel. Plugs were then carefully loaded individually into the wells of the gel. The 
final lane of the gel was loaded with a slice of lambda DNA size marker. Molten PFGE-grade 
agarose was used to seal wells. A PFGE tank was then filled with 2.5L of pre-chilled 0.5M 
TBE. The following PFGE conditions were then set: 19 hours, switch time initial 5 sec, final 45 
sec, 6V/cm, 120⁰ angle, 14⁰C. 
 
After running, the gel was removed from the tank and placed in 250mls TBE buffer/ 80mcl 
gel red dye. This was incubated at room temperature for 30 mins at 60rpm, followed by 
washing in SDW for 5 minutes at 60rpm. The gel was imaged using a UV trans-illuminator 




5.4.1 MinION outputs 
A single MinION run was undertaken. After setting up, the MinION was left to run overnight. 
Unfortunately, due to an unexpected hospital generator test, the MinION did not run in full, 
but did lead to the generation of nine folders of fast5 files.  
 
Calculation of read coverage for a draft genome was not possible as this was a mixed minion 
run containing DNA from 34 isolates. However, an estimate of coverage per isolate can be 
made. The overall read coverage for the pooled MinION run was 28.71. This coverage figure 
was obtained after fast5 to fastq conversion using canu. The average coverage per isolate 
(n=34): 28.71/34 = 0.84. 
 
Table 5.1: Poretools output for MinION reads from one sequencing run 
Total reads 24053 
Total base-pairs 145,463,948 
Mean read length (bp) 6047.64 
Median read length (bp) 2516 
Min read length (bp) 16 
Max read length (bp) 1,125,149 
 
 
5.4.2 Identification of plasmid DNA 
The isolation and characterisation of CTX-M-bearing plasmids was undertaken using several 
approaches which included: screening illumina data for putative plasmid contigs, transfer of 
the CTX-M-plasmid to a plasmid free laboratory strain followed by transconjugant 
sequencing, and hybrid assembly using both short and long read sequencing.  
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5.4.2.1 Identification of plasmid contigs 
After WGS and analysis of draft assemblies using abricate software (Seemann, 2017a), 198 
isolates of E. coli from travellers were identified which carried a blaCTX-M gene (See Chapter 
3). Artemis software was used to locate the CTX-M contig for each isolate, to determine 
whether any plasmid genes were co-located on the same contig, and to establish the genetic 
context of blaCTX-M. At this stage, plasmid genes included plasmid replicon and plasmid 
transfer operon (tra) genes. Where a volunteer faecal sample yielded >1 E. coli MLST type, or 
if clonally disparate isolates within the same ST were found by SNP-typing, an isolate from 
each clone was subjected to an Artemis search.  
 
Thirty-five CTX-M-15-producing isolates, and four CTX-M-14 producing isolates were 
identified for further investigation using this screening approach (Table 5.2). CTX-M-contigs 
were found to be of plasmid origin in 22/39 (56%); chromosomal in 15/39 (38%), and not 
known in 2/39 cases (Table 5.2). Contigs assembled using the hybrid assembly are indicated 





Table 5.2. CTX-M-bearing contigs with origin designated as plasmid, chromosomal or NK (not known). N=39.  
 
Nb. Where the isolate is a transconjugant, the donor MLST is indicated. Contigs originated from the illumina 





Isolate MLST CTX-M genotype 
Contig 
size, bp Origin 
1a4 349 15 50865 plasmid 
3a1 43 15 6868 NK 
3b2 38 15 495603* chromosome 
3b4 1193 15 642401 chromosome 
3c1 38 15 107577 chromosome 
3c3 1193 15 642401 chromosome 
3d1 1193 15 318516 chromosome 
3d3 1193 15 80715 chromosome 
3e1 405 15 110977 plasmid 
3e2 405 15 110977 plasmid 
3f3 405 15 110850 plasmid 
4a2T donor 2732 14 68680 plasmid 
4a6 69 15 461991 chromosome 
4d1 648 15 709547* chromosome 
5.3e 131 15 128593 plasmid 
5a1 48 15 235946* chromosome 
5b4 48 15 86675 chromosome 
5c1 10 15 26815 plasmid 
5e4 38 15 10044 NK 
5f1 88 15 86170 plasmid 
6c1 2221 15 108112 chromosome 
8a1 448 15 101796 plasmid 
8b1 648 15 4992 plasmid 
8g1 131 15 358309* chromosome 
9a1 4 15 80715 plasmid 
9c3 2617 15 6451 plasmid 
12a2 43 15 95470 plasmid 
12a3T donor 43 15 71111* plasmid 
15a3 167 15 33988 plasmid 
16a1 38 14 1112871 chromosome 
16b1 227 15 35059 plasmid 
16b2 131 15 290931 chromosome 
17a1 450 15 5669 plasmid 
19a1 43 14 4153 plasmid 
19a2 43 14 13142 plasmid 
20a3 162 15 99441 plasmid 
20c4 226 15 166927 plasmid 
20e4 405 15 872498* chromosome 
22a1 226 15 271110 chromosome 
 154 
5.4.2.2 CTX-M plasmid identification after conjugation into a sensitive recipient 
In vitro conjugation was used to transfer the blaCTX-M-14 plasmid from strain 4a2 to a 
laboratory E. coli K12 strain. The resulting transconjugant, 4a2T, and plasmid-free recipient 
strain were then sequenced, allowing identification of the transferred plasmid. The same 
procedure was carried out for CTX-M-15-producing E. coli strain 12a3, leading to the 
creation of the transconjugant 12a3T.  
 
Figure 5.1 shows a line-up of the transconjugant 4a2T, and the recipient strain, TG1. The 
transferred plasmid can be identified as the sequence containing blaCTX-M which is only 
present in 4a2T, and not present in TG1. Figure 5.2 shows a different representation of the 
same experiment carried out for 12a3, displaying a mauve output for TG1 which lacks the 



















Figure 5.1. Mauve line-up of TG1 and 4a2T. 
Locally co-linear blocks (LCBs) are represented by coloured sections. The ringed space, 
where there is no sequence match between transconjugant and the recipient, contains 
blaCTX-M-14 (confirmed using BLAST. Note that Mauve has incorrectly assigned the CTX-M 








p12a3T (CTX-M contig from strain 12a3T) 
Figure 5.2 Mauve line-up of TG1 and p12a3T.  
Locally co-linear blocks (LCBs) are represented by coloured sections. Mauve assigns blaCTX-M genes according to their group: group 1 CTX-M in this case, which was 
confirmed to be blaCTX-M-15 after BLAST analysis.   
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5.4.2.3 Hybrid assembly after long and short read sequencing 
A hybrid assembly approach using long and short read sequencing, with both illumina and 
Oxford Nanopore sequencers, (Wick et al., 2017), was a further approach used to determine 
blaCTX-M plasmid sequences. Thirty-four isolates were subjected to the hybrid assembly 
(Table 5.3). For 59% (20/34) of isolates, showed an increase in the assembled contig size 
after unicycler assembly compered to illumina short read assembly alone. In the remaining 
14 isolates there was a decrease in the assembled contig size (35%; 12/34) or no difference 
after unicycler assembly, compared to the initial illumina assembly (6%; 2/34). However, it 
must be noted that the illumina assembly method when used in isolation, gave contig sizes 
>1000 bp higher than the unicycler assembly in only 5/34 cases (15%). 
 
Four plasmid sequences were circularised using the unicycler hybrid assembly (Table 5.3). 
Unicycler confirms that a sequence is circular, but an extra check for circularisation was 
performed. Contigs were confirmed to be circular sequences by mapping illumina sequence 
reads to the concatenated ends of the contig under investigation. The circularised plasmids 
are from donor isolates 3f3 from volunteer 3 (plasmid pERB3f3); 9a1 from volunteer 9 
(pERB9a1); 4a2T from volunteer 4 (pERB4a2); and isolate 12a3T from volunteer 12 
(pERB12a3). An example of the circularistion check is shown for pERB3f3 (Figure 5.3). 
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Table 5.3. CTX-M-EC strains subjected to unicycler hybrid assembly.  
Boxed isolates indicate circularised plasmids. Rows are shown in light grey where the 
unicycler assembly produced the largest contig; and in dark grey where the illumina 
assembly produced the largest contig. 
 





1a2 15 349 127505 50865 
3a1 15 43 6614 6868 
3b2 15 38 495603 107492 
3b4 15 1193 1193064 642041 
3c1 15 38 496320 107577 
3f3 15 405 110850 110977 
4a2T 14 donor 2732 68680 17093 
4d1 15 648 709547 487721 
4e1 15 69 5181 461991 
4e2 15 69 5224 461029 
5a1 15 48 235946 86674 
5e4 15 38 10044 2692 
8a1 15 448 101542 101796 
8b1 15 648 4736 4992 
8e1 15 648 73044 4992 
8g1 15 131 358309 288622 
9a1 15 4 80715 5621 
9c2 15 2617 70913 6451 
9c3 15 2617 70900 6451 
12a3T 15 donor 43 71111 71979 
12c1T 15 donor 43 71079 72822 
12d2T 15 donor 43 72068 72068 
12e1T 15 donor 43 72765 72765 
12a2 15 43 95470 71048 
12c2 15 43 95462 61093 
12d4 15 43 96294 71879 
15a1 15 167 33796 28790 
16a1 14 38 1112871 677002 
17a2 15 450 97215 5734 
19a1 14 43 3732 4153 
19a2 14 43 3732 13147 
20a3 15 162 27983 99441 
20c1 15 131 116824 3419 












Figure 5.3 Artemis image confirming circularisation of pERB3f3. 
















5.4.3 Genetic contexts of blaCTX-M 
Six genetic context types designated (i)-(vi) are displayed in Table 5.4. These were 
distributed among 33 CTX-M-EC strains (Figure 5.4).  
 
5.4.3.1 Context (i) 
The most common genetic context was ISECp1-blaCTX-M-15-orf477-Tn3, context (i), which was 
found in 11/35 cases among eight volunteers. For isolate 4d1, the Tn3 element was 
truncated by a hypothetical protein, and for 9c3 the ISECp1 was truncated by a spacer 
sequence between ISECp1 and catA2 (Figure 5.4; and Figure 5.6e). 
 
5.4.3.2 Context (ii) 
There were nine occurrences of CTX-M-EC with context (ii), ISECp1-blaCTX-M-15-orf477, 
across seven volunteers, although it must be noted that in two cases the genetic 
environment could not be fully revealed due to being present close to the end of a contig. In 
one case (isolate 4a6), the orf477 was found to be truncated by non-coding DNA (Table 5.4 
and Figure 5.4).  
 
5.4.3.3 Context (iii) 
The CTX-M Context ParA-blaCTX-M-15-orf477-Tn3 (iii), was found on six occasions in E. coli 
from five volunteers (Table 5.4 and Figure 5.4). In 5/6 cases for context (iii), the Tn3 was 
followed by an IS3 element (Table 5.4).  
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5.4.3.4 Context (iv) 
Context (iv), which was defined as IS26-ISECp1-blaCTX-M-15-orf477-Tn3-IS26, (or minor 
variations thereof) was found in three E. coli clones. These included the ST648 strain 8e1, 
(Section 5.4.6.3, Figure 5.6g) and presumably the 8b1 strain which was truncated by being 
present on a short contig (Figure 5.4). For 8b1, the presumed position of IS26 is indicated in 
Figure 5.4, according to the position of IS26 on the clonal isolate 8e1 (Figure 5.6g). Context 
(iv) was also found in strain 9a1, with IS26 flanking both ends of IS26-ISECp1-blaCTX-M-15-
orf477-Tn3-IS26 (Figure 5.4 and Section 5.4.5.3, Figure 5.6c). IS26 was also present in strain 
20c4 in the formation -blaCTX-M-15-orf477-Tn3-IS26 with unknown genes upstream of blaCTX-M-
15 due to being present at a contig boundary (Figure 5.4). More detailed analysis from strain 
9a1 allowed identification of the plasmid pERB9a1, with the following genes surrounding 
blaCTX-M: qnrS1-IS2-IS26-ISECp1-blaCTX-M-15-orf477-Tn21-IS26 (Figure 5.6c).  
 
5.4.3.5 Contexts (v) and (vi) 
Context (v), -blaCTX-M-15-orf477-Tn3-IS26, was found in two isolates, 5.3e and 20e4. The 
context IntI1-DTn3 -blaCTX-M-15-orf477-Tn3-IS26, was found in one isolate, 5.3e, where Tn3 
has been truncated by xerD, a tyrosine recombinase (5.4).  20e4 had a slightly different 
blaCTX-M genetic context, ISECp1-blaCTX-M-15-orf477-Tn3-IS26 (Table 5.4 and Figure 5.4). 
However, the contig boundary for 20e4 just preceded ISECp1 and so additional upstream 
genes could not be determined.  
 
Context (vi), ISECp1-blaCTX-M-15-orf477-Tn3-IS3, was found in a single isolate, 22a1 (Table 5.4 





Table 5.4. blaCTX-M-15 genetic context types for post travel E. coli 
Context Context and schematic representation Isolates [frequency] Previous descriptions 
i 
 
                                           ISECp1       blaCTX-M-15     orf477             Tn3  
[11]: 3a1, 3b2, 3b3, 3d1, 6c1, 7b3, 
20c3, 16b4, 9c3(DISECp1), 8c2, 
4d1(DTn3) 




ISECp1    blaCTX-M-15     orf477 [9]: 3f3, 4a6 (Dorf477), 5a1, 5f2, 
5f3, 7b4, 8a1, 15a3, 17a1 
(Eckert, Gautier and Arlet, 2006) 
iii 
                                  Par        blaCTX-M-15    orf477                Tn3                          IS3 [6]: 1a4, 5c1, 5f1, 20a3, 16b1, 12a3 
(IS3 absent) 
(Akiba et al., 2016) 
iv 
Group B & N* 
     IS26        ISECp1     blaCTX-M-15         orf477              Tn3                          IS26+  [3]: 8b1(t), (see plasmid 
pERB8e1_f) 9a1, 20c4(t) 
(Fortini et al., 2015; Akiba et al., 2016; Jousset et al., 
2018) 
v 
    IntI1    DTn3               ISECp1  blaCTX-M-15   orf477          Tn3                   IS26  
[2]: 5.3e, 20e4 (t) 
(Woodford et al., 2009; Forde et al., 2014; Stoesser 
et al., 2016) 
vi 
 ISECp1     blaCTX-M-15      orf477                   Tn3                              IS3 
[1]: 22a1 (Johnson et al., 2016) 
Other Contig truncation-blaCTX-M-15-orf477 (8g1, 16d1);  IS26-blaCTX-M-15-orf477-Contig truncation (9d2) 
(t) = sequence truncated by contig boundary. +The second IS26 downstream of Tn3 was not present in the ST349 strain 8b1 or plasmid pERB8e1_f. Plasmid pERB8e1_f (BRIG figure X) shows the full non-truncated sequence. 
*Detail in italics describes where the groups match to genetic environments using the A-R designation, as previously described (Dhanji, Murphy, et al., 2011; Amos et al., 2014) 
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Figure 5.4 Genetic contexts of CTX-M-15-producing post travel E. coli.  
Coloured arrows represent genetic context elements as in table 5.4. Pastel shaded coloured blocks are Mauve 
local co-linear blocks. White rectangles are ORFs. White rectangles without annotation are hypothetical 
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PRP: penta-peptide repeat protein
Tn3-res: Tn3 resolvase
dnaT: primosomal protein I
recE: exo-DNAse 8
yecD: isochorismatase family protein
aspS: aspartate tRNA ligase
nudB: dihydroneopterin triphosphate diphosphatase
yebC: transcriptional regulatory protein YebC
ruvA/B/C: crossover junction endodeoxyribonuclease
clpX: ATP-binding subunit
rnhA: ribonuclease HI




yfgF_2: cyclic di-GMP phosphodiesterase
nupC: nucleoside permease
mntH: divalent metal cation transporter 
yfeO: iron transport protein






















nupC mntH glK fryB fryC ypdF ptsl_2ypdE

















Figure 5.4 (Continued) Genetic contexts of CTX-M-15-producing post travel E. coli 
Coloured arrows represent genetic context elements as in table 5.4. Pastel shaded coloured blocks are Mauve 
local co-linear blocks. White rectangles are ORFs. White rectangles without annotation are hypothetical 
proteins according to RAST. 
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5.4.4 ISECp1-blaCTX-M-15 spacer sequence 
Twenty-three contigs containing blaCTX-M-15 contained the ISECp1-blaCTX-M-15 configuration. In 
23/23 cases, the spacer sequence between ISECp1 and blaCTX-M-15 were indistinguishable. The 
spacer comprised of 49bp from the end of ISECp1 to the start codon of blaCTX-M-15 (Figure 
5.5). Comparisons were also made between the 23 isolates from the present study, and 
blaCTX-M-15-ISECp1 spacer sequences previously deposited in the NCBI genbank database, 
finding no variation between the spacer sequences already deposited. These included the 
ISECp1-blaCTX-M-15 spacer sequences described by Dhanji and colleagues (Dhanji, Patel, et al., 
2011), as well as the blaCTX-M-15-contianing plasmids p2189 (no publication, origin: E. coli 
isolated from human urine in Ghana), pKJNM8C2.1, (no publication: origin: K. pneumoniae 
isolated from a nasal swab of a preterm human infant, West Bengal, India),  and pV234a 












Figure 5.5 Nucleotide sequences of spacer between ISECp1 and blaCTX-M-15. (Mauve). 
Includes representative isolates from the present study and previously published sequence data deposited in 
NCBI genbank. This panel is the reverse strand. Isolate or plasmid names are located below each sequence. The  
arrow represents the spacer sequence. The ISECp1 stop-codon is indicated by the black cursor. ISECp1 and 




Figure 5.5 (Continued). Nucleotide sequences of spacer between ISECp1 and blaCTX-M-15. (Mauve). 
Includes representative isolates from the present study and previously published sequence data deposited in 
NCBI genbank. This panel shows the forward strand. Isolate or plasmid names are located below each 
sequence. The arrow represents the spacer sequence. The ISECp1 stop-codon is indicated by the black cursor. 




Figure 5.5 (Continued). Nucleotide sequences of spacer between ISECp1 and blaCTX-M-15. (Mauve). 
Includes representative isolates from the present study and previously published sequence data deposited in 
NCBI genbank. This panel shows the forward strand. Isolate or plasmid names are located below each 
sequence. The arrow represents the spacer sequence. The ISECp1 stop-codon is indicated by the black cursor. 
ISECp1 and blaCTX-M-15 sequences are displayed on the first two rows. 
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Figure 5.5 (Continued). Nucleotide sequences of spacer between ISECp1 and blaCTX-M-15. (Mauve). 
Includes representative isolates from the present study and previously published sequence data deposited in 
NCBI genbank. This panel shows reverse and forward strands. Isolate or plasmid names are located below each 
sequence. The arrow represents the spacer sequence. The ISECp1 stop-codon is indicated by the black cursor. 




5.4.5 Sequence comparisons of circularised plasmids 
Each of the four circularised plasmids (pERB4a2, pERB3f3, pERB9a1, and pERB12a3) were 
subjected to a BLAST search with results then run through BLAST Ring Image Generator 
(BRIG) and presented visually (Tables 5.5 a-d, and Figures 5.6 a-d). In addition to the 
circularised plasmids, CTX-M-containing contigs which were not found to be circular, but 
were nevertheless confirmed to be plasmid fragments, are displayed in Figures 5.6 e-j with 
three BLAST comparisons per contig.  
 
The nomenclature for plasmids arising from this study were devised based on the following 
rules, using pERB3e1(f) as an example. (1) ‘pERB’ at the start of each plasmid name denoting 
‘plasmid’ (p) followed by the author’s initials (ERB); (2) The following numbers and letters 
correspond to the isolate from which the plasmid originated, therefore for pERB3e1 with ‘3’ 
representing volunteer 3, ‘e’ representing the fifth post-travel faecal sample, with the 
following ‘2’ denoting the second E. coli colony pick from the stool culture plate; (3) where 
followed by ‘(f)’ the plasmid is incomplete and is a non-circularised fragment (CTX-M contig, 
confirmed to be plasmid in origin).
 
Table 5.5a. BLAST matches to pERB4a2 (68680bp). Note: volunteer 4 travelled to Sri Lanka.  









pHK01 70262 E. coli Human/animal isolates China 14 72670 100 99 (Ho et al., 2012) 
pEG356 70275 S. sonnei Human faeces Vietnam 24 72670 100 99 (Nhu et al., 2010) 
pSJ_82 82288 E. coli Pheasant China 14 54580 100 99 none 
pEC545 70152 E. coli Human Vietnam 27 46119 97 99 none 
pCA08 154789 E. coli Human infection USA 14 51014 85 99 (J.-J. Li et al., 2015) 
pBH100 105801 E. coli Human urine Brazil None  73876 83 99 none 
pHK23a 73607 E. coli Porcine China 3 53518 83 99 (Ho et al., 2013) 
pTC1 91019 E. coli Porcine ETEC Hungary None 73928 81 99 (Fekete et al., 2012) 
pVR50 70533 E. coli Human urine Australia None 54307 81 99 (Beatson et al., 
2015) 
pV035b 77687 metagenome WWTP India 15* 50639 63 99 (Akiba et al., 2016) 








Table 5.5b. BLAST matches to pERB3f3. (110850bp). Volunteer 3 travelled to India. 
Plasmid 
 










pECAZ162 109057 E. coli Human USA None 1.2x105 95 99 N/A 
pECOH89 111741 E. coli Human WS Germany 15 45740 92 98 (Falgenhauer et al., 2014) 
pV234a 112009 metagenome WWTP India 15* 68530 91 99 (Akiba et al., 2016) 
pAnCo1 112210 E. coli Bov. feedlot USA 15 68511 91 99 (Colavecchio et al., 2017) 
pPSUO78_2 109613 E. coli Chicken Per. USA None 51273 89 97 N/A 
pM160133_p3 113428 E. coli Human U USA None 39449 86 99 (Gilrane et al., 2017) 
pMRY16-002_2 108986 E. coli  Swine Japan None 39449 88 97 (Sekizuka et al., 2017) 
pTIC 113109 metagenome WWTP Canada None 45794 83 97 N/A 
pSLy3 114472 E. coli Swine USA None 38797 83 99 (Meinersmann et al., 2016) 
p09EL50 109274 E. coli VTEC stool Georgia None 34321 82 98 (Ahmed et al., 2012) 
*unpublished data determined with individual BLAST search of NCBI sequence file. WS, wound swab; WWTP, wastewater treatment plant; Bov., bovine; Per., 









Table 5.5c. BLAST matches to pERB9a1. (80715bp). Volunteer 9 travelled to Sri Lanka.  










pC15-1a 92353 E. coli Human  Canada 15 20111 76 99 (Boyd et al., 2004) 
pV035-b 77687 metagenome WWTP India 15* 38978 73 100 (Akiba et al., 2016) 
pU25P002 172679 K. pneumoniae Human U India 15 20094 71 99 (Rafiq, Sam and 
Vaidyanathan, 2016) 
p1002-1 183508 E. coli Human BSI China 14+ 20094 69 99 N/A 
pFAM22321 78962 E. coli Dairy cow Switz. 14 20094 69 99 unpublished 
p48896_1 131243 K. pneumoniae Human RS Pakistan 15 18733 69 98 (Nahid, Zahra and 
Sandegren, 2017) 
pEC743_3 65196 E. coli Human  UAE none 18733 66 98 unpublished 
pTC_N37410PS 66289 E. coli Cattle farm USA 27 19344 65 98 unpublished 
pEcoCTX-M-15 68362 Shewanella spp. Human bile France 15 37768 26 100 (Jousset et al., 2018) 
pPGRT46 83155 E. coli Human FC Nigeria 15 36766 26 100 (Fortini et al., 2015) 
*unpublished data determined with individual BLAST search of NCBI sequence file. WWTP, waste-water treatment plant; U, urine; BSI, bloodstream infection; RS, 










Table 5.5d. BLAST matches to pERB12a3 (71111bp). Volunteer 12 travelled to India. 









pSH4469 91109 S. sonnei Human faeces S. Korea 15 72448 99 99 (Kim et al., 2014) 
pEK204 93732 E. coli  Human clinical UK 3 72323 99 99 (Woodford et al., 2009) 
pEC545_1 96926 E. coli Human Vietnam 27 70210 99 99 N/A 
pKHSB1 94089 S. sonnei Human faeces Vietnam 15  67839 99 99 (Holt et al., 2013) 
pH1519-88 88678 E. coli Human faeces Switz. 1 70288 97 98 (Wang et al., 2014) 
p2411 91353 E. coli Canine Switz. 1 68781 97 99 N/A 
pKPC-LKEc 145401 E. coli Clinical isolate Taiwan 3+ 52259 96 99 (Chen et al., 2014) 
pSKLX3330 89672 E. coli Human urine China 55 72535 96 99 N/A 
p2474-3 86725 E. coli Human BSI China 15^ 54373 95 99 (Zheng et al., 2016) 
pV233_b 97055 metagenome WWTP India none 52381 93 99 (Akiba et al., 2016) 
























Figure 5.6g pERB8e1_f with BLAST matches.  
 
  








Figure 5.6j. pERB5.3e_f with BLAST matches. 
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5.4.5.1 Sequence comparisons of pERB4a2 
Plasmid pERB4a2 was a 68680 bp molecule containing the IncFII replicon, with >40% of the 
sequence comprised of the transfer (Tra) operon (Figure 5.6a). Notably, pERB4a2 also 
contained two toxin-antitoxin systems: the relB/relE system, and the PsiA system; and an 
iron transport operon. The only antibiotic resistance gene present on pERB4a2 was blaCTX-M-
14. Detail from BLAST matches are displayed in Table 5.5a. 
 
5.4.5.2 Sequence comparisons of pERB3f3 
The 110850 bp plasmid pERB3f3 was not found to contain a plasmid replicon after both RAST 
annotation and a search against the plasmid-finder database using BLAT and is also notable 
for the absence of a Tra operon and toxin-anti toxin genes. However, pERB3f3 did contain 
several phage genes including a large phage tail fibre protein (Figure 5.6b). The antimicrobial 
resistance genes carried by pERB3f3 were blaCTX-M-15 and dihydrofolate reductase (dfr), which 
encodes trimethoprim resistance. The genetic context of the bla consisted of the well 
described ‘international context’: ISECp1-blaCTX-M-15-orf477 (Figure 5.6b). BLAST matches to 
3f3  are all within a narrow size range (109-114kbp), and all 10 hits had >80% coverage of the 
query sequence (Table 5.5b).  
 
 5.4.5.3 Sequence comparisons of pERB9a1 
The IncFII plasmid, pERB9a1 is an 80715 bp circular sequence, which includes a large transfer 
(Tra) operon (Figure 5.6c). Plasmid pERB9a1 also contains two toxin-antitoxin systems: the 
PemI/PemK system, and the RelE/StbE system (Figure 5.6c). The antimicrobial resistance 
genes carried by pERB9a1 are blaCTX-M-15 and the plasmid-mediated quinolone-resistance 
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gene, qnrS1. BLAST matches of the 80715 bp plasmid, pERB9a1 had relatively low coverage 
compared to the other circularised plasmids in this study. Only three BLAST hits had query 
coverage >70%: pC15-1a (76%); pV035-b (73%); and pU25P002 (71%) (Figure 5.6c and Table 
5.5c). 
 
Plasmid pERB9a1 has the following genes surrounding blaCTX-M: qnrS1-IS2-IS26-ISECp1-
blaCTX-M-15-orf477-Tn21-IS26. This context is also present in pV035-b from Indian wastewater 
(73% query cover, 100% identity); pECOCTX-M-15 from human bile E. coli (26% query cover, 
100% identity); and pPGRT46 rom a healthy human faecal sample (26% query cover, 100% 
identity. It can also be seen from Figure 5.6c that p9a1 includes a Tn21 transposition unit 
within the Tra operon, which is not present in any of the BLAST matches. 
 
5.4.5.4 Sequence comparisons of pERB12a3  
The plasmid designated pERB12a3 was a 71111 IncI1 plasmid which was predominantly 
composed of the transfer operon (41 kbp) (Figure 5.6d). The antimicrobial resistance content 
of pERB12a3 included only blaCTX-M-15, within the genetic context: ParA-blaCTX-M-15-orf477-
Tn21 (Figure 5.4 and Figure 5.6d). Other notable plasmid genes present on pERB12a3 
included a nickel transporter gene, and a gene encoding a post-segregation killing protein.  
 
BLAST matches to pERB12a3 included plasmids isolated from human carriage or clinical 
samples: pSH4469, from South Korea; pEK204 from the UK; pEC545_1 from Vietnam; 
pKHSB1 from Vietnam; pH1519-88 from Switzerland; pKPC-LKEc from Taiwan; pSKLX3330 
from China; and p2474-3 from China (table of hits and BRIG figure pERB12a3). One BLAST 
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match was pV233_b, isolated from a wastewater treatment plant in India (Figure 5.6d). The 
query cover for BLAST hits in Figure 5.6d is 93-99%. A lower coverage in 4/10 BLAST matches 
is due to the lack of Tn21 transposase in pV233-b, p2474-3, pSKLX3330, and pKPC-LKEc.  
 
5.4.6 Analysis of other plasmid-like CTX-M Contigs 
Contigs containing blaCTX-M which were found to be of plasmid origin but could not be 
circularised were termed ‘plasmid-like’ CTX-M contigs. The additional notation of ‘_f’ 
(fragment) after the plasmid name was used where the plasmid could not be circularised. 
 
5.4.6.1  pERB9c3_f 
The closest BLAST matches to pEB9c3_f were pHNHN21 (73% query cover; 93% identity), 
pM109_FII (70% query cover; 93% identity), and pHeBE7 (69% query cover; 93% identity) 
BLAST matches showed close homology to the plasmid backbone which included the Tra 
operon and the IncFII replicon, but there were no BLAST hits which covered the variable 
region which included several mobile genetic elements and antimicrobial resistance genes 
(Figure 5.6e).   
 
5.4.6.2  pERB20c1_f 
The plasmid-like contig pERB20c1_f, which was 116824 bp, contained a plasmid Tra operon 
and a 30 kbp multi-drug resistance (MDR region) (Figure 5.6f). This MDR region is likely to 
represent a cassette of antimicrobial resistance genes which was mobilised by one or a 
combination of mobile genetic elements present within the MDR region. The blaCTX-M-15 gene 
is flanked by the Tn3-family transposon at each end in the arrangement: Tn3-catA2-ISECp1-
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blaCTX-M-15-orf477-Tn3, which suggests that the Tn3 transposon was involved in blaCTX-M and 
catA2 co-mobilisation in this case. Other insertion sequences present on pERB20c1_f 
include: IS3, IS66, IS26, IS5, IS1, and Tn1721. The hallmark of a class I integron, the intI1 
gene, which encodes integrase, is also found on pERB20c1_f, in close association with 
aminoglycoside resistance genes (Figure 5.6f). 
 
The MDR region of pERB20c1_f includes genes encoding resistance to five antibiotic classes: 
beta lactams including cephalosporins (blaCTX-M-15, blaOXA-1, and blaTEM-1); 
chloramphenicol (CatA2); aminoglycosides (AAC(3), AAC(6’)-Ib, APH(3’)-Ia); lincosamides 
(lnu); and tetracyclines (TetA and TetR). The closest BLAST plasmid matches to pERB20c1_f 
did not cover the MDR region of pERB20c1_f continuously (Figure 5.6f). A further BLAST 
search with the query sequence submitted as the 30 kbp MDR region of pERB20c1_f was 
therefore carried out, which revealed that no sequences with coverage of above 81% for this 
MDR region were present in the NCBI blast database. 
 
BLAST plasmid matches to pERB20c1_f were of relatively low query cover (67-73%) 
compared to other plasmids in this study. Plasmids with the highest coverage of pERB20c1_f 
were all non-published GenBank submissions and were either isolated from Chinese Poultry 







The 73044 bp contig pERB8e1_f carried the IncFII replicon and two AMR genes: blaCTX-M-15 
and blaTEM-1 (Figure 5.6g). The genetic context of blaCTX-M is as follows: IS26-ISECp1-blaCTX-M-
15-orf477-Tn3-blaTEM-1. The BLAST hits for pERB8e1_f have 67-85% query coverage.  
 
5.4.6.4  pERB1a2_f 
The plasmid-like contig pERB1a2_f was 127505 bp, and included a tra operon and an IncFII 
replicon. The AMR genes present in pERB1a2_f were blaCTX-M-15 and QnrB. The genetic 
context of blaCTX-M was ParA-blaCTX-M-15-orf477-Tn3. The highest query cover for the BLAST 
plasmid matches to pERB1a2_f were collected from E. coli strains from the USA: pAPEC-O2-R 
(48%); pECO-fce (48%); and pSLy2 (47%), isolated from an avian source, a human source, and 
from a swine source, respectively (Figure 5.6h).  
 
 
5.4.6.5  pERB8a1_f 
The plasmid-like contig pERB8a1_f contained the IncFIB replicon and was found to be largely 
composed of phage genes (approximately 40 kbp), without any plasmid transfer operon. 





5.4.6.6 pERB5.3e_f  
The plasmid-like contig pERB5.3e_f contained an IncFII plasmid replicon, a Tra operon and a 
30 kbp MDR region which included AMR genes encoding resistance to seven 
antimicrobial/antiseptic classes. These were beta lactams/ cephalosporins (blaCTX-M-15 and 
blaOXA-1), tetracyclines (TetA and TetR), trimethoprim (dfr), aminoglycosides (AAC(6’)-Ib; 
AAC(6’)-II; and APH(3’)-Ia), quaternary ammonium compounds (qacED1), sulphonamides 
(sul2), and macrolides (mphA). The MDR region also included a chromate transport gene 
(chrA) (Figure 5.6j). 
 
Mobile genetic elements present within the 30 kbp MDR region included: IS26, IS6100, Tn21, 
and Tn3. A class I integron was also present, with the IntI1 gene present between Tn21 and 
dfr (Figure 5.6j). BLAST matches to pERB5.3e_f include the following plasmids isolated from 
human clinical E. coli strains: p46212 (from the UK), pEC958 (from Australia) and pEK499 
(from the UK) (Table BRIG). All three plasmid matches have 100% coverage of the MDR 
region of pERB5.3e_f.  
 











Toxin-antitoxin systems AMR genes 
pERB3f3* unknown No Yes none blaCTX-M-15; dfr 
pERB4a2 IncFII Yes Yes relBE bla-CTX-M-14 
pERB9a1 IncFII Yes Yes PemI/PemK; relBE blaCTX-M-15; qnrS1 
pERB12a3 IncI1 Yes Yes PndA blaCTX-M-15 
pERB9c3_f IncFII Yes Yes none blaCTX-M-15; AAC(3)-IId; catA2 
pERB20c1_f unknown Yes No none 
blaCTX-M-15; bla-TEM-1; CatA2 (x3); blaOXA-1; 
AAC(6’)-Ib; AAC(3); Lnu; tetA/R 
pERB8e1_f IncFII Yes No PemI/PemK blaCTX-M-15; blaTEM-1 
pERB1a2_f IncFII Yes No Doc/PhD blaCTX-M-15; qnrB 
pERB8a1_f* IncFIB No Yes Doc/PhD blaCTX-M-15 
pERB5.3e_f IncFII Yes No 
PemI/PemK; Doc/PhD; 
VapC/VapB (x2); CcdA/CcdB 
blaCTX-M-15; blaOXA-1; mph(A); sul2; QacED1; 
APH(3’)-Ia; AAC(6’)-Ib/-II dfr; tetR/A 




5.4.7 Plasmids in post travel E. coli strains are conjugative 
5.4.7.1 Isolate screening prior to conjugation experiments 
Isolates were subjected to a screening process before being put forward into conjugation 
experiments on filters. This was to ensure that isolates contained the appropriate 
characteristics to be successful donor strains in the conjugation experiment. The screening 
process including the number of isolates excluded and reasons for exclusion are outlined in 
Figure 5.7. A total of 109 isolates were subjected to initial screening, with 45 isolates 
excluded (Figure 5.7). The reasons for exclusion, with numbers of isolates excluded were: (1) 
isolates did not contain blaCTX-M (n=8); (2) Isolates rejected due to being non-lactose 
fermenting E. coli (n=33); and (3) Isolates rejected due to being resistant to rifampicin (n=4) 
(figure 5.7).  
 
A representative example of lactose fermenting E. coli (pink colonies) and non-fermenting E. 
































3.2 Outcome of Conjugation Experiments 
3.2.1 Results of Conjugation  
The results of all conjugation experiments are outlined in table 3. When conjugation 
experiments were undertaken, 8 isolates failed to grow any colonies on the dilution 
plates after conjugation. 2 of these isolates again failed to grow when the experiment 
was repeated, and therefore were discarded. These isolates were both from the same 
volunteer.  
 
For 62/64 isolates where conjugated was attempted, there was growth on the 
experimental dilution plates. In all but three of these cases, there was growth on the 
most concentrated dilution plate. In these three cases there was growth on lower 
dilution plates. There was also growth of E.coli on the control plates in the case of 15 
isolates. This growth was attributed to the development of mutational rifampicin 
resistance in the unconjugated donor traveller isolates. Bacteria that had grown on 




109 E. coli subjected to initial screening 
8 isolates rejected as blaCTX-M absent 
101 E. coli confirmed blaCTX-M 
91 blaCTX-M group 1 / 10 blaCTX-M group 9 
33 isolates rejected as non-lactose fermenting 
28 blaCTX-M group 1 / 5 blaCTX-M group 9 
68 isolates confirmed blaCTX-M and lactose 
fermenting 
63 blaCTX-M group 1 / 5 blaCTX-M group 9 
4 isolates rejected as resistant to rifampicin 
4 blaCTX-M group 1 / 0 blaCTX-M group 9 
64 isolates confirmed blaCTX-M, lactose 
fermenting and rifampicin sensitive 
59 blaCTX-M group 1 / 5 blaCTX-M group 9 
64 isolates progressed to conjugation 
experiments 
59 blaCTX-M group 1 / 5 blaCTX-M group 9 
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Figure 5.8a. Lactose fermenting E. coli 
Figure 5.8b. Non-lactose fermenting E. coli 
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5.4.7.2 Conjugation experiments 
Conjugation experiments were undertaken to investigate the transferability of plasmids 
carrying bla-CTX-M. We found 45% of volunteers (5/11 volunteer E. coli tested) carried CTX-M-
EC which could transfer the bla-CTX-M plasmid after overnight conjugation on filters (Table 
5.7). Seven donor isolates (7/24= 29%) with unique STs had plasmids carrying blaCTX-M 
capable of in-vitro conjugation, under the specific conditions used in this study, with no 
particular ST predominating (Table 5.7). In each case where the phenotype corresponding to 
a transconjugant was found — non-lactose fermenting E. coli growing on agar supplemented 
with cefotaxime and rifampicin — PCR was used to confirm the presence of bla-CTX-M (Table 
5.7). 
 
Further analysis of the 19 E. coli STs which were not capable of blaCTX-M conjugative transfer 
was undertaken to determine the reason for conjugation failure. In 7/19 cases, the blaCTX-M 
was found to be on the chromosome, rather than on a plasmid. In 4/19 cases, blaCTX-M was 
located on a plasmid which lacked a transfer operon. For 1/19 STs (ST4 isolate:  9a1 and 9a3, 
both ST4, volunteer 19), the plasmid transfer operon was disrupted with a Tn21 transposon 
(Figure 5.6c and Table 5.7), which may explain the lack of conjugation for this ST. However, it 
is notable that isolate 9a4 (also ST4), was a successful donor of blaCTX-M by conjugation. 
Unfortunately, a comparison between the plasmids carried by the conjugator 9a4, and the 
non-conjugators 9a1 and 9a3, was not possible. This was because the 9a4 plasmid could not 
be fully resolved due to blaCTX-M being present on a small contig (5600 bp), and failure of 
growth on culture plates prior to the intended WGS of the transconjugant. Similarly, in 3/19 
cases, isolates failed to conjugate when different clonal isolates of the same ST had already 
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successfully transferred the blaCTX-M plasmid (isolates 12a3, 4d3, and 20c4). A ST2617 isolate, 
(9c3), also failed as a conjugation donor of blaCTX-M, despite having an intact transfer operon. 
In 3/19 cases, the reason for non-conjugation could not be assessed, because blaCTX-M was 










Growth on experimental 








10X 100X 1000X 10X 100X 1000X 
Reason for blactx-m non-
conjugation 
3a1 43 1 ü û û û û û Fermenter  NK: contig <10kbp 
3a2 43 1 ü ü û û û û Fermenter  NK: contig <10kbp 
3b2 38 1 ü û û ü û û Fermenter  chromosomal 
4a2 2732  9 ü û û û û û Non-Fermenter ü  
4d1 648 1 ü û û ü û û Fermenter  chromosomal 
4d2 648 1 ü ü û û û û Fermenter  chromosomal 
4d3 648 1 ü û û û û û Non-Fermenter ü  
4d4 648 1 ü û û û û û Fermenter  chromosomal 
4e1 69 1 ü û û ü û û Fermenter  chromosomal 
5a1 48 1 ü û û û û û Fermenter  chromosomal 
5b1 48 1 ü ü û û û û Fermenter  chromosomal 
5c3 10 1 ü û û û û û Fermenter  Plasmid fragment: 28kbp 
5e3 38 1 ü ü û û û û Fermenter  Chromosomal* 
5e4 38 1 ü û û û û û Fermenter  Chromosomal* 
7a1 10 1 û û û û û û Fermenter  blaCTX-M lost from strain 
7b1 10 1 û û û û û û Fermenter  blaCTX-M lost from strain 
7c1 200 1 ü û û û û û Fermenter  blaCTX-M lost from strain 
8a1 448 1 ü ü û ü û û Fermenter  Plasmid: no tra 
8b1 648 1 ü û û û û û Fermenter  Plasmid: no tra 
8g3 38 1 ü û û û û û Non-Fermenter ü  
9a1 4 1 ü û û û û û Fermenter  Plasmid: tra disrupted 
9a3 4 1 ü û û û û û Non-Fermenter û Plasmid: tra disrupted 
9a4 4 1 ü û û ü û û Non-Fermenter ü  
9c3 2617 1 ü ü û û û û Fermenter  NK, plasmid with tra 
12a2 43 1 ü ü ü û û û Fermenter  Unknown 
12a3 43 1 ü ü ü û û û Non-Fermenter ü  
12a4 43 1 ü ü ü û û û Fermenter  Unknown 
12b1 43 1 ü ü û û û û Non-Fermenter ü  
12c1 43 1 ü ü û ü û û Fermenter ü  
12c2 43 1 ü ü ü ü û û Fermenter  Unknown 
12c3 43 1 ü û û ü û û Fermenter  Unknown 
NK, not known. Tra, transfer operon. 
 
 
Table 5.7. Conjugation Experiment  
 
Isolate MLST blaCTX-M group 
Growth on experimental 







Reason for blaCTX-M non-
conjugation 10X 100X 1000X 10X 100X 1000X 
12d1 43 1 ü ü ü ü ü û Non-Fermenter ü  
12d2 43 1 ü ü ü û û û Non-Fermenter ü  
12d3 43 1 ü ü ü û ü û Fermenter  Unknown 
12d4 43 1 ü ü ü û û û Fermenter  Unknown 
12e1 43 1 ü ü û ü û û Non-Fermenter ü  
12e2 43 1 ü ü ü ü û û Non-Fermenter ü  
12e3 43 1 ü ü û û û û Non-Fermenter ü  
12e4 43 1 ü ü ü û û û Fermenter  Unknown 
15a1 167 1 ü ü û û û û Fermenter  Plasmid: no tra 
15a2 167 1 ü û û û û û Fermenter  Plasmid: no tra 
15a3 167 1 ü û û ü û û Non-Ferment. û Plasmid: no tra 
15a4 167 1 ü û û û û û Fermenter  Plasmid: no tra 
17a1 450 1 ü û û û û û Non-Ferment. û chromosomal 
17a2 450 1 ü û û û û û Fermenter  chromosomal 
17a3 450 1 ü û û û û û Fermenter  chromosomal 
17a4 450 1 ü û û ü û û Fermenter  chromosomal 
19a1 43 9 ü û û û û û Non-Ferment. û NK: contig <10kbp 
19a2 43 9 ü û û û û û Fermenter  NK: contig <10kbp 
19a3 43 9 ü ü û ü û û Fermenter  NK: contig <10kbp 
19a4 43 9 ü û û û û û Fermenter  NK: contig <10kbp 
20a1 NT 1 ü ü ü û û û Non-Fermenter ü  
20a2 NT 1 ü û û û û û Non-Fermenter ü  
20a3 162 1 ü ü û ü û û Fermenter  Plasmid: no tra 
20a4 162 1 ü ü û ü û û Fermenter  Plasmid: no tra 
20b1 162 1 ü ü ü û û û Fermenter  Plasmid: no tra 
20b2 162 1 ü ü û ü û û Fermenter  Plasmid: no tra 
20b3 162 1 ü û û û û û Fermenter  Plasmid: no tra 
20b4 162 1 ü ü û û û û Fermenter  Plasmid: no tra 
20c2 226 1 ü û û û û û Non-Ferment. û NK 
20c4 226 1 ü û û û û û Non-Fermenter ü  
20e3 405 1 ü û û û û û Fermenter  Chromosome 
20e4 405 1 ü û û û û û Fermenter  Chromosome 
NK, not known. Tra, transfer operon. 
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5.4.7.3 Confirmation of plasmid transfer using pulsed field gel electrophoresis (PFGE) 
Pulsed field gel electrophoresis (PFGE) was used to visualise the plasmid transferred in 
conjugation experiments. The transferred plasmid for nine isolates is displayed in Figure 5.9a 
and Figure 5.9b. For each isolate tested in conjugation experiments, the donor plasmid and 
the corresponding transconjugant (denoted with ‘T’ after isolate name) are displayed, 
showing that a matching plasmid has been transferred in each case (Figure 5.9a and Figure 




















Figure 5.9a. Confirmation of plasmid transfer using PFGE gel electrophoresis. Representative donor isolates 
and transconjugant isolates (‘T’ designation) are paired in boxes. G1+ , group 1 CTX-M positive control 
containing pEK499. I145, E. coli K12 containing marker plasmids. TG1, plasmid-free recipient strain. Lambda 









experiments involving volunteer 12 implies that this plasmid is transferred particularly 
easily.  
 
The genome of the transconjugant produced from experiments involving isolate 8g3 
was over-digested with S1-nuclease to the point at which no useful information could 
be gained in all PFGE experiments involving this isolate. In the case of isolate 20c4 
no plasmid could be demonstrated in the recipient even after the experiment was 
repeated. The final images obtained from PFGE gels run after 2 hours of incubation 
are shown in figures 10-12. The images shown have had their colours inverted using 
GIMP to allow bands to be more easily visualised.  
 
 
FIGURE 10 – Gel photo from the first PFGE experiment. Shared plasmids are shown in red. 































































Figure 5.9b. Confirmation of plasmid transfer using PFGE gel electrophoresis. Representative donor isolates 
and transconjugant isolates (‘T’ designation) are paired in red boxes. G1+ , group 1 CTX-M positive control 
containing pEK499. I145, E. coli K12 containing marker plasmids. TG1, plasmid-free recipient strain. Lambda 
phage sizing ladder is present at each end of the gel. 8g3T and I145 produced a chromosomal smear, therefore 







FIGURE 12 – Gel photo from the third PFGE experiment. Shared plasmids are shown in red. 
FIGURE 11 – Gel phot  from the second PFGE exp riment. Shared plasmids re sh wn in red. 

































































































































































5.4.7.4 Minimum inhibitory concentration testing of donor and recipient isolates  
Determination of minimum inhibitory concentration (MIC) of donor, recipient, and 
transconjugants, using the VITEK2 platform, was used to confirm the phenotypic changes 
which would be expected after a successful conjugation of a blaCTX-M-bearing plasmid into 
the recipient TG1 (Table 5.8).  
 
All transconjugants had an antibiogram consistent with cephalosporinase production. 
Particular phenotypes corresponded with genotypic findings after isolate screening with 
WGS and resistance-finder. For example, the CTX-M-14-producing transconjugant 4a2T 
showed high level resistance to cefotaxime, but not to ceftazidime as is typical for the CTX-
M-14 enzyme. As expected, the CTX-M-15 producers had a higher-level resistance to 
ceftazidime (Table 5.8).  
 
The antibiogram of 20a1 and 20a2 included high level resistance to cefoxitin, which is a 
hallmark of AmpC production, differentiating them from CTX-M producers (Wu et al., 2005). 
This finding corresponded with a lack of blaCTX-M genes in these transconjugants. Instead, a 
plasmid carrying blaDHA-1 was transferred. Isolates 20a1 and 20a2 also had resistance to 
nalidixic acid and trimethoprim, suggesting the presence of an MDR plasmid in these 
isolates. Characterisation of the specific plasmid in question was not possible due to a small 
contig size for 20a1 and 20a2. However, resistance gene finder was applied to the illumina 
sequence data which showed presence of tetA, mphA, sul1, blaDHA-1, QnrB4, aadA1/A5, and 
dfrA1. The standard gram-negative VITEK2 antibiogram does not include testing for 
tetracyclines, macrolides, sulphonamides, or streptomycin, therefore these were not tested. 
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However, given the presence of the aforementioned resistance genes in 20a1 and 20a2, 
these isolates would be expected to be resistant to these additional antibiotics (see also 









































Table 5.8 Minimum Inhibitory Concentration (MIC) data for recipient strain and selected transconjugants. 
MIC data was obtained using VITEK2. Breakpoints to determine ‘resistant,’ ‘intermediate,’ or ‘sensitive,’ are 
from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) Values in dark grey indicate 
‘resistant,’ pale grey indicates ‘intermediate’ and unshaded values indicate ‘sensitive’.  
 
Antibiotic 















Temocillin <4 <4 8 8 8 8 8 
Ampicillin <2 >32 >32 >32 >32 >32 >32 
Amoxicillin/Clavulanic Acid <2 8 4 4 4 >32 >32 
Piperacillin/Tazobactam <4 <4 <4 <4 <4 16 32 
Cefalexin <4 >64 >64 >64 >64 >64 >64 
Cefuroxime 4 >64 >64 >64 >64 >64 >64 
Cefuroxime Axetil 4 >64 >64 >64 >64 >64 >64 
Cefoxitin <4 <4 <4 <4 <4 >64 32 
Cefotaxime <1 >64 >64 >64 >64 4 8 
Ceftazidime <1 <1 2 2 4 >64 >64 
Cefepime <1 <1 <1 <1 <1 <1 <1 
Ertapenem <0.5 <0.5 <0.5 <0.5 <0.5 <0.5 <0.5 
Meropenem <0.25 <0.25 <0.25 <0.25 <0.25 <0.25 <0.25 
Gentamicin <1 <1 <1 <1 <1 <1 <1 
Nalidixic Acid 4 8 <2 8 4 16 >32 
Ciprofloxacin <0.25 <0.25 <0.25 <0.25 <0.25 <0.25 <0.25 
Fosfomycin <16 <16 <16 <16 <16 <16 <16 
Nitrofurantoin <16 <16 <0.5 <16 <16 <16 <16 
Trimethoprim <0.5 <0.5 <0.5 <0.5 <0.5 >16 >16 
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5.4.7.5 Conjugation frequency experiments 
The frequency of conjugation was determined for donor isolates which had already been 
shown to transfer blaCTX-M in overnight conjugation experiments. Conjugation frequencies for 
each isolate tested are displayed in Figure 5.10 a-b. Conjugation frequency was determined 
for 8 different sequence types (total isolates, n=12 plus one positive control). Donor isolate 
20c4 showed conjugation frequency one log higher than all other tested strains, therefore 


































































Figure 5.10a. Conjugation frequency for selected donor isolates. 
Error bars show 95% confidence limits. Note that isolates 12a3, 12b1, 12c1, 12d1, 12e1 are all ST43. All other 
isolates are from different sequence types: 4a2 (ST2732), 4d3 (ST648), 8g3 (ST38), 8g4 (ST131), 9a4 (ST4), 19a1 



















































Figure 5.10b. Conjugation frequency for donor 
isolate 20c4 (ST226).  






5.5 Discussion  
This chapter has focussed on the CTX-M-EC plasmids acquired by returning travellers from 
South Asia. The blaCTX-M containing contigs were classified as either plasmid or chromosomal 
in origin, and fully or partially sequenced plasmids were determined after hybrid assembly 
using short and long read sequencing. Particular attention was paid to the genetic context of 
blaCTX-M and the conjugative ability of blaCTX-M plasmids. Sequence comparisons with 
previously sequenced plasmids were undertaken using the BLAST ring image generator 
(BRIG). 
 
5.5.1 MinION long read sequencing 
The outputs from long read sequencing are displayed in Table 5.1 and 5.3. There were 
several limitations from the MinION run which must be noted. Firstly, only one flow-cell was 
available and only one run was carried out. Secondly, the MinION run terminated early, 
resulting in a slightly lower than expected number of fast5 folders. However, 9 folders each 
with up to 4001 files per folder were outputted successfully.  
 
A large number of isolates were pooled before running on the MinION (n=34). This approach 
was used in order to maximise the plasmid content of sequence data, as all strains were CTX-
M-producers. However, this did result in an average read coverage per isolate of <1. 
Therefore, a de-novo assembly would not be possible using this approach. Instead, a hybrid 
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assembly approach was used so that MinION long reads could be linked to isolates and 
plasmids already identified using short read sequencing.  
Further work would involve repeating the MinION run after barcoding pooled isolates. This 
would allow a de-novo assembly using long reads only. A hybrid assembly after following this 
method, would allow closure/sequencing of multiple plasmids of interest. 
 
5.5.2 Plasmid and chromosomal blaCTX-M 
CTX-M-contigs were found to be of plasmid origin in 22/39 (56%); chromosomal in 15/39 
(38%), and not known in 2/38 cases. It is possible that the blaCTX-M has become increasingly 
fixed on the chromosome in E. coli, due to increased antibiotic selective pressure in the 
environment. 
 
Chromosomal integration of blaCTX-M has been described before. The first description of this 
occurrence was reported in 2002, when 2/15 CTX-M-producing isolates from Guangzhou, 
China, had blaCTX-M on the chromosome (Chanawong et al., 2002). In a collection of non-
clonal clinical E. coli isolates collected between 1996-1999 from Barcelona, Spain, where in 
1/30 isolates, blaCTX-M was found on the bacterial chromosome (García et al., 2005). In a 
South Korean study, 21/25 isolates of Proteus mirabilis carried blaCTX-M on the chromosome 
(Song et al., 2011). In a study including CTX-M-15-producing E. coli isolates from around the 







5.5.3 Plasmid assembly 
The unicycler hybrid assembly was found to improve the contig size compared to the original 
illumina assembly, in 59% of isolates. It is notable that in 5/34 isolates subjected to the 
unicycler assembly, the hybrid assembly approach failed because the original short read-only 
illumina assembly yielded contigs much larger (>1000 bp larger) compared with unicycler 
(Table 5.3).  
 
In future work involving MinION long read-sequencing, the best approach for optimal read 
depth would be DNA quantification and barcoding strains before sequencing, allowing the 
completion of entire bacterial genomes after one MinION run using a de-novo assembly, 
followed by hybrid assembly for each strain (Bayliss et al., 2017). 
 
The use of conjugation to transfer the CTX-M plasmid from the travel-acquired E. coli into a 
laboratory E. coli strain was achieved for 5/11 volunteers. However, only two plasmids were 
successfully sequenced using this approach. This is due to the fact that after confirming 
successful conjugation on filters, transconjugants were frozen on beads at -80 to be 
sequenced at a later date – allowing batching of strains prior to illumina WGS. 
Unfortunately, on subculture from -80 stock, the transconjugant with the CTX-M-containing 
plasmid could not be grown, suggesting that storage at -80 led to the loss of the CTX-M 
plasmid in most cases. In future experiments it would be advisable to carry out DNA 
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extractions from transconjugant isolates before storage, to prevent plasmid loss from 
strains.  
 
5.5.4 CTX-M-contig sequence analysis 
5.5.4.1 Genetic contexts of blaCTX-M 
5.5.4.1.1 Context (i) 
In the present study we found that the commonest genetic environment surrounding blaCTX-
M-15 was context (i): ISECp1-blaCTX-M-15-orf477-Tn3 (Table 5.4 and Figure 5.4). The Tn1, Tn2, 
and Tn3 type transposons were first described associated with the blaTEM family of resistance 
genes in 1974 (Hedges and Jacob, 1974), and Tn3 was later found to have a strong 
association with blaTEM-1a transposition (Heffron et al., 1979). 
 
The particular association between Tn3 and blaCTX-M-15 is well described. The Tn3 transposon 
was first described in association with blaCTX-M-15 in isolates from New Delhi and Paris 
(Lartigue, Poirel and Nordmann, 2004). The Tn3-family of transposons are likely to play a role 
in the acquisition of blaCTX-M-15 onto plasmids. For example, the E. coli plasmid pEK204 from 
the UK, likely evolved via a tn3-mediated transposition event, resulting in acquisition of 
blaCTX-M-15 onto the R64 plasmid backbone (Woodford et al., 2009). In addition, a specific 
Tn3-mediated transposition event with blaCTX-M-15 led to the formation of pEC_Bactec, which 
was isolated from an E. coli strain originating from the septic joint of a horse in Belgium 




5.5.4.1.2 Context (ii) 
The finding of genetic context (ii), ISECp1-blaCTXM-15-orf477, on eight occasions, from 
seven different volunteers is not at all surprising when considering that this context has 
been reported on numerous occasions. It is notable that context (ii) has been widely 
described as “group A,” and the “international genetic context” (Dhanji, Patel, et al., 2011; 
Amos et al., 2014) due to being present globally (Cantón and Coque, 2006).  
 
Genetic context (ii) has been widely reported as the commonest context for blaCTX-M-15. 
Context (ii) was found in 16/41 isolates from a UK waste-water treatment plant (Amos et al., 
2014); and 108/174 CTX-M-EC isolates from patients with post-travel diarrhoea in London, 
UK (Dhanji, Doumith, et al., 2011).   
 
5.5.4.1.3 Context (iii) 
No previous published studies noting the association between ParA and blaCTX-M-15 were 
found, however using a BLAST search of the 1500 bp region upstream of bla CTX-M-15 for the 
isolates with the ParA genetic environment, there was only one hit with both 100% query 
cover and 100% identity. This BLAST match, part of pV150-a, was a plasmid originating from 
an Indian wastewater-treatment plant, deposited into the NCBI database by Akiba and 
colleagues (Akiba et al., 2016). This is an important finding: the unusual ParA-blaCTX-M 
genetic environment which was identified from five volunteers who all travelled to India 
(volunteers 1, 5, 12, 16, and 20) – has also been found in the environment in India before – 
pointing to an epidemiological link between travellers in the present study and acquisition of 
CTX-M-EC in India.  
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Two additional BLAST hits matched the 1500 bp region upstream of bla-CTX-M (the ParA-
blaCTX-M region) with 100% query coverage: (1) Enterotoxigenic E. coli, N. Carolina, USA, 85 
kbp (strain 2014EL-1345-2, unnamed plasmid, unpublished) with 99% identity to the query 
sequence; and (2) Enterotoxigenic E. coli, S. Korea, (plasmid pET20160881, unpublished), 
with 99% identity to the query sequence. The ParA-blaCTX-M genetic environment is therefore 
present in a broad range of E. coli including strains from environmental, and clinical isolates 
– thus underlying the importance of this genetic environment in the propagation of blaCTX-M-
15 in a variety of niches.  
 
5.5.4.1.4 Context (iv) 
Context (iv) includes the IS26-ISECp1-blaCTX-M-15-orf477 sequence, which is shared by ‘group 
B’ (Dhanji, Doumith, et al., 2011) and ‘group N’ (Amos et al., 2014) genetic contexts. 
However, it is possible that group B and/or group N actually include a Tn3-IS26 sequence 
downstream of orf477, as described in the present study for context (iv). The limited ‘range’ 
of PCR primer walking used to describe group B (Dhanji, Murphy, et al., 2011) and group N 
(Amos et al., 2014), compared with the use of WGS in the present study, may account for 
these differences.  
 
The position of IS26 upstream of blaCTX-M-15, is well described, first being found in the 
formation of IS26-ISECp1-blaCTX-M-15 and IS26-ISECp1-blaCTX-M-3 in clinical E. coli isolates 
from Paris (Eckert, Gautier and Arlet, 2006). IS26 was found in six CTX-M-EC genetic context 
types, across three volunteers. IS26 is an important insertion sequence, which was first 
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identified in association with kanamycin resistance (Terawaki, Takayasu and Akiba, 1967). In 
order to transfer a sequence, for example, a resistance gene, IS26 must be present at each 
end of the sequence to be transferred. IS26 is an important player in the spread of resistance 
genes in gram negative bacteria and it is likely that a number of sequential events - starting 
with the plasmid transfer of IS26 from an environmental bacterium - has led to the success 
of this IS (Toleman and Walsh, 2011).   
 
In particular, IS26 has been implicated in the spread of clinically worrisome antibiotic 
resistance genes such as blaSHV: IS26 mediated the transfer of blaSHV from the chromosome 
of Klebsiella pneumoniae onto plasmids, allowing dissemination throughout the 
Enterobacteriaceae (Ford and Avison, 2004). Furthermore, IS26 is  likely to have played a 
role in the capture of bla-CTX-M by epidemic plasmids, and maintenance of blaCTX-M in the 
gene pool thereafter (Ensor et al., 2006; Johnson et al., 2016). (see introduction in this 
chapter). 
 
Context (iv) is also present in pV035-b from Indian wastewater (Akiba et al., 2016); 
pECOCTX-M-15 from human bile E. coli (Jousset et al., 2018); and pPGRT46 rom a healthy 
human faecal sample (Fortini et al., 2015). Therefore context (iv) is likely to be a key player 
in the worldwide dissemination of blaCTX-M-15. 
 
5.5.4.1.5 Context (v) 
Context (v) was found to be part of a wider MDR region on a plasmid, pERB5.3e_f, as 
displayed in Figure 5.6j and discussed in section 5.5.6.6. The plasmid pERB5.3e_f was 
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acquired by volunteer 5 after travel to Uzbekistan. The 30 kbp MDR region included genes 
encoding resistance to seven antimicrobial and antiseptic classes. This MDR region carried 
the hallmarks of a so-called ‘clinical class I integron’ and Tn21 transposon  which includes the 
chrA chromate resistance gene, the orf encoding putative gene padR, and mph(A) (Partridge, 
2011).  
 
The BLAST hits to pERB5.3e_f were all isolated from clinical E. coil isolates: p46212 from the 
UK (99% query coverage) (Stoesser et al., 2016); pEC958 from Australia (92% query 
coverage) (Forde et al., 2014); and pEK499 from the UK (82% query coverage) (Woodford et 
al., 2009). The high query coverage of each of these plasmids points to pERB5.3e_f being an 
epidemic plasmid which is present in human E. coli strains in Uzbekistan, Australia and the 
UK. Furthermore, the MDR region is conserved between pERB5.3e_f and each of the BLAST 
hits to this plasmid, providing evidence that this particular MDR cassette has become ‘fixed’ 
within a plasmid backbone. The MDR region of pERB5.3e_f allows antibiotic selection for 
plasmid propagation with any of the antibiotic, antiseptic classes with resistance genes 
present on the plasmid. In addition, resistance to chromate, and the presence of five toxin-
anti toxin systems, allow plasmid survival in the host in the absence of antibiotic selection 
pressure.  
 
 The CTX-M genetic context of isolate 5.3e was subjected to a BLAST search which found 
100% query coverage and 100% identity to the blaCTX-M-15 genetic context to p46212, which is 




5.5.4.1.6 Context (vi) 
Context (vi), ISECp1-blaCTX-M-15-orf477-Tn3-IS3, was found in one isolate, 22a1 (Table 5.4 and 
Figure 5.4). No published studies include a discussion of this genetic context. However, after 
running a contig BLAST search, this genetic context matches with 96% query coverage and 
100% sequence identity to plasmid pJJ2434, isolated from a human clinical isolate from New 
York City (Johnson et al., 2016). Strain JJ2434 (the strain bearing pJJ2434), was a pathogenic 
H30Rx ST131 E. coli (Johnson et al., 2016), and therefore context (vi) must play an important 
role in the dissemination of blaCTX-M-15 within the H30Rx clade. 
 
5.5.4.2 ISECp1-blaCTX-M-15 spacer sequence 
The analysis of the ISECp1-bla-CTX-M spacer sequence presented in this chapter 
demonstrates that the 49 bp spacer does not vary between isolates which contain the 
ISECp1 promotor directly upstream of blaCTX-M-15. The spacer sequence was identical 
between all twenty-three traveller isolates included in the analysis, and between other 
representative ISECp1-bla-CTX-M-containing sequences, including those originating from 
India and from the UK. 
 
Dhanji and colleagues undertook a study which included 174 CTX-M-15-producing E. coli 
strains which were isolated from the faeces of returning travellers, which all contained 
variations of ISECp1-blaCTX-M-15, with an intervening 48 bp spacer sequence  (Dhanji, Patel, et 
al., 2011). Each of the Dhanji blaCTX-M-15 genetic environment sequences deposited in 
genbank, were downloaded and compared to the twenty-three isolates in this study (Figure 
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5.5). The Dhanji ISECp1-blaCTX-M-15 spacer sequences, and the ISECp1-blaCTX-M-15 spacer 
sequences from the present study were found to be identical, and all sequences, including 
those downloaded from genbank, were 49 bp in length. It must be noted that Dhanji et al 
stated that the spacer is 48 bp in length, but when each spacer sequence was analysed for 
this study, in each case there was 49 bp between the stop codon of ISECp1 and the start 
codon of blaCTX-M-15. This 1bp difference may reflect differing sequencing methods between 
the present study (illumina short read) verses sanger sequencing in the Dhanji study.  
 
Lartigue and colleagues also reported a 48bp spacer sequence between ISECp1 and blaCTX-M-
15 in clinical Enterobacteriaceae from France, Turkey and Poland (Lartigue, Poirel and 
Nordmann, 2004). The same study also reported that this spacer was identical between 
isolates with ISECp1CTX-M-15, ISECp1-blaCTX-M-10, and ISECp1-blaCTX-M-3, which are each part of 
the group 1 CTX-Ms (Lartigue, Poirel and Nordmann, 2004). Lartigue also showed that the 79 
bp upstream sequence of blaKLUC-1 from K. cryocresens shared 79% and 77% sequence 
identity with the corresponding regions directly upstream of bla-CTX-M-3 and blaCTX-M-15, 
respectively (Lartigue, Poirel and Nordmann, 2004). 
 
Eckert et al described the genetic environment of eleven CTX-M-15-producing strains from 
clinical isolates in Paris (Eckert et al., 2004). In keeping with Lartigue, Eckert also found that a 
48 bp ISECp1-blaCTX-M-15 spacer sequence was characteristic of all CTX-M-15 producing 
isolates analysed (Eckert, Gautier and Arlet, 2006).  
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The influence of the ISECp1-CTX-M spacer on bla-CTX-M expression has also been 
investigated (Ma, Siu and Lu, 2011). Ma et al constructed recombinant plasmids containing 
varying spacer sizes between ISECp1 and bla-CTX-M-3, showing that the highest levels of bla 
expression and higher levels of resistance to cefotaxime were reached with the shortest (42 
bp) spacer (Ma, Siu and Lu, 2011).  
 
The conserved 49bp ISECp1-blaCTX-M-15 spacer sequence found in 23/23 isolates analysed in 
the present study, is not surprising, given that the same spacer sequence is found among 
CTX-M-15-producing isolates globally. Furthermore, the level of CTX-M expression is 
influenced by the spacer sequence directly upstream (Ma, Siu and Lu, 2011), therefore it 
would seem likely that any disruption  of the 49 bp spacer would lead to reduced levels of 
resistance to 3GCs, and so selection pressure to carry blaCTX-M in this situation would be 
reduced. 
 
Since the development and widespread use of whole genome sequencing, no studies have 
used WGS to analyse the ISECp1-blaCTX-M spacer. The present study is the first to use WGS to 
analyse the ISECp1-blaCTX-M-15 spacer and included twenty-three diverse E. coli in the spacer 
sequence analysis. It was hypothesised that variation in the ISECp1-blaCTX-M-15 spacer could 
act as a ‘molecular-clock,’ providing more clues to the origin of the blaCTX-M-15 sequences in 
this study. The lack of any variation in the twenty-three spacer sequences means that any 
such molecular-clock analysis is not possible. However, further work in this area would 
include expanding the spacer sequence analysis to Kluyvera species, and to other blaCTX-M 
genotypes, building on the work of Lartigue et al, providing a large scale WGS-based 
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evolutionary account of the origin of the ISECp1-blaCTX-M from Kluyvera. In future work, a 
similar approach could be taken in the analysis of the spacer sequence between blaCTX-M and 
orf477.  
 
5.5.5 Sequence comparisons of circularised plasmids 
5.5.5.1 pERB4a2 
Previously identified plasmids which had the greatest coverage of pERB4a2 were pHK01 
(100%), pEG356 (100%), pSJ82 (100%) and pEC545 (97%). These plasmids have been isolated 
from bacterial isolates in China (pHK01 and pSJ_82) and Vietnam (pEG356 and pEC545) and 
contain a variety of CTX-M genotypes (Table 5.5a). A number of other plasmids share a 
significant plasmid backbone with pERB4a2 – including the entire Tra (transfer) operon 
(pTC1, pBH100, pHK23a, pVR50, pV035b and pCA08) (Figure 5.6a and table 5.5a). However, 
there is a notable absence of common genes between these plasmids and pERB4a2, 
including the iron transport operon and the maltoporin phage lambda receptor.  
 
The genetic context of: ISECp1-blaCTX-M-14-IS903; found in plasmid pERB4a2, is the most 
common genetic environment for blaCTX-M-14, and was also found in the closely related 
plasmids pHK01, pEG356, pSJ_82, and pEC545.     
 
Plasmid pERB4a2 is notable for its lack of a multi-drug resistance region – only possessing 
one AMR gene, blaCTX-M-14. This phenomenon has been described on several occasions 
(Cottell et al., 2011; P L Ho et al., 2011), as demonstrated by the BLAST matches for pERB4a2 
(Figure 5.6a). Plasmid pERB4a2 does not contain other AMR genes, therefore co-selection in 
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the human gut via exposure to non-cephalosporin antibiotics, or to exposure to antibiotics in 
the environment, does not play a role in the propagation of pERB4a2. The two toxin-
antitoxin systems present in pERB4a2, and the beneficial iron-transport genes are likely to 
contribute to the stable maintenance of this plasmid in the absence of cephalosporin-
selective pressure. 
 
The BLAST match of pERB4a2 to pHK01 is a particularly interesting finding, because pHK01 is 
a well described ‘epidemic plasmid’ – with pHK01-like plasmids found across strains in 
animals and humans in Hong Kong and mainland China (Ho et al., 2012). However, pHK01-
like plasmids have not been previously reported in isolates from Sri Lanka. While CTX-M-15 
are the most common ESBL in Sri Lanka, CTX-M-14-producing E. coli are also found in Sri 
Lanka (Tillekeratne et al., 2016), therefore the fact that volunteer 4 acquired both genotypes 
is not an unexpected finding. Our study confirms that the pHK01 plasmid has become 
globally disseminated since being first isolated in China. A study of bovine E. coli plasmids 
isolated from the environment in Mexico also found a plasmid – pMEX01 – with homology 
(88% coverage) to the pHK01 isolated in China, supporting the finding in this study, that 
pHK01 and its homologues are globally disseminated (Soto-Alonso et al., 2015).  
 
The genetic context of blaCTX-M-14 in pERB4a2: ISECp1-blaCTX-M-14-IS903 has been described on 
numerous occasions (Zhao and Hu, 2013). It is notable that this particular genetic context 
was found in the first description of blaCTX-M-14 in a plasmid, pOZ174, from China, in an isolate 
collected in 1998 (Chanawong et al., 2002), as well as the epidemic plasmid pCT (Cottell et 
al., 2011). The genotype blaCTX-M-14 is globally successful, especially in China, and the 
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presence of a common genetic context surrounding blaCTX-M-14 is likely to be an important 
contributor to the success of this blaCTX-M genotype (Bevan, Jones and Hawkey, 2017).  
 
The plasmid matches to pERB4a2 come from a wide range of sources including human 
clinical isolates, human commensal E. coli, as well as animal and environmental niches 
(Figure 5.6a and table 5.5a). This supports both the notion of epidemic plasmid spread 
between humans, animals, and the environment (Carattoli, 2009; Bevan, Jones and Hawkey, 
2017).  
 
5.5.5.2 Sequence comparisons of pERB3f3 
Plasmid pERB3f3 lacked a number of features which are present in other blaCTX-M carrying 
plasmids. Plasmid pERB3f3 lacked an identifiable plasmid replicon, toxin-antitoxin genes, and 
plasmid transfer genes, but did carry a number of bacteriophage genes including phage tail 
fibre protein, structural protein P5, putative phage protein gp42, and a cell attachment 
protein (Figure 5.6b). Therefore, pERB3f3 can be described as a phage-like plasmid.  
 
Three BLAST plasmid hits matching pERB3f3 included ISECp1-blaCTX-M-15-orf477 (Figure 5.6b 
and Table 5.5b). These three hits were pECOH89, a human clinical isolate (Falgenhauer et al., 
2014); pV234a from Indian wastewater (Akiba et al., 2016); and pAnCo1, isolated from an 
American bovine feed-lot (Colavecchio et al., 2017). Like pERB3f3, each of pECOH89, 
pV234a, and pAnCo1, lacked an identifiable plasmid replicon gene, which is likely due to the 
fact that these plasmids are likely to have originated from a bacteriophage, rather than from 
Enterobacteriaceae.   
 222 
 
Plasmid pECOH89, isolated from E. coli cultured from a wound swab from an inpatient in 
Germany, had 92% query coverage and 98% identity to pERB3f3 (Figure 5.6b and Table 
5.5b), (Falgenhauer et al., 2014). Plasmid pAnCo1 was isolated in E. coli cultured from bovine 
feed-lots in Colorado, USA (Colavecchio et al., 2017).  
 
Both pECOH89 and pAnCo1 are phage-like plasmids which have close homology to the 
bacteriophage SSU5, with pECOH89 having 109/128 (85%) of genes homologous to SSU5 
genes (Falgenhauer et al., 2014), and pAnCo1 having 92/130 (71%) genes homologous to 
SSU5 (Colavecchio et al., 2017). Bacteriophage SSU5 did not appear in a list of 200 BLAST hits 
to pERB3f3, probably because this bacteriophage has not been submitted to the NCBI BLAST 
database.  
 
Bacteriophage SSU5 was first identified as having a tropism for S. Typhi strains, and 
therefore a potential tool in phage therapy (Kim, Kim and Ryu, 2012). Gilcrease and 
colleagues propose that SSU5 represents a distinct supercluster of temperate 
bacteriophages which have an affinity for the Enterobacteriales (Gilcrease and Casjens, 
2018). SSU5 is 103 kbp in length and shares >94% homology with sequences from over 650 
Enterobacteriales in the NCBI database (Gilcrease and Casjens, 2018). 
 
 
Plasmid pV234a was isolated from an Indian wastewater treatment plant and also shares 
close homology to pERB3f3. Volunteer 3 travelled widely in India (Chapter 3, Table 3.3 and 
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3.4) and acquired E. coli bearing CTX-M-15-producing plasmids, one of which was 
circularised in the present study (p3f3). The plasmid pERB3f3 matched with a previously 
sequenced plasmid – pV234a (91% coverage of query sequence, Figure 5.6b and Table 5.5b) 
which was isolated from an Indian wastewater treatment plant (WWTP) in Karnataka, (Akiba 
et al., 2016) (Figure 5.11). Volunteer 3 did visit Karnataka province, albeit 240km from the 
particular wastewater treatment facility (Figure 5.11). Therefore, the acquisition of E. coli 
carrying pERB3f3 in the faecal microbiome of volunteer 3 provides further evidence for the 
role of epidemic plasmids in the dissemination of CTX-M-EC between environmental and 



































5.5.5.3 Sequence comparisons of pERB9a1 
The plasmid pERB9a1 BLAST matches, pV035-b and pU25P002, were isolated from sources in 
India, in wastewater and human urine, respectively. Volunteer 9 travelled to Sri Lanka, but 
did travel back to the UK via India, which included a day in Bangalore airport. Volunteer 9 
reported severe symptoms of gastroenteritis on return to the UK, and attributes this to food 
consumed in Bangalore. Given this history, and the similarity between p9a1 and each of 
pV035-b, and pU25P002, it seems likely that volunteer 9 acquired E. coli with blaCTX-M-15-
bearing plasmids during the brief time in Bangalore. 
 
The 92 kbp plasmid, pC15-1a (Figure 5.6c and Table 5.5c) was isolated from an E. coli isolate 
implicated in a CTX-M-15-producing E. coli outbreak in Toronto, Canada (Boyd et al., 2004). 
Plasmid pC15-1a failed to match to pERB9a1 across a 14 kbp which included the qnrS1 gene 
RelE/StbE toxin/antitoxin system (Figure 5.6c). The same 14 kbp segment was also missing 
from BLAST matches pU25P002, p1002-1, pFAM22321, p48896_1, pEC743_3, and 
pTC_N37410PS (Figure 5.6c). Plasmids which do match with pERB9a1 for this 14 kbp region 
were pV035-b, pEcoCTX-M-15, and pPGRT46. The finding that 7/10 BLAST matches to pERB9a1 
do not match across the same 14 kbp region suggests that a transposition event may have 
occurred, accounting for the differences in pERB9a1 and the seven other plasmid BLAST 
matches (Figure 5.6c). Such a transposition event - leading to the insertion of the 14 kbp 
segment into pERB9a1 - was probably mediated by IS26 which flanks either end of the 
segment (Figure 5.6c).  
Plasmid pV035-b, from an Indian environmental E. coli, matched to 73% of pERB9a1, which 
included the 14kbp aforementioned segment. Plasmid pV035-b did not match to a 17 kbp 
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section of pERB9a1 which included an IncFII stability locus, a prophage partitioning protein, 
and several housekeeping genes annotated in black in the BRIG figure (BRIG figure). A 
fragment of Tn21 is found at one end of this 17kbp sequence which implies that a Tn21-
mediated transposition event may account for the 17kbp-difference between pERB9a1 and 
pV035-b. 
 
5.5.5.4 Sequence comparisons of pERB12a3  
Volunteer 12 acquired CTX-M-EC carrying pERB12a3 which has close homology to plasmids 
isolated from around the world. Although volunteer 12 travelled to India, apart from 
pV233_b isolated from an Indian wastewater treatment plant, the BLAST matches to 
pERB12a3 were from South Korea, China, Vietnam, Taiwan, Switzerland, and the UK. The 
pERB12a3-like plasmids were found in E. coli and Shigella sonnei and included a variety of 
bla-CTX-M genotypes (Figure 5.6d and Table 5.5d), indicating that pERB12a3 is an epidemic 
plasmid. One of the pERB12a3-like plasmids, pV2474-3, (Figure 5.6d and Table 5.5d) was 
isolated from E. coli from a human blood culture from Jining, China, and contained blaCTX-M-
15, blaNDM-1, and mcr-1 (Zheng et al., 2016). The propensity for a pERB12a3-like plasmid to 
carry this combination of antimicrobial resistance genes is extremely worrisome, because a 
clinical isolate with high level resistance to 3GCs, carbapenems and colistin, would be very 
difficult to treat. This study has demonstrated that pERB12a3-like plasmids are globally 
disseminated, and it is fortunate that p2474-3 has not yet become an epidemic plasmid.  
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5.5.6 Analysis of other plasmid-like CTX-M Contigs 
5.5.6.1 pERB9c3_f 
 
The lack of BLAST matches to the pERB9c3_f variable region is unsurprising given the 
number of mobile genetic elements in this region which included four copies of IS26, the Tn3 
transposon sequences sited at three locations, as well as one copy each of IS3 and IS2 
(Figure 5.6e).  
 
The bla-CTX-M genetic environment of pERB9c3_f consisted of: IS26-Tn3-catA2-ISECp1-blaCTX-
M-15-orf477-Tn3, which was only found in BLAST hit pHNHN21, with blaCTX-M-55 in place of 
blaCTX-M-15. Plasmid pHNHN21 was isolated from an E. coli originating from a pigeon in China, 
with no publication associated with the genbank entry. Another of the plasmid matches, 
pM109_FII, isolated from human clinical E. coli from Myanmar, was a 90214 bp conjugative 
plasmid. Plasmid pM109_FII did not contain a blaCTX-M gene, but did contain blaNDM-4 as well 
as AAC(3)-IId (Sugawara et al., 2017). The acquisition of pERB9c3_f by volunteer 9, who 
travelled to Sri Lanka and India, suggests widespread dissemination of the plasmid transfer 
operon, which is often capable of capturing MDR regions through transposition events, 
which can include carbapenemase genes.  
 
5.5.6.2 pERB20c1_f 
The finding of the Lnu gene as part of a class I integron on pERB20c1_f is an unusual finding 
in Enterobacteriaceae, but has been previously described (Heir et al., 2004). Heir and 
colleagues also found a lincosamide resistance on a class I integron structure, but in this case 
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the lincosamide resistance gene was linF, which was closely associated with aadA2, encoding 
aminogyloside resistance. The finding of the gene lnu on pERB20c1_f as part of an MDR 
cassette is a novel finding (Figure 5.6f).  
 
5.5.6.3 pERB8e1_f 
The three highest coverage BLAST matches to pERB8e1_f are presented in Figure 5.6g. It is 
notable that the NCBI genbank submissions for the BLAST matches indicated 3/3 matches 
originated from animal isolates in China. However, none of these genbank submissions were 
associated with published data. The finding of further matches of travel-acquired plasmids 




Figure 5.6h displays the top three coverage BLAST hits for pERB1a2_f. The BLAST matches 
come from human, avian, and swine sources. However, it must be noted that the query 
coverage was <50% for each hit, which limits the interpretation of these BLAST matches. 
 
5.5.6.5 pERB8a1_f  
The plasmid-like contig of pERB8a1_f contained a preponderance of phage genes (Figure 
5.6i), therefore pERB8a1_f is a phage-like plasmid. BLAST results indicated that pERB8a1_f is 
closely related to the P1 supercluster of Bacteriophages, with closely related plasmids that 
are globally disseminated, isolated from Enterobacteriales in human clinical samples (Billard-
Pomares et al., 2014; Shin and Ko, 2015) and from pig faeces (Li et al., 2017).  
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Bacteriophage P1 had 80% query coverage of pERB8a1_f (Figure 5.6i). P1 bacteriophage is a 
temperate phage capable of a lysogenic or lytic lifecycle, which was first described in 1951 
(Bertani, 1951). In the lytic phase, P1 undergoes phage multiplication, cell lysis, and 
dissemination of progeny, whereas in the lysogenic phase, P1 exists as a low copy number 
plasmid, behaving like self-replicating plasmids of bacterial origin (Malgorzata et al., 2004). 
In addition, bacteriophage P1 is able to integrate into the bacterial chromosome, in the form 
of a prophage, at one copy per chromosome. Bacteriophage P1 is known to possess plasmid 
maintenance systems such as the Doc/PhD toxin-antitoxin system (Malgorzata et al., 2004), 
also present in pERB8a1_f (Figure 5.6i). 
 
Plasmid pERB8a1_f is not the first P1 bacteriophage-like plasmid to be described carrying 
blaCTX-M-15. A CTX-M-15-producing, 267645 bp phage-like plasmid, pKP12226, which had 
query coverage of pERB8a1_f of 81%, was isolated from a K. pneumoniae strain from the 
blood cultures of a patient in South Korea (Shin and Ko, 2015).  
 
P1 bacteriophage plasmids are also widely disseminated in animal as well as human 
Enterobacteriales (Gilcrease and Casjens, 2018), and have a role in mobilising the mcr-1 gene 
(Li et al., 2017). Plasmid pHYEC7-mcr1, which had a coverage of 72% of pERB8a1_f, was 
described in a study by Li and colleagues. The plasmid pHYEC7-mcr was isolated from an E. 
coli obtained from pig faeces in Guangdong, China, and carried mcr-1, encoding colistin 
resistance (Li et al., 2017).  
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Billard-Pomares and colleagues described the role of P1 bacteriophages in the dissemination 
of ESBL genes, describing a P1 bacteriophage, RCS47, carrying the blaSHV gene in E. coli 
(Billard-Pomares et al., 2014). The same study also investigated the prevalence of P1 
prophages in a collection of E. coli, by screening a collection of 363 clinical E. coli isolates for 
repL using a PCR-based approach: repL is the P1 lytic replication gene and is conserved 
among P1 bacteriophages. The repL gene was found in 12.6% of 363 isolates screened, and 
the authors concluded that P1 phages are widespread in clinical E. coli isolates, but were not 
found to be significantly associated with ESBL-producing E. coli (Billard-Pomares et al., 2014). 
 
Other phage-like plasmids carrying blaCTX-M genes in the literature include pECOH89 and 
pAnCo1, which did not feature in any of the BLAST hits to pERB8e1_f but did match with 
pERB3f3 as already described (Figure 5.6b).  
 
5.5.6.6 pERB5.3e_f  
The plasmid-like contig pERB5.3e_f (Figure 5.6j), was acquired by volunteer 5 after travel to 
Uzbekistan. The 30 kbp MDR region included genes encoding resistance to seven 
antimicrobial and antiseptic classes. This MDR region carried the hallmarks of a so-called 
‘clinical class I integron’ and Tn21 transposon  which includes the chrA chromate resistance 
gene, the orf encoding putative gene padR, and mph(A) (Partridge, 2011).  
 
The BLAST hits to pERB5.3e_f were all isolated from clinical E. coil isolates. The BLAST hits 
included p46212 from the UK (99% query coverage) (Stoesser et al., 2016); pEC958 from 
Australia (92% query coverage) (Forde et al., 2014); and pEK499 from the UK (82% query 
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coverage) (Woodford et al., 2009). The high query coverage of each of these plasmids points 
to pERB5.3e_f being an epidemic plasmid which is present in human E. coli strains in 
Uzbekistan, Australia and the UK. Furthermore, the MDR region is conserved between 
pERB5.3e_f and each of the BLAST hits to this plasmid, providing evidence that this particular 
MDR cassette has become ‘fixed’ within a plasmid backbone. The MDR region of pERB5.3e_f 
allows antibiotic selection for plasmid propagation with any of the antibiotic, antiseptic 
classes with resistance genes present on the plasmid. In addition, resistance to chromate, 
and the presence of five toxin-anti toxin systems, allow plasmid survival in the host in the 
absence of antibiotic selection pressure (Figure 5.6j).  
 
 The CTX-M genetic context of isolate 5.3e was subjected to a BLAST search which found 
100% query coverage and 100% identify to the blaCTX-M-15 genetic context to p46212, which is 
a 160 kbp plasmid from an ST131 E. coli isolated from human urine in the UK (Stoesser et al., 
2016). 
 
5.5.7 Association of plasmids in this study with wastewater treatment plasmids in 
India 
Notably, in addition to the pERB3f3 homology with pV234a, three other circularised plasmids 
in this study which were subjected to extensive BLAST searches, also had homology to 
plasmids identified from the same waste-water treatment plant (WWTP) in India (Tables 
5.5a, 5.5c, 5.5d). Plasmid pERB4a2 matched to pV035b (63% coverage); pERB9a1 also 
matched to pV035-b (73% coverage); and pERB12a3 matched to pV233-b (93% coverage).  
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With respect to beta-lactamase gene content, of these WWTP plasmids (Akiba et al., 2016), 
two carried blaCTX-M-15 (pV234a and pV035-b), and one plasmid carried bla-CMY-2 (pV233-b). 
The study by Akiba and colleagues which produced several plasmid sequences from WWTP is 
the only study which has published plasmid sequences from India (Akiba et al., 2016). The 
present study is therefore valuable in providing a rare sample of ‘Indian’ plasmids, acquired 
by the travellers. 
 
The success of similar plasmids carried by E. coli strains and travellers in different parts of 
the world highlights the continued global success of pandemic plasmid lineages. 
Furthermore, the various plasmids with close matches to pERB4a2, pERB3f3 , pERB9a1, and 
pERB12a3, are found across the world, in a variety of environmental, animal and human 
niches, including in E. coli infecting strains. The plasmids identified in this study are (1) 
readily acquired from the environment by travellers; and (2) being stably maintained in 
colonising E. coli after return to the UK, given the global success of similar plasmids in varied 
hosts.  
 
5.5.8 Plasmid toxin-antitoxin systems  
Toxin anti-toxin (TA) systems are often encoded on bacterial plasmids and are a mechanism 
by which the plasmid maintains itself within daughter cells. TA systems have been found to 
have three major functions: (1) post segregational killing (PSK); (2) abortive infection; and (3) 
inducing a persister-state (Harms et al., 2018). Plasmid toxin-antitoxin (TA) systems were 
found in 7/10 plasmids presented in this chapter.  One plasmid, pERB5.3e_f possessed four 
different toxin-antitoxin systems. (Table 5.6 and Figure 5.6j).  
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PSK allows so-called plasmid addiction, by prevention of the loss of a plasmid from a 
bacterium. The toxin and antitoxin genes are expressed leading to protein production of 
both components of the system. The toxin is stable and lasts longer than the unstable-
antitoxin, therefore loss of a plasmid leads to rapid degradation of the anti-toxin, causing 
accumulation of toxin leading to host death. A typical example is  plasmid F, which encodes 
the TA system ccdAB (Harms et al., 2018). The TA system ccdAB was found to be carried by 
pERB5.3e_f (Figure 5.6j). 
 
The TA system PemIK was present on three plasmids described in the present study: 
pERB9a1, pERB8e1_f, and pERB5.3e_f (overview table and BRIG figure). PemIK is another 
example of a PSK system: (also known as pemIK, homologous to mazEF) originally described 
in plasmid R1 (Tsuchimoto, Ohtsubo and Ohtsubo, 1988). A homologue to PemIK is the 
mazEF system which has been shown to provide protection from bacteriophage insult 
(Alawneh et al., 2016). Phage immunity, also known as abortive infection, is a system 
whereby the TA system is activated when bacteriophages attack. For example the presence 
of the mazEF TA system in E. coli, leads to significantly reduced bacteriophage progagation 
compared with a parallel experiment where the mazEF system was inactivated (Alawneh et 
al., 2016).  
 
The pndA gene, which was present on plasmid pERB12a3, is a member of the hok/sok family 
system and can lead to PSK (Nielsen and Gerdes, 1995). The pnd gene encodes a protein 
toxin, PndA, which destroys the host cell by depolarisation of the cell membrane. The pnd 
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anti-toxin is the antisense RNA to pndA mRNA, and functions by binding pnd mRNA, 
preventing translation of the PndA toxin protein. PndA toxin is more stable than the anti-
sense RNA, leading to cell death of plasmid-free segregants (Nielsen and Gerdes, 1995). 
 
The RelBE TA system was found on plasmids pERB4a2 and pERB9a1. RelE is a superfamily of 
ribosome-dependent mRNA endonucleases which inhibit translation. RelE is one of the 
commonest TA systems in E. coli K12, with 7/13 TA system toxins in K12 belonging to the 
RelE family (Harms et al., 2018). The RelE system is involved in the bacterial stress response: 
reducing amino acids in-vitro, leads to upregulation of RelE, leading to a global reduction in 
protein translation. This in turn, leads to reduced bacterial energy consumption, and 
potential upregulation of RelE-resistant cellular processes (Christensen and Gerdes, 2003). 
Such a response can be interpreted as an evolutionarily advantageous persister state 
whereby the host cell becomes dormant and therefore potentially tolerant to some 
antimicrobial compounds (Harms et al., 2018).  
 
The phd/doc TA was present on pERB1a2_f, pERB8a1_f, and pERB5.3e_f (overview table and 
BRIG figure). The phd/doc TA is typically found within P1 bacteriophages acting as a PSK 
inducer, or in achieving bacterial persistence in S. Typhi (Harms et al., 2018). 
 
The VapC/VapB TA system, found on pERB5.3e_f (overview table and BRIG figure), is a TA 
system whereby an antitoxin protein (VapB) binds a toxin protein (VapC). VapC is a site-
specific tRNase which acts by cleaving tRNA anticodons between the loop and stem, leading 
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to bacteriostasis. This may lead to loss of expression of specific proteins, potentially playing 
a key role in inducing a bacterial persister state (Winther and Gerdes, 2011).  
 
Toxin-antitoxin systems function on a spectrum between one extreme of post segregational 
killing, and another extreme of downregulation of protein expression leading to bacterial 
persistence under stressful conditions, e.g. an antibiotic-containing environment. Therefore, 
having a greater number and variety of TA systems, as in the case of pERB5.3e_f, which 
carries four different TA systems, gives the plasmid an evolutionary edge. Plasmid 
pERB5.3e_f probably has at least one TA system which is geared towards post segregational 
killing, therefore maintaining the plasmid in the host: this can be described as a parasitic or 
selfish plasmid (Van Melderen and De Bast, 2009). On the other hand, the variety of TA 
systems present on pERB5.3e_f allows the plasmid to respond to a variety of stressors, 
leading to downregulation of specific functions, depending on the external insult. The 
resulting bacterial persister state is beneficial for not only plasmid survival but host bacterial 
survival: the TA system is promoting a symbiotic relationship between plasmid and host. 
 
5.5.9 Plasmids in post travel strains are conjugative 
5.5.9.1 Pre-conjugation screening and identification of non-lactose fermenting E. coli 
Prior to putting potential donor CTX-M-EC isolates forward for conjugation experiments, the 
lactose-fermenting ability of strains was checked by plating onto MacConkey agar. This was 
an essential step, as any candidate donor organisms needed to be lactose-fermenting, 
allowing differentiation from non-fermenting recipient (TG1).  
 
 236 
Lactose fermenting status was chosen as a phenotypic screening method for putative 
transconjugants because (1) the recipient strain, TG1, was a lactose non-fermenter; and (2) 
wild-type E. coli are typically lactose fermenters (Chaudhuri and Henderson, 2012). As part 
of the screening of potential donor isolates before entry into conjugation experiments, 
33/101 (33%) isolates were excluded because they were non-lactose fermenting E. coli. This 
was a surprising finding, as lactose-fermenting ability was originally used as one of the tests 
to identify E. coli (Edwards and Ewing, 1972).  
 
Overall, the non-lactose fermenting E. coli were found across six different E. coli STs, from 
five different volunteers, and ST131 non-lactose fermenting CTX-M-EC was found in 3 
volunteers. Lactose fermenting ST131 CTX-M-EC, were less common that non-fermenters, 
only being found in 2 volunteers: volunteer 5 and volunteer 16. The volunteer 5 lactose 
fermenting CTX-M-EC was cultured after the volunteer had visited Uzbekistan, and before 
visiting India, suggesting acquisition of the strain in Uzbekistan and not in India. The lactose 
fermenters present in volunteer 16 faecal cultures were actually closely related by SNP-
typing to non-lactose fermenters, suggesting that the lactose fermenting gene(s) in these 
isolates is present on a mobile genetic element, such as a plasmid. The possibility of a 
lactose-fermenting strain becoming a non-fermenter after loss of the lac operon, presents 
an issue for in-vitro conjugation experiments using these strains. Theoretically, lactose 
fermenting isolates which contain blaCTX-M, could become rifampicin-resistant via mutational 
resistance during the experiment, as well as becoming non-lactose fermenting. This would 
give a false positive (phenotypic) result in the current experiment. The only way to prove 
transconjugant status in this situation would be to sequence the genome of the putative 
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transconjugant, to confirm that the genome was that of TG1, with the addition of a blaCTX-M 
plasmid. Fortunately, in the two cases where putative transconjugants were sequenced, 
their status as transconjugants was confirmed with WGS.   
 
Very few studies have described the prevalence of non-lactose fermenting E. coli (Chang et 
al., 2014; Johnson et al., 2018). Chang and colleagues described a 20% (33/166) prevalence 
of non-lactose fermenting E. coli in a collection of isolates causing urinary tract infection in 
South Korea, which included variety of E. coli sequence types (Chang et al., 2014). Chang also 
found that 8/33 non-fermenting isolates were ST131 strains but found no statistical 
difference in ESBL carriage rate between non-lactose fermenting and lactose-fermenting E. 
coli. The ESBL genotypes were not determined (Chang et al., 2014). In another study, all 427 
clinical/faecal E. coli ST1193 isolates from a Minnesota microbiology laboratory were lactose 
non-fermenting (Johnson et al., 2018). 
 
The cause of the lactose-non-fermenting phenotype in E. coli may be due to plasmid loss 
(Walia et al., 1987), or a problem within the lac operon, such as a deficiency in lactose 
permease, encoded by the LacY gene (Fernández-Castané et al., 2012). Notably, a frame-
shift mutation in the LacY gene has been implicated in the non-fermenting phenotype of E. 
coli ST1193 strains (Johnson et al., 2018).  
 
Further bioinformatic work stemming from the present study would involve investigation of 
the genetic basis of lactose non-fermenting status in the non-fermenting E. coli strains 
described above, compared with lactose fermenting strains. In particular, an investigation 
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could be done, into whether the lac operon is present on a plasmid or transposon, which 
could result in clonally indistinguishable strains having different phenotypes when grown on 
MacConkey agar. 
 
5.5.9.2 Conjugation rate 
In the present study, 5/11 volunteers (45%) carried CTX-M-EC where blaCTX-M could be 
transferred by conjugation on filters. To our knowledge, no studies have determined the 
conjugative ability of travel-acquired ESBL-producing E. coli before. However, clinical isolates 
from patients in Lebanon (Harajly et al., 2010) and Tunisia (Mnif et al., 2013) demonstrated 
conjugation rates of 49% and 80% respectively.  
 
5.5.9.3 Reasons for non-conjugation 
The main reason for non-conjugation was presence of blaCTX-M on the chromosome (7/19 
cases) (Table 5.7). A large proportion of blaCTX-M contigs in this study were found to be 
chromosomal: 15/39 (38%). Assuming the traveller cohort in the present study is 
representative of CTX-M-EC acquisitions in India, (and provides a snapshot of CTX-M-EC 
which exist in the environment), the presence of blaCTX-M on the chromosome does limit the 
conjugation potential of blaCTX-M in these E. coli populations. Contrastingly, mobilisation of 
blaCTX-M via transposition events, allowing stable carriage on the bacterial chromosome, is an 
important phenomenon, which warrants further study. 
 
A further reason for non-conjugation was that the blaCTX-M plasmid contained no conjugation 
machinery, therefore these strains would have the ability to create a conjugation pilus. One 
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of these strains, pERB8a1_f is a phage-like plasmid (see discussion section 5.5.6.5). Phage-
like plasmids would not be expected to conjugate using conventional in-vitro experiments on 
filters. Instead, inducing pERB8a1_f transfer would likely require stimulation of a lysogenic 
function, allowing propagation of new bacteriophages into the extracellular environment, 
and thereby infecting other bacterial strains.  
 
For isolate 9c3, which possessed an intact Tra operon, an alternative explanation is needing 
to explain the lack of conjugative ability. A modification in environmental conditions such as 
pH and/or temperature for conjugation does have an effect on the ability of some plasmids 
to conjugate (Hardiman et al., 2016). Therefore, the modification of conjugation experiment 
parameters may have resulted in a higher conjugation success rate.  
 
In Volunteer 9 plasmid pERB9a1, which contains the Tra operon, but which failed to 
conjugate the CTX-M plasmid in-vitro, we found a Tn21 transposon upstream of TraD (Figure 
5.6c). This insertion may be the cause of the failure of pERB9a1 to conjugate. However, in 
order to prove this hypothesis, experiments using a transposon inserted into the Tra operon 
in this position would be required.  
 
In the case of 3/19 STs which failed conjugation, different isolates of the same clonally 
indistinguishable STs did produce transconjugants. The failure of isolates of the same ST, 
from the same volunteer, to conjugate blaCTX-M may represent plasmid differences between 
clonal strains, or subtle methodological differences between experiments with different 
strains. Different isolates from the same ST were sometimes processed in conjugation 
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experiments on different days, therefore subtle changes in methodology or in room 
temperature could explain the differences between clonal isolates. 
 
5.5.9.4 Conjugation experiment: limitations and suggested further work 
The principle of a conjugation experiment is the use of at least 2 markers – usually antibiotic-
supplemented agar – to select for (1) strains with the plasmid (cefotaxime resistance in the 
present study); and (2) recipient strains with a resistance phenotype which is absent from 
donor strains (rifampicin resistance in present study). Unfortunately, when using a 
chromosomally mediated resistance marker, such as rifampicin-resistance, to select for 
putative transconjugants, an important issue is the emergence of rifampicin-resistant donor-
E. coli, which often grow on transconjugant agar plates. Therefore, control plates are needed 
in parallel, to determine if rifampicin-mutations are emerging in donor strains (Table 5.7). 
Phenotypically, it is not possible to differentiate rifampicin-mutant donor strains from true 
transconjugants. Therefore, all conjugation experiments should include a third marker to 
confirm phenotypically, that a colony is a transconjugant, rather than a cefotaxime-resistant 
donor strain which has become rifampicin-resistant. 
 
In the present study, the lactose non-fermenting status of the recipient strain was used as a 
marker of transconjugant status: therefore, any non-fermenting colony growing on LB media 
containing rifampicin plus cefotaxime, was assumed to be a transconjugant, pending blaCTX-M 
PCR confirmation. However, this approach resulted in 33% of travel-acquired CTX-M-EC 
being excluded from entry into conjugation experiments due to being non-lactose 
fermenting E. coli. In further work, an approach to investigate the conjugative potential of 
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these isolates could not use lactose fermenting ability as a marker of transconjugant status. 
Instead, sodium azide could be used as a marker for successful conjugation – as resistance is 
rare in wild type strains. An appropriate laboratory E. coli which is azide-resistant, would be 
required for use as a conjugation recipient, as used in previous studies (Harajly et al., 2010).  
 
A further limitation of this experiment was that the conditions used in the conjugation 
experiments in this study were fixed and were not necessarily representative of in-vivo 
conditions. For example, conjugation frequencies can vary at different temperatures, 
depending on the plasmid under investigation. It seems plausible that different plasmids 
may be better able to undergo conjugative transfer at temperatures outside the human 
physiological norm of 37 degrees. It seems reasonable to assume that in the natural 
environment, plasmids and their hosts have evolved, allowing transfer more effectively at 
lower and high temperatures, depending on environmental conditions. Varying the 
temperature used would be an additional aspect to investigate in future conjugation 
experiments with the traveller E. coli strain collection.  
 
A further limitation to our conjugation experiment methodology is that we used a laboratory 
E. coli K12 MG1655 strain (TG1) as a recipient. This strain was chosen because (1) It has been 
successfully used in our laboratory before as a recipient strain in conjugation experiments; 
and (2) TG1 is plasmid-free, allowing straight-forward plasmid sequencing by WGS of any 
plasmids transferred.  The issue with using a laboratory recipient is that this strain is not 
representative of wild-type E. coli strains which receive plasmids in the natural environment, 
or in the gastrointestinal tract of humans. In future, conjugation experiments should use a 
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wild type recipient, to better replicate in-vivo conditions. Ultimately, a gut model should be 
used, to allow the best representation of gastrointestinal conditions. Models of the 
gastrointestinal tract for the purpose of investigating bacterial horizontal gene transfer, have 
been developed ex-vivo in the form of culture chemostats simulating conditions in the 
chicken caecum (Card et al., 2017); and a porcine gut bioreactor (Peeters et al., 2017). 
Chemostat-based models of the human faecal microbiome have also been developed 
(Patrick De Boever, Deplancke and Verstraete, 2000; Cinquin et al., 2004; McDonald et al., 
2013; Crowther et al., 2014), however no studies have investigated the conjugative potential 
of strains using such a model. There is certainly scope to develop an in-vitro chemostat-
based model for bacterial conjugation, with a view to then investigating the effect of 
external modifications such as antibiotic concentrations and putative inhibitors of 
conjugation.  
 
5.5.9.5 Determination of Conjugation Frequency 
Among eight discrete CTX-M-EC sequence types, there was notable variation in conjugation 
frequencies (Figure 5.10a-b). These differences are likely to be due to different plasmids with 
different conjugative abilities being present in each strain. However, it must be noted that 
these differences were not statistically significant in most cases, as indicated by the 
overlapping confidence intervals (Figure 5.10a-b). This was due to a low number of replicate 
experiments carried out (three per isolate tested) due to time limitations.  
 
Conjugation rates for blaCTX-M genes in the present study were comparable to Amos et al 
who tested 51 isolates (from >9 sequence types), which all had conjugation frequencies 
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between 10-3 and 10-7 (Amos et al., 2014). The frequencies of conjugation in the present 
study are also comparable to data from Cottell and colleaugues who showed that the 
frequency of transfer of the blaCTX-M-14 plasmid, pCT, varies between 10-2 and 10-6 (Cottell, 
Webber and Piddock, 2012). 
 
In one case, for isolate 20c4 which carried the AmpC gene blaDHA-1, the conjugation 
frequency was significantly higher (around x1 log difference) compared to all other strains 
(CTX-M-producers) (Figure 5.10a-b). The in-vitro conjugal transfer of blaDHA-1 has been 
described in previous studies using clinical isolates from South Korea (Yoon et al., 2011) and 
India (Ingti et al., 2017). However, the conjugation frequency of a blaDHA-1 plasmid is not 
described in the current literature. It is likely that the plasmid carrying blaDHA-1 in isolate 20c4 
was particularly well-adapted to transfer under the experimental conditions used in the 
conjugation experiment.  
 
The reason that conjugation frequency differed so much for strain 20c4 compared to the 
blaCTX-M strains, may be reflective of a more efficient transfer operon present in the 20c4 
plasmid. Alternatively, 20c4 may possess greater ‘fitness’ than the CTX-M-producing strains 
tested, allowing the donor 20c4 to reach higher concentrations on the conjugation plates, 
thus leading to higher rates of conjugation. Further work to investigate these possibilities 
would involve a detailed comparison of the plasmid transfer operons between the 
transconjugants, as well as competition experiments between the strains in question.  
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5.5.10 PFGE as an additional check on plasmid transfer 
PFGE was utilised as an additional check on plasmid transfer, and also provided an estimate 
of plasmid size. This was an especially useful method in the pre-WGS era to confirm plasmid 
conjugation had occurred and has been utilised for this purpose in the past (Chanawong et 
al., 2002).  
 
5.5.11 Confirming transfer using VITEK sensitivity testing 
Undertaking phenotypic sensitivity testing of transconjugants is important, because this 
confirms the potential clinical impact of the dissemination of AMR via horizontal gene 
transfer (HGT). The phenotypic and genotypic characteristics of transconjugant strains 
demonstrates the transfer of MDR cassettes via plasmid HGT (see Chapter 4 section 4.3.6). 
 
In turn, the demonstration of HGT of MDR cassettes in vitro provides weight to phenomenon 
of antibiotic co-selection leading to propagation of strains which contain MDR cassettes.  
There are two key situations where this phenomenon is important: (1) human therapeutics, 
e.g. the wide unregulated use of fluoroquinolones in human medicine (Hawkey, 2015); and 
(2) environmental contamination with MDR organisms from a variety of sources including 
human and animal waste (Wellington et al., 2013). The problem of environmental 
contamination with MDR-Enterobacteriaceae from humans and animals is confounded by 
further environmental contamination with antibiotics from the human/animal food chains, 
as well as the wastewater from antibiotic manufacture (Wellington et al., 2013). In 
Hyderabad, India, a study assessed the impact of environmental contamination from 
antibiotic manufacture on AMR-gram negative bacteria in the environment  (Lübbert et al., 
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2017). Lubbert and colleagues found a strong association between antibiotic contamination 
and AMR at all their sampling sites. Notably, 23/23 sites sampled in Hyderabad had gram 
negative bacteria which were ESBL and carbapenemase-producers (Lübbert et al., 2017). 
 
The poor standards of basic sanitation in countries like India are an additional factor which in 
part explains the high level of environmental contamination with CTX-M-EC in South Asia 
and in turn, the high acquisition rates among travellers from the West who visit these 
countries (Bevan, Jones and Hawkey, 2017). 
 
5.5.12 Overview of phage-like plasmids 
In the present study, we found that 6/10 plasmids (and plasmid-like contigs) contained 
genes of bacteriophage origin. In the case of 2/10 plasmids, pERB8e1_f and pERB3f3, which 
matched to bacteriophage P1-like plasmids and bacteriophage SSU5-like plasmids, 
respectively (Figures 5.6b and 5.6g). These are the two bacteriophage superclusters which 
target Enterobacteriales: P1-like bacteriophages and SSU5-like bacteriophages, which may 
both co-exist as circularised plasmids with the host bacterium (Gilcrease and Casjens, 2018). 
Both types of bacteriophage have been found in Enterobacteriales carrying ESBLs (Billard-
Pomares et al., 2014; Falgenhauer et al., 2014; Shin and Ko, 2015; Akiba et al., 2016; 
Colavecchio et al., 2017) and mcr-1 (Li et al., 2017).  
 
Given the small sample size of plasmids, this suggests that phage-like plasmids play a key 
role in the dissemination of blaCTX-M genes globally – perhaps equalling the role of epidemic 
plasmids of bacterial origin. Further work is needed in interrogating isolate sequence 
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repositories for phage-like plasmids, including all strains sequenced in the present study. 
This will further the understanding the role of bacteriophage-mediated spread of AMR in 
gram negative bacteria, which will help inform strategies to combat the spread of multi-
resistant strains. 
 
5.5.13 The challenge of plasmid assembly 
The experiments described in this chapter support the notion that plasmid assembly is a 
challenge – whether this is done by conjugation or by whole genome sequencing using a 
hybrid assembly approach. Due to the presence of multiple repetitive sequences, short read 
illumina sequencing is not well suited to the assembly and circularisation of large plasmids 
(>50 kbp) (Arredondo-Alonso et al., 2017). There are several options to allow plasmid 
sequence completion: (1) plasmid DNA isolation and short read sequencing without 
chromosomal DNA; (2) plasmidome network analysis after short read sequencing; (3) short 
read sequencing of a transconjugant with the plasmid of interest; (4) long read sequencing 
plus short read sequencing followed by hybrid assembly. 
 
Each option for plasmid sequencing has particular limitations. For option (1), the isolation of 
low-copy number plasmid DNA in sufficiently high concentrations requires high volumes of 
bacterial culture, and is highly labour intensive even for the sequencing of a single plasmid 
(Cottell et al., 2011). Option (2) requires utilisation of a tailor-made bioinformatic pipeline, 
‘Plasmid Constellation Network’ (PLACNET) (Lanza et al., 2014); and option (3), the 
transconjugant analysis, is limited by donor suitability issues and plasmid instability in the 
recipient E. coli. Option (4): hybrid assembly, relies on achieving good read depth of long 
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sequence reads (Ashton et al., 2015). In the present study we used options (3) and (4) to 
resolve plasmid sequences, as these methods were well-suited to the resources available for 





The first hypothesis presented in this chapter, that blaCTX-M genes are primarily plasmid-
mediated was confirmed, with 56% of CTX-M-EC isolates with blaCTX-M found on a plasmid, 
rather than on the bacterial chromosome.  
 
A further hypothesis was that travel acquired blaCTX-M containing plasmids are more closely 
related to Indian plasmids, than to UK plasmids. This is rather a challenging hypothesis to 
investigate, as relatively few CTX-M plasmids from the Indian subcontinent have been 
sequenced. There was homology between travel acquired CTX-M plasmids and Indian 
plasmids, for example with the Indian wastewater treatment plasmid, pV234a. However, this 
study has also demonstrated that travel-acquired CTX-M plasmids are not specific to the 
Indian subcontinent – there are close homologues found from around the world.  
 
The genetic context of blaCTX-M is key to its global spread in E. coli and other 
Enterobacteriales. Six main types of blaCTX-M genetic context were described in this chapter, 
all with homologues in previously sequenced, geographically widespread Enterobacteriales. 
A specific epidemiological link to India was found for context (iii): the only previous 
description of this context (which included ParA-blaCTX-M-) was found in BLAST hits from 
previously sequenced Indian waste-water plasmids. This finding serves to re-enforce the 
importance of human travel in the dissemination of blaCTX-M in a novel genetic context. 
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A strong promotor sequence is provided by ISECp1 and the highly conserved ISECp1-blaCTX-M-
15 spacer sequence is likely to be important in maintaining blaCTX-M expression and 
propagation. This was contrary to the hypothesis that there may be geographic variation in 
the ISECp1-blaCTX-M-15 spacer sequence. An additional level of blaCTX-M propagation are the 
plasmid-borne TA systems. TA systems have been shown to play an important role in 
plasmid maintenance, for the mutual benefit of the plasmid, and the host bacterium. 
 
The sources of the plasmids described in this chapter were global clinical, animal, and 
environmental strains with epidemic plasmids crossing into each of these niches. Identifying 
CTX-M-EC plasmids from the faecal microbiome of returning travellers is an innovative 
approach to sampling environmental E. coli from the Indian subcontinent. This approach also 
provides a new insight into the promiscuity of epidemic plasmids. Two main classes of 
plasmid identified have been identified: those of bacterial origin, and those of phage-like 
origin. A limitation of the approach used is reliance on sequence comparisons with 
previously annotated plasmids, already submitted to the NCBI database. Unknown or 
unannotated plasmids are inevitably missed.  
 
After confirming that CTX-M-EC acquired by travellers possess the conjugation machinery for 
horizontal gene transfer (HGT), it would be expected that HGT occurs in vivo – i.e. within the 
human faecal microbiome, or in the natural environment. HGT by plasmid conjugation does 
occur in the human gut, although reports are limited to case reports (Gona et al., 2014) and 
self-administration of bacterial cultures (Smith, 1969). Measuring the in-vivo transfer rates 
of CTX-M-EC plasmids in the human gut would be possible , as this approach has been used 
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before (Smith, 1969), although there are potential ethical issues with conducting a similar 
experiment in the 21st century.  
 
We used SNP typing of non-CTX-M-EC pre-travel strains versus CTX-M-EC post travel strains 
to look for instances where pre-existing host flora acquired a plasmid with blaCTX-M and 
found no evidence of this occurrence (see Chapter 4, section 4.3.7). We also looked for 
common plasmids shared between different E. coli strains in the same faecal sample but did 
not find any.  
 
This study supports the notion of globally successful conjugative epidemic plasmids in the 
spread of CTX-M-EC – plasmids are readily acquired by our healthy volunteers– and are 
carried on return to the UK, providing further opportunities for onward dissemination.  
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Chapter 6: Conclusion  
 
This study has provided analysis and discussion of the molecular epidemiology of CTX-M-EC 
in the faecal microbiome of returning travellers. The world-wide prevalence of ESBL-
producing Enterobacteriaceae continues to increase in all regions, and blaCTX-M-15 and blaCTX-
M-14 continue to be globally predominant, although other blaCTX-M genes such as blaCTX-M-27 
and blaCTX-M -55 are becomingly increasingly prevalent in genotype surveys. There is little 
doubt that a combination of human factors has increased the propagation of bla-CTX-M. 
Antibiotic overuse in humans and animals, increased global migration and population 
density, and inadequate access to basic sanitation in developing countries promote the 
spread of CTX-M-EC (Bevan, Jones and Hawkey, 2017). Attempts must be made to mitigate 
these risks through preventative strategies, such as improving access to latrines in 
developing countries, better antimicrobial stewardship in humans and animals, 
environmental controls, and targeted evidence-based ESBL screening strategies (O’Neil, 
2016). 
 
The evolution of globally successful clones of CTX-M-EC is important, and ExPEC CTX-M-
producing strains are dominated by the ST131 lineage (Roer et al., 2017; Harris et al., 2018). 
Colonisation of CTX-M-EC after travel was found to be due to the polyclonal acquisition of 
novel CTX-M-EC strains, which colonised the faecal microbiome for up to a year after travel 
(Bevan et al., 2018). The present study is the first to report that pre-travel E. coli strains are 
not completely displaced from the faecal microbiome by CTX-M-EC, but are maintained as a 
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minority population throughout travel and become detectable again as a majority 
population after travel (Bevan et al., 2018). Therefore, non-pathogenic, non-CTX-M-EC 
strains were identified which have the ability to out-compete CTX-M-EC after return to the 
UK.  
 
Further work could involve the use of these non-CTX-M strains as part of a strategy to 
decolonise individuals who have CTX-M-EC in the faecal microbiome. Such undesirable AMR 
bacteria are not limited to CTX-M-EC, but also include CPE and mcr carrying strains. Non-
pathogenic E. coli, such as the Nissle 1917 strain have been formulated as a drug 
(Mutaflor®), which is used in Germany as an effective treatment for preventing relapses of 
inflammatory bowel disease (Rembacken et al., 1999; Sonnenborn and Schulze, 2009). 
However, Nissle fails to displace AMR E. coli from the faecal microbiome in humans (Tannock 
et al., 2011) and in swine (Mourand et al., 2017). Further work is required to determine the 
microbiological properties of the non-CTX-M-EC in the present study, which allow persistent 
colonisation and could support the development of an effective AMR-displacing probiotic.  
 
Case reports suggest that faecal microbiota transplantation (FMT) is an effective means to 
de-colonise selected patients who are faecally colonised with of AMR bacteria (Singh et al., 
2014; Lagier et al., 2015; Wei et al., 2015). However, the microbiological follow-up of these 
patients did not exceed three months, raising the possibility of persisting minority AMR 
strains over a longer time period after FMT. Several trials are underway to assess the 
effectiveness of FMT for decolonisation of MDR Enterobacteriaceae (Manges, Steiner and 
Wright, 2016). After further strain characterisation and screening for pathogenicity factors, 
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the pre-travel non-CTX-M-EC identified in the present study (Bevan et al., 2018), could be 
utilised as part of FMT to decolonise patients.  
 
The data presented in Chapter 5 reinforces the importance of epidemic plasmid spread in 
the global dissemination of CTX-M-EC. It is notable that no instances of horizontal gene 
transfer (HGT) of the blaCTX-M plasmid from a travel-acquired strain onto a pre-existing host 
strain were found. Therefore, if HGT occurs, it is most likely to be at a low frequency, as it 
was not detected in the present study.  
 
There are two lines of evidence from this study which suggest that HGT is possible in CTX-M-
EC-colonised individuals. Firstly, epidemic plasmids are found carried by CTX-M-EC in 
returning travellers, which have sequence matches to plasmids isolated from different 
ecological niches from around the world (Chapter 5, See Tables 5.5a-c). Plasmid matches 
come from different E. coli STs. For example, pERB4a2 was isolated from an E. coli ST2732 
strain, whereas the BLAST match pHK01 has been found in multiple different STs (P. L. Ho et 
al., 2012). Similarly, pERB12a3 (from an ST43 strain) matches to pEK204 (ST131 strain) 
(Woodford et al., 2009), and pERB3f3 (from an ST405 strain) matches to pM160133_p1 
(from an ST1485 strain) (Gilrane et al., 2017). Secondly, plasmids in this study can be 
transferred by conjugation in-vitro (Chapter 5, Table 5.7), implying that horizontal gene 
transfer also occurs in vivo, in the human faecal microbiome. 
 
Characterising the role of blaCTX-M-encoding plasmids from CTX-M-EC acquired by travellers 
will help to support the development of novel strategies to displace these plasmids from the 
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host strain, such as plasmid curing (Hale et al., 2010) and conjugation inhibition (Ripoll-
rozada et al., 2016). 
 
Studying CTX-M-EC acquisition in healthy volunteers helps inform future studies in hospital 
patients and is an important surrogate for future spread of carbapenemase genes. E. coli is 
the single most common cause of bacteraemia in the UK. Determining the mechanism of 
spread of resistance genes in E. coli underpins infection prevention and control practices, 
decreasing excess mortality, and allows the preservation of existing classes of antibiotics for 




• Determine the pathogenicity factors and colonisation ability of travel-acquired CTX-M-EC and 
pre-travel non-CTX-M-EC and compare these to the E. coli Nissle strain. 
• Utilise non-pathogenic, non-CTX-M-EC in an in-vivo setting in healthy human volunteers 
known to be colonised with CTX-EC. In a new traveller study, pre-travel resident non-CTX-M-
EC could be provided to volunteers to consume after travel, aiming to speed up de-
colonisation of CTX-M-EC. 
• Provide further characterisation of blaCTX-M-encoding plasmids using repeat long read 
sequencing after strain barcoding. Identify plasmids which are amenable to plasmid curing 
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Table S1. E. coli Isolates before and after travel with corresponding sample collection time 
points and MLSTs. Normal font: non-CTX-M-EC. Bold: CTX-M-EC. 
 
   
E. coli Isolate Faecal sample time-point (pre or post-travel) MLST Phylogenetic group 
1.1a 
10 days pre 
131 B2 
1.1b 131 B2 
1.1c 131 B2 
1.1d 131 B2 
1.1e NS  
1.1f NS   
1.2a 
5 days pre 
131 B2 
1.2b 131 B2 
1.2c 131 B2 
1.2d NS  
1.2e NS  
1.2f NS   
1a1 
4 days post 
349* D 
1a2 349 D 
1a3 349 D 
1a4 349 D 
1b1 19 days post 394 D 
1c1 31 days post  69 D 
1.e.1 
122 days post 
131 B2 
1.e.2 131 B2 
1.e.3 131 B2 
1.e.4 131* B2  
3.1a 
28 days pre 
69 D 
3.1b 941 B2 
3.1c 941 B2 
3.1d 69 D 
3.1e 69 D 
3.1f 69 D 
3.2a 
14 days pre 
69 D 
3.2b 69 D 
3.2c 69 D 
3.2d 69 D 
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3.2e 69 D 
3.2f 2008 NG 
3.3a 
3 days pre 
69 D 
3.3b 69 D 
3.3c 69 D 
3.3d 69 D 
3.3e 69 D 
3.3f 69 D 
3a1 
7 days post 
43 A 
3a2 43 A 
3b2 
7 days post 
38 D 
3b3 1193 B2 
3b4 1193 B2 
3c1 
28 days post 
38 D 
3c3 1193 B2 
3d1 
56 days post 
1193 B2 
3d2 1193 B2 
3d3 1193 B2 
3d4 1193 B2 
3.e.1 
84 days post 
405 D 
3.e.2 405 D 
3.e.3 38 D 
3.e.4 405 D 
3f1 
274 days post 
405 D 
3f2 405 D 
3f3 405 D 
3f4 405 D 
4.1a 
14 days pre 
10 A 
4.1b 10 A 
4.1c 10 A 
4.1d 10 A 
4.1e 10 A 
4.1f 10 A 
4.2a 
7 days pre 
10 A 
4.2b 10 A 
4.2c 10 A 
4.2d 10 A 
4.2e 10 A 
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4.2f 10 A 
4a1 
7 days post 
2732 NG 
4a2 2732 NG 
4a3 2732 NG 
4a4 2732 NG 
4a5 2732 NG 
4a6 69 D 
4b1 
30 days post 
69 D 
4b2 69 D 
4b3 69 D 
4b4 69 D 
4c1 
49 days post 
69 D 
4c2 69* D 
4c3 69* D 
4c4 69 D 
4d1 
91 days post 
648 B1 
4d2 648 B1 
4d3 648 B1 
4d4 648 B1 
4.e.1 
152 days post 
69 D 
4.e.2 69 D 
4.e.3 69* D 
4.e.4 69 D 
5.1a 
7 days Pre-Uzbekistan 
452 B2 
5.1b 452 B2 
5.1c 452 B2 
5.1d 452 B2 
5.1e 452 B2 
5.1f 452 B2 
5.2a 
4 days post Uzbek. 
38 D 
5.2b 38 D 
5.2c 38 D 
5.2d 405 D 
5.2e 38 D 
5.2f 38 D 
5.3a 
29 days post Uzbek. 
405 D 
5.3b 405 D 
5.3c 405 D 
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5.3d 131 B2 
5.3e 131 B2 
5.3f 131 B2 
5a1 
3 days post India 
48 A 
5a2 48 A 
5a3 48 A 
5a4 48 A 
5b1 
8 days post India 
48 A 
5b2 48* A 
5b3 48 A 
5b4 48 A 
5c1 
28 days post India 
10 A 
5c2 10 A 
5c3 10 A 
5c4 48 A 
5d1 
60 days post India 
10 A 
5d2 10 A 
5d3 10 A 
5d4 10 A 
5.e.1 
91 days post India 
6338 NG 
5.e.2 6338 NG 
5.e.3 38 D 
5.e.4 38 D 
5f1 
183 days post India 
88 C 
5f2 48* A 
5f3 48 A 
5f4 88 C 
5g1 
244 days post India 
3478 A 
5g2 3478 A 
5g3 3478 A 
5g4 3478 A 
5H1 
364 days post India 
10 A 
5H2 10* A 
5H3 10 A 
5H4  NS   
6.1a 
42 days pre 
69 D 
6.1b 69 D 
6.1c 73 B2 
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6.1d 69 D 
6.1e 73 B2 
6.1f 69 D 
6.2a 
28 days pre 
73 B2 
6.2b 73 B2 
6.2c 73 B2 
6.2d 73 B2 
6.3a 
1 day pre 
73 B2 
6.3b 73 B2 
6.3c 73 B2 
6.3d 73 B2 
6.3e 73 B2 
6.3f 73 B2 
6a1 
4 days post 
450 NG 
6a2 450 NG 
6a3 450 NG 
6a4 450 NG 
6b1 
21 days post 
8095 D 
6b2 8095 D 
6b3 8095 D 
6b4 8095 D 
6c1 
42 days post 
2221 B1 
6c2 73 B2 
6c3 450 NG 
6c4 73 B2 
6d1 
180 days post 
73 B2 
6d2 73 B2 
6d3 73 B2 
6d4 73 B2 
7.1a 
60 days pre 
10 A 
7.1b 10 A 
7.1c 10 A 
7.1d 10 A 
7.1e 10 A 
7.1f 10 A 
7.2b 29 days pre 69 D 
7.3a 
7 days pre 
69 D 
7.3b 10 A 
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7.3c 10 A 
7.3d 10 A 
7.3e 10 A 
7.3f 10 A 
7a1 
5 days post 
10 A 
7a2 6438 NG 
7a3 6438 NG 
7a4 6438 NG 
7b1 
10 days post 
10 A 
7b2 10 A 
7b3 10* A 
7b4 43 A 
7c2 
28 days post 
200 B1 
7c3 200 B1 
7c4 200 B1 
7d1 
60 days post 
200 B1 
7d2 200 B1 
7d3 200 B1 
7d4 200 B1 
7.e.1 122 days post 450 NG 
7f2 
245 days post 
3036 NG 
7f4 69 D 
8.1a 
7 days pre 
69 D 
8.1b 1163 NG 
8.1c 69 D 
8.1f 2712 D 
8.2a 
1 day pre 
10 A 
8.2b 10 A 
8.2c FS  
8.2d 10 A 
8.2e 10 A 
8.2f 10 A 
8a1 
10 days post 
448 B1 
8a2 448 B1 
8a3 448 B1 
8a4 448 B1 
8b1 
16 days post  
648 B1 
8b2 10 A 
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8b3 10 A 
8b4 10 A 
8c1 
40 days post 
10 A 
8c2 10 A 
8c3 10 A 
8c4 10 A 
8d1 
58 days post 
10 A 
8d2 10 A 
8d3 648 B1 
8d4 10 A 
8.e.1 
120 days post 
648 B1 
8.e.2 648 B1 
8.e.3 648 B1 
8.e.4 648 B1 
8f1 
244 days post 
648 B1 
8f2 648 B1 
8f3 648 B1 
8f4 648 B1 
8g1 
330 days post 
131 B2 
8g2 131 B2 
8g3 38 D 
8g4 131 B2 
9.1a 
28 days pre 
NT Clade V^ 
9.1b NT Clade V^ 
9.1c NT Clade V^ 
9.1d NT Clade V^ 
9.1e NT Clade V^ 
9.1f NT  Clade V^ 
9.2a 
30 days pre 
NT Clade V^ 
9.2b 69 D 
9.2c 69 D 
9.2d 69 D 
9.2e 69 D 
9.2f 69 D 
9.3a 
7 days pre 
3727 NG 
9.3b 3727 NG 
9.3c 3727 NG 
9.3d 3727 NG 
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9.3e 3727 NG 
9.3f 3727 NG 
9a1 
5 days post 
4 A 
9a2 200 B1 
9a3 4 A 
9a4 4 A 
9b1 
14 days post 
2617 F 
9b2 2617 F 
9c1 
35 days post 
2617 F 
9c2 2617 F 
9c3 2617 F 
9c4 2617 F 
9d1 
91 days post 
2617 F 
9d2 2617* F 
9d3 2617 F 
9d4 2617 F 
9.e.1 
152 days post 
2617 F 
9.e.2 2617 F 
9.e.3 2617 F 
9.e.4 2617 F 
9f1 
210 days post 
2617 F 
9f2 2617 F 
9f3 2617 F 
9f4 2617 F 
10.1a 
61 days pre 
354 F 
10.1b 354 F 
10.1c 354 F 
10.1d 354 F 
10.1e 354 F 
10.1f 354 F 
10.2a 
30 days pre 
354 F 
10.2b 354 F 
10.2c 354 F 
10.2d 354 F 
10.2e 354 F 
10.2f 354 F 
10.3a 
7 days pre 
642 B1 
10.3b 642 B1 
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10.3c 642 B1 
10.3d 642 B1 
10.3e 642 B1 
10.3f 642 B1 
10a1 
5 days post 
200 B1 
10a2 34 A 
10b1 
14 days post 
200 B1 
10b2 200 B1 
10c1 35 days post 10* A  
10e.1 
152 days post 
10* A 
10e.2 10*  A 
12.1a 
14 days pre 
1314 A 
12.1b 1314 A 
12.1c 10 A 
12.1d 10 A 
12.1e 1314 A 
12.1f 10 A 
12.2a 
7 days pre 
10 A 
12.2b 10 A 
12.2c 752 A 
12.2d 10 A 
12.2e 770 NG 
12.2f 10 A 
12a1 
3 days post 
43 A 
12a2 43 A 
12a3 43 A 
12a4 43 A 
12b1 
21 days post 
43 A 
12b2 43 A 
12b3 43 A 
12b4 43 A 
12c1 
29 days post 
43 A 
12c2 43 A 
12c3 43 A 
12c4 43 A 
12d1 
56 days post India 
43 A 
12d2 43 A 
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12d3 43 A 
12d4 43 A 
12.e.1 
115 days post India 
43 A 
12.e.2 43 A 
12.e.3 43 A 
12.e.4 43 A 
12fs 213 days post India 1276 F 
12g1 
305 days post India 
189 A 
12g2 189 A 
12g3 189 A 
12g4 189 A 
12h1 
360 days post India 
5919 NG 
12h2 5919 NG 
12h3 216 A 
12h4 5919 NG 
15.1a 
28 days pre 
210 NG 
15.1b 210 NG 
15.1c 10 A 
15.1d 10 A 
15.1e 210 NG 
15.1f 210 NG 
15.2c 
14 days pre 
10 A 
15.2d 10 A 
15.2e 210 NG 
15.2f 210 NG 
15a1 
1 day post 
167 A 
15a2 167 A 
15a3 167 A 
15a4 167 A 
15b 122 days post 52 A 
15c1 
150 days post 
10 A 
15c2 10 A 
15c3 10 A 




16.1b 349 D 
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16.1c 349 D 
16.1d 349 D 
16.1e 349 D 




16.2b 349 D 
16.2c 349 D 
16.2d 349 D 
16.2e 349 D 
16.2f 349 D 
16a1 
7 days post 
38 D 
16a2 38 D 
16a3 38 D 
16a4 38 D 
16b1 
40 days post 
227 A 
16b2 131 B2 
16b3 38 D 
16b4 227 A 
16c1 
91 days post 
131 B2 
16c2 131 B2 
16c3 227 A 
16c4 131 B2 
16d1 
121 days post 
131 B2 
16d2 131 B2 
16d3 131 B2 
16d4 131 B2 
16 e1 
179 days post 
131 B2 
16 e2 131 B2 
16 e3 131 B2 
16 e4 131 B2 
17.1a 
30 days pre 
NT clade V^ 
17.1b NT clade V^ 
17.1c NT clade V^ 
17.1d NT clade V^ 
17.1e NT clade V^ 
17.1f NT  clade V^ 
17.2a 
3 days pre 
131 B2 
17.2b 131 B2 
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17.2c 131 B2 
17.2d 131 B2 
17.2e 131 B2 
17.2f 131 B2 
17a1 
21 days post 
450 NG 
17a2 450 NG 
17a3 450 NG 
17a4 450 NG 
17b1 
42 days post 
43 A 
17b2 43 A 
17b3 43 A 
17b4 43  A 
17c1 
84 days post 
131 B2 
17c2 131 B2 
17c3 131 B2 
17c4 131 B2 
18.1a 
54 days pre 
NS  
18.1b NS  
18.1c NS  
18.1d NS  
18.1e NS  
18.1f NS   
18.2a 
36 days pre 
NS  
18.2b NS  
18.2c NS  
18.2d NS  
18.2e NS  
18.2f NS   
18a1 
11 days post 
NS  
18a2 NS  
18a3 NS  
18a4 NS   
18b 27 days post NS   
19.1a 
42 days pre 
10 A 
19.1b 10 A 
19.1c 10 A 
19.1d 10 A 
19.1e 10 A 
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19.1f 10 A 
19.2a 
30 days pre 
10 A 
19.2b 10 A 
19.2c 10 A 
19.2d 10 A 
19.2e 10 A 
19.2f 10 A 
19a1 
14 days post 
43 A 
19a2 43 A 
19a3 43 A 
19a4 43 A 
20.1a 
10 days pre 
10 A 
20.1b 10 A 
20.1c 10 A 
20.1d 10 A 
20.1e 452 NG 
20.1f NT  B2 
20.2a 
4 days pre 
10 A 
20.2b 10 A 
20.2c 10 A 
20.2d 10 A 
20.2e 10 A 
20.2f 10 A 
20a1 
7 days post 
6438 NG 
20a2 6438 NG 
20a3 162 NG 
20a4 162 NG 
20b1 
42 days post 
162 NG 
20b2 162 NG 
20b3 162 NG 
20b4 162 NG 
20c1 
56 days post 
131 B2 
20c2 226 NG 
20c3 131 B2 
20c4 226 NG 
20.e.3 
91 days post 
405 NG 
20.e.4 405 NG 
20f1 120 days post 10 A 
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20g1 
183 days post 
10 A 
20g2 10 A 
20g3 10 A 




21.1c NS  
21.1d NS  
21.1e NS  




21a2 NS  
21a3 NS  




21b2 NS  
21b3 NS  




21c2 NS  
21c3 NS  




22.1b 2619 B2 
22.1c 2619 B2 
22.1d 2619 B2 
22.1e 2619 B2 
22.1f 2619 B2 
22.2a 
 11 days 
2619 B2 
22.2b 2619 B2 
22.2c 2619 B2 
22.2d 2619 B2 
22.2e 2619 B2 
22.2f 2619 B2 
22a1 6 226 A 




22c2 2967 A 
22c3 7174 NG 
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22c4 7174 NG 
 
 
NT: no sequence type based on Warwick MLST scheme;  
NG: no phylogenetic group assigned to the Warwick MLST;  
NS: not sequenced.  
No data shown for sample 10d as no gram-negative bacteria grew from faecal cultures 
(only Enterococcus spp.). 
FS: failed assembly post short read sequencing 
 
*MLST typing with WGS data failed on a single locus. Core phylogenetic analysis using 
SNPs with parsnp confirmed clustering with this ST. 
 
^MLST confirmed E. coli but no ST type determined using Enterobase 
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from regulatory authorities or from the NHS Trust, where it is relevant to 
my taking part in this research. I give permission for these individuals to 


















PARTICIPANT INFORMATION & CONSENT FORM 
Do visitors travelling to the Indian subcontinent acquire local 
antibiotic resistant E.coli and carry those on return, or do 
resistance genes transfer via a plasmid to their resident E.coli? 
________________________________________________________ 
 
We would like to invite you to take part in a research project investigating 
the mechanisms of antibiotic resistance in returning travellers. 
It is entirely up to you whether to take part in the research. This 
information sheet explains why we are undertaking this research and 
what to expect if you decide to participate 
 
WHY IS THIS RESEARCH BEING DONE? 
Infections caused by antibiotic resistant bacteria are an increasing international 
problem. The bacterium Escherichia coli (E.coli) normally inhabits the bowel in 
healthy individuals, but is also the commonest cause of urinary tract infections and 
septicaemia in adults. Unfortunately, E.coli is often resistant to the most effective 
antibiotics available, and this is a particular problem in countries such as India, 
Pakistan, Bangladesh and Sri Lanka.   
 
The spread of resistant E.coli through international travel presents a significant 
challenge, as these bacteria may spread within hospitals. Travellers from western 
countries who visit India, Pakistan, Bangladesh or Sri Lanka often become 
asymptomatic carriers, sometimes for several months after their return home. For 
example, in a recent study, 88% of those travelling to India acquired antibiotic-
resistant E.coli1.  The mechanism of acquisition of resistant bacteria in these cases is 
not fully understood. 
 
DNA is the genetic material carried within all bacterial cells, and is the blueprint for 
the production of proteins which are essential for bacterial survival. Genes are long 
segments of DNA which encode specific proteins, e.g. proteins capable of degrading 
antibiotics which would otherwise be lethal to the bacteria. Genes for antibiotic 
resistance are often carried on circular rings of bacterial DNA called plasmids which 
can move between different bacterial cells of the same or different species. Resistant 
E.coli are acquired from environmental sources, such as contaminated food or 
drinking water, which leads to asymptomatic colonisation of the bowel. It is possible 
that in returning travellers, these new E.coli either: 
1. Remain as colonisers of the bowel  
or 
2. Transfer their antibiotic resistance genes to existing ‘normal’ host E.coli in the 
bowel via plasmid transfer 
 
Using a group of volunteers who plan to travel to India, Pakistan, Bangladesh or Sri 
Lanka, this study will determine the mechanism by which antibiotic resistant genes 
are acquired. This study is important because it will support the development of 
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techniques to prevent the acquisition of antibiotic-resistant bacteria, and the removal 
of resistant bacteria using new technologies.  Written informed consent will be 
obtained from all volunteers.  
 
This research is also part of a PhD being carried out by Edward Bevan, who is 
funded through Public Health England (PHE). 
 
PARTICIPANT INSTRUCTIONS 
1. We will ask you to attend an initial 15 minute meeting with an investigator to 
complete a pre-travel questionnaire, and to collect specimen containers. 
2. You will also be asked to complete a travel questionnaire about your trip on return 
to the UK. This will include questions on the specific places you visited, and 
whether you became unwell or took medication at any point. 
3. We will ask you to submit stool samples on several occasions before and after 
travel: 
a. 8 weeks pre-departure 
b. 4 weeks pre-departure 
c. 2 weeks pre-departure 
d. As soon as possible on return to the UK 
e. 1 week after return 
f. 4 weeks after return 
g. 8 weeks after return 
h. 16 weeks after return 
i. If you still carry resistant E.coli at 16 weeks, we will ask you for 2-3 further 
samples up to a year after you return. 
 
Stool samples should be collected using the spatula and container provided, then 
sealed in the transparent plastic bag. 
 
Samples can be submitted in person to an investigator (Dr Ed Bevan) at the 
Biosciences Building, University of Birmingham, or to the Microbiology 




• Please note that your individual results cannot be made available to you 
• Stool samples will be frozen and retained for the duration of the research period 
(4 years). Bacterial cultures may be retained indefinitely for further research. 
• Your contact details will be needed for the purposes of follow-up. Your details will 
be stored securely on a University password protected computer for the duration 
of the research period (4 years). Any paper-based documents will be stored 
securely at the university. 
• You may also be contacted relating to different ethically-approved research  
• You may withdraw your consent for participation at any time. 
• Fully anonymised results of the study will be published in international literature, 
and will form part of a PhD thesis, however no identifiable information will be 
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published or be disclosed to any third parties who are not directly involved in the 
research. 
• Please do not hesitate to contact the lead investigator with any additional 
questions about the study: .    
 
WHAT ARE THE RISKS OF TAKING PART? 
• There are no risks to your health 
• The study involves devoting a small amount of time in completing questionnaires 
and delivering samples to the Biosciences Building on campus. 
• Your contact details and completed questionnaires will be treated as highly 
confidential and will not be transferred beyond the University. Should a lapse in 
data protection occur, you will be informed immediately. 
• For ethical and legal purposes, the study is sponsored and insured by University 
of Birmingham. 
 
WHAT IF SOMETHING GOES WRONG? 
• If you have any concerns or complaints about this research, please contact one of 
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